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Abstract 
The work in this thesis describes the use of self-assembled monolayers (SAMs) to capture 
peptides on a gold-coated MALDI chip for mass spectrometric analysis.  A SAM was formed 
on the gold-coated MALDI chip, onto which 4-bromophenylalanine was coupled (giving 
peaks due to 4-bromophenylalanine-SAM species a characteristic isotopic distribution).  
Simple single peptides and tryptic peptides from single proteins have been analysed using 
the developed technology.  The capture of peptides on SAMs for mass spectrometric 
analysis has many advantages; all steps (chemistry and analysis) take place in situ on the 
gold-coated MALDI chip.  This means that there are no sample transfer steps, reducing 
sample loss.  Additionally, unreacted reagents and buffers can be removed from the surface 
of the gold-coated MALDI chip through washing.  Buffers which are not compatible with 
mass spectrometric analysis (e.g. phosphate-based buffers) can be used for peptide capture 
as the buffer is washed away prior to analysis.   
 
This thesis describes an alternative cleaning strategy for the removal of organic material 
from the surface of the gold-coated MALDI chips.  Two plasma instruments were 
investigated for their abilities to remove organic material from the gold-coated MALDI chips, 
and both were shown to be a suitable safe alternative cleaning strategy to the caustic, 
potentially explosive piranha solution currently used.   
 
Finally, in-solution dimethyl labelling was investigated, as a labelling strategy which could be 
adapted for used with the SAM technology.  Quantification was performed using standard 
solutions of light and heavy labelled simple protein digests mixed in a range of ratios.  Two 
different commercially-available software packages were investigated to assess their ability 
to analyse the generated data in order to determine whether one is more suitable for 
dimethyl labelling quantification.   A set of complex standard samples was dimethyl labelled 
and analysed, to define parameters for most effectively determining quantification ratios, 
before application to a set of ‘real’ samples.  Muscle protein samples were analysed and a 
set of potentially differentially abundant proteins identified for further validation.  
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1.1. Protein analysis 
Proteomics is the study of the proteome; which is all the proteins being expressed in a 
particular organism, tissue or cell, at a particular time by a genome.  It is a complementary 
technique to genomics.  The field of proteomics aims to use protein-level measurements of 
gene expression to characterise biological processes.
1
  Therefore, the ability to identify, and 
potentially quantify (see Section 1.3), proteins in organelles, cells, tissues or fluids in order to 
understand biological processes is fundamental to the field of proteomics.  The term 
proteome was first used by Wasinger et al. in 1995.
2,3
  Proteomics is complicated by the 
molecular complexity and dynamic nature of proteomes;
3
  it can change with stimuli, 
sometimes on a very short timescale.  Proteins can be expressed at different levels in 
response to changes within the cell and external conditions.  In addition to protein 
expression levels changing, proteins can be modified in the process of post-translational 
modification (PTM).  PTMs are physiological changes which happen to the protein either 
during or after protein synthesis, and increase the diversity of the proteome.
4
  PTMs can 
occur on amino acid side-chains, or at the N- or C-terminal, and are usually the addition, 
removal or modification of a functionality.  The modifications that a protein can undergo 
include phosphorylation, glycosylation, methylation, acetylation, ubiquitination and N- and C-
truncation.
4
  Whilst the human genome comprises between 20,000 and 25,000 genes
5
, the 
number of proteins generated from these genes is estimated to be nearly 2 million.
6
   
A protein cannot be subjected to multiplication techniques such as polymerase chain 
reactions which are used in genomics; therefore, however much of a protein there is, that is 
the amount available for analysis, as it cannot be amplified.
7
   
The Edman degradation technique has been used to sequence peptides and proteins for 
many years (Figure 1.1).
8
  The alpha amino group on the amino acid at the N-terminus is 
reacted with phenylisothiocyanate under basic conditions.  The resulting derivative cyclises 
and the derivatised terminal amino acid is cleaved and then identified using techniques such 
as electrophoresis or liquid chromatography.  The process can be repeated multiple times, 
each time removing the terminal amino acid group of the remaining chain to uncover another 
alpha amino group.  However, these consecutive cleavages result in a lower yield at each 
step, because the cyclisation and cleavage may not reach completion at each step, and so 
the cumulative effect of many consecutive steps results in less and less sample for each 
subsequent step.  The Edman degradation process is also a very lengthy process, but can 
be fully automated.  One of the main limitations of the process is that, if there is a 
modification to the N-terminus which prevents the N-terminal alpha amino group from being 
nucleophilic, the amino acid will not react with the phenylisothiocyanate.   
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Figure 1.1: Edman degradation process 
 
1.1.1. Gel electrophoresis 
Gel electrophoresis is a technique used to separate charged molecules based on properties 
such as charge or size, as they pass through the gel.  In gel electrophoresis, samples are 
loaded into wells at one end of a slab of gel.  This gel is then placed in an electrophoresis 
chamber with an electrophoresis buffer solution.  A voltage is applied across the ends of the 
gel, which creates a potential and causes the proteins to migrate in the electric field.  The 
rate that a protein moves through the gel is related to its size and charge (i.e. a larger 
protein moves more slowly than a smaller protein).
9
  Gel electrophoresis is usually 
performed in either one or two dimensions.   
One-dimensional gel electrophoresis (1-DGE) is a fast way to determine protein molecular 
weight and assess protein purity.  There are different forms of 1-DGE, with the two main 
examples relevant to proteomics being sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE)
10
 (used for determining molecular weight) and isoelectric 
focusing (used to determine the isoelectric point of a protein, and useful to detect small 
changes in proteins due to PTMs)
11
.  Laemmli incorporated the use of SDS (an anionic 
detergent which denatures proteins by non-covalently binding to the protein chain) into the 
native PAGE systems which had previously been used, to create the first SDS-PAGE 
systems.
10
  Once the proteins have been denatured and given a negative charge due to 
binding the SDS, they are then subjected to gel electrophoresis.  The proteins are 
essentially separated by molecular weight, since the longer the protein chain, the more SDS 
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molecules they bind.  Proteins can be stained, using stains such as Coomassie brilliant blue 
stain
12
 or silver staining
13
 in order to visualise them.  This generates an image of the gel, and 
allows proteins from the sample(s) to be visualised.  Their migration can then be compared 
to those of standard proteins of known molecular mass, which are run alongside the 
unknown samples, and provide a ‘molecular weight ladder’.
14
  The whole gel lane of the 
sample (or a small section of it) can be excised and the proteins in it subjected to in-gel 
proteolytic digestion, with the resulting peptides being subjected to mass spectrometric 
analysis.
15
    
Two-dimensional gel electrophoresis (2-DGE) generally separates proteins based on their 
isoelectric point (pI) and size.  The technique was described independently in 1975 by both 
O’Farrell
14
 and Klose
16
.  In the first dimension, the protein mixture is loaded into a 
polyacrylamide gel strip, which has a pH gradient immobilised in it.
17
  A voltage is applied 
across the gel which causes the proteins to move through the gel until they reach the pH 
value which corresponds to their isoelectric point (the pH at which the protein has no net 
charge), at which point they stop moving.  The proteins are then separated in an orthogonal 
second dimension based on their molecular weight, using SDS-PAGE.  The proteins can 
then be stained, and following image analysis, protein spots can be excised and in-gel 
digested before mass spectrometric analysis.   
A western blot can be used to detect specific proteins in a developed gel.
18,19
  The proteins 
are transferred to a nitrocellulose blotting membrane from the gel, which creates a ‘copy’ of 
the gel, which can be further analysed.  A voltage is used which creates a potential and 
allows the negatively charged proteins from the gel to be attracted to the positively charged 
nitrocellulose membrane.
18
  Once the proteins have been transferred, the membrane is 
treated with a generic protein solution (e.g. bovine serum albumin (BSA)) to bind to ‘sticky’ 
places on the nitrocellulose (i.e. anywhere on the surface of the nitrocellulose where protein 
binding could occur).  The binding of a generic protein to the remaining sites on the 
membrane prevents non-specific binding of a subsequent antibody, with the aim to maximise 
specific binding.
20
  The antibody used is chosen to have specificity for a target protein, and 
binding, and thus staining, is obtained where a cross-reacting protein is present on the 
surface of the membrane.  A common detection strategy is to use a two-step process in 
which primary and secondary antibodies are used.
21
  The primary antibodies are generated 
when a host species or immune cell culture is exposed to the target protein (or a part 
thereof).  The membrane is incubated in a solution of the primary antibodies which recognise 
and bind to the target (and other cross-reacting) protein.
20
  After washing the membrane to 
remove unbound primary antibodies, secondary antibodies are introduced, which are 
directed towards a species-specific portion of the primary antibodies.  The secondary 
antibodies are usually linked to a conjugate, such as a reporter enzyme (e.g. horseradish 
peroxidase), which reacts with a development reagent or is used to cleave a 
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chemiluminescent reagent, resulting in a degree of luminescence which is proportional to the 
amount of protein present.   
 
1.1.2. Mass spectrometry 
Protein analysis has seen rapid development since the early 1990s saw an increased 
interest in the field. 
8
  In particular, mass spectrometry has seen significant development to 
make protein analysis a viable analytical tool.  Proteins and peptides can be separated using 
a method such as gel electrophoresis or HPLC, and then analysed by mass spectrometry.  
Mass spectrometry is used to determine accurate masses, amino acid sequences, and the 
nature and site of modifications of proteins and peptides.
22
   
Proteomics experiments can be classified as top-down or bottom-up experiments.  In a 
bottom-up experiment, one or more proteins are broken down into constituent peptides 
before mass spectrometric analysis.
23
  A proteolytic enzyme, for example, trypsin, is used.  
Trypsin cleaves the protein on the carboxyl (C)-terminal side of arginine and lysine residues 
(unless followed by proline), creating peptides that generally therefore have a basic residue 
(arginine or lysine) at the C-terminus of the peptides.
24
  Bottom-up proteomics is a high 
throughput analysis method, and many proteins can be identified in a complex mixture.
25
  
Quantitative proteomics strategies are well established for application in the bottom-up 
proteomics approach, which can yield a lot of information.  However, post-translational 
modification and isoform information may be lost as only one or two peptides from a protein 
may be detected, leading to protein identification based only on those one or two peptides, 
which may not contain the modifications.
26
  Information about low abundance 
peptides/proteins can also be lost using this approach, as ions due to these 
peptides/proteins may be lost amongst information from more abundant peptides/proteins.   
In a top-down proteomics experiment, a protein is analysed in its intact form, and usually 
subjected to gas-phase fragmentation in the mass spectrometer to allow protein 
sequencing.
27
  There are advantages to the top-down approach, for example post-
translational modifications can be detected (which may be lost in a bottom-up experiment),
27
 
and localisation of non-covalently bound ligands may be possible.
26,28,29
  Protein isoform 
identification is also possible with the top-down approach.
29
  However, pure samples or 
simple mixtures are required, and there can be limited sensitivity and throughput.
28
   
There are three mass spectrometry strategies which are commonly used in proteomic 
workflows: shotgun, directed and targeted.
30
  The term ‘shotgun’ proteomics is used when 
an entire proteome is digested and analysed; usually through a combination of liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) and protein sequence database 
searching.
7,31,32
  The LC component of the analysis gives separation of the tryptic peptides 
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generated upon digestion.  A typical approach is to record an MS survey scan, and allow the 
software to select a pre-defined number of precursor ions for MS/MS analysis, to enable 
identification of the peptides.
30,31
  There are disadvantages to the shotgun proteomic 
technique, with the main one being that the connection between intact proteins and their 
peptides is lost, and has to be recreated computationally after analysis.
33
  Another 
disadvantage is the fact that lots of peptides are generated during proteome digestion, but 
not all of these peptides may be observed during mass spectrometric analysis.
34–36
  If a 
sample is analysed multiple times, then it is likely that different peptides are identified in the 
replicate analyses.  This is largely influenced by the sampling speed of the mass 
spectrometer, the complexity of the sample and the separation capability of the LC system.
36
  
Although there have been vast improvements in the capabilities of both mass spectrometers 
and LC systems, there is a drive to analyse more and more complex samples.  With 
complex proteomes the mass spectrometer cannot sample the LC output quickly enough to 
perform MS/MS analysis of every peptide as it elutes from the column, but coverage is 
improved by the use of replicates.
36
   
Directed and targeted proteomic strategies are used when there is prior information which 
defines specific protein or peptide sets to be analysed.
30
  A directed proteomics strategy 
differs from shotgun proteomics in that quantification and identification of tryptic peptides 
occur in separate experiments.
30
  At least two LC-MS or LC-MS/MS analyses are 
undertaken; one collects survey scans for quantification, and the second records product-ion 
spectra based on an inclusion list generated following analysis of the survey scans to 
determine which peptides need to be identified.
37
   
Targeted proteomic studies differ from directed studies in that targeted experiments are 
hypothesis driven.  This means that a specific subset of peptides is targeted in the 
analysis.
30
  Targeted analyses are usually performed on a triple quadrupole mass 
spectrometer, using selected reaction monitoring
38,39
 of a set of target peptides.   
 
1.2. Mass spectrometry 
Mass spectrometry is an instrument-based analytical technique, first introduced by J. J. 
Thomson in the early 1900s, whereby the mass-to-charge ratio (m/z) of ions from the 
sample under investigation is determined.  A mass spectrometer is made up of three main 
components; an ionisation source, a mass analyser and a detector.   
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1.2.1. Ionisation 
1.2.1.1. Electrospray ionisation (ESI) 
Electrospray ionisation (ESI) was developed by Fenn et al. in the 1980s, and is termed a soft 
ionisation technique due to the low energy input and consequent very limited fragmentation 
of the analyte.
40
  A schematic of an ESI source is shown in Figure 1.2.   
 
Figure 1.2: ESI source schematic 
An analyte is introduced in solution through a capillary at atmospheric pressure.
40
  The 
capillary has a voltage applied to it, which generates analyte ions (either positive or negative 
depending on the required mode) within the solution.
40,41
  The charges in the liquid repel 
each other and lead to the liquid at the surface ‘stretching out’ and eventually to droplets 
pinching off to ‘escape’ from the repelling charges.  This is known as the formation of a 
Taylor cone (Figure 1.3).
42,43
   
 
Figure 1.3: Formation of a Taylor cone from the spherical droplet emerging from the capillary 
(left) to a Taylor cone (right) 
The droplet at the end of the capillary is initially spherical but it elongates due to charge 
accumulation in the capillary tip, forming the Taylor cone.  Eventually the Coulombic 
repulsion forces within the droplet are higher than the surface tension and a stream of small 
droplets is released from the surface.
44
  The stream of droplets is released into the ionisation 
chamber where they are attracted to the cone/spray plate because the cone/spray plate is 
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held at a lower potential than the capillary.
41
  The expelled droplets undergo solvent 
evaporation as they travel towards the analyser; solvent evaporation is aided by a stream of 
drying gas through which the droplets pass.  The analyte ions are subjected to a counterflow 
of nitrogen gas as they pass through the transfer capillary in order to remove remaining 
solvent vapour, before subsequently being accelerated by the skimmers, which are set at 
increasing potential, towards the mass analyser.    
There are two proposed methods for ion formation from the charged droplets: the charged 
residue model (IUPAC nomenclature)
45,46
 and the ion-evaporation model.
47
  The charged 
residue model was proposed by Dole et al. in the 1960s.
46
  In the charged residue model, 
the droplet size decreases through solvent evaporation, resulting in an increase in the 
charge density at the droplet surface.  Eventually the Rayleigh limit is reached, where the 
Coulombic force of ion repulsion overcomes the solvent surface tension.  This causes the 
droplet to undergo Coulombic explosion, creating smaller droplets.  This process of solvent 
evaporation, charge repulsion and Coulombic explosion is repeated until all the solvent has 
been removed, leaving a series of unsolvated charged analyte ions (Figure 1.4).   
 
Figure 1.4: Charged residue model  
The ion-evaporation model was proposed by Iribarne and Thomson in the 1970s.
47
  The 
model assumes that when a droplet reaches a critical radius, through evaporation of solvent, 
the droplet surface field strength becomes high enough to desorb a solvated ion directly 
from the droplet and into the gas phase (Figure 1.5).  This temporarily reduces the surface 
tension within the remaining droplet, until further solvent evaporation occurs and the charge 
density within the droplet becomes too high again causing further desolvation.  The process 
of evaporation and ion desorption continues until a series of charged analyte molecules are 
left.   
 
Figure 1.5: Ion-evaporation model  
Limited fragmentation is observed in ESI mass spectra.
48
  Usually, the molecular species 
observed are either protonated ([M+H]
+
) or deprotonated ([M-H]
-
) molecules, depending on 
Chapter 1: Introduction 
34 
 
whether the voltage applied to the capillary is positive or negative.
44
  Other molecular 
species, such as [M+Na]
+
 or [M+Cl]
-
 can arise, depending on contaminants present in the 
sample, or additional elements in the mobile phase (e.g. buffers or modifiers).  It is also likely 
that high molecular mass analytes, such as proteins, with multiple protonation sites can 
acquire multiple charges.
41,44,46
   
 
1.2.1.2. Matrix-assisted laser desorption/ionisation (MALDI) 
Matrix-assisted laser desorption/ionisation (MALDI) was introduced as a mass spectrometric 
ionisation technique by Karas and Hillenkamp in the 1980s.
49,50
  It uses a matrix and laser to 
ionise non-volatile molecules, including proteins and peptides.  As with ESI, little 
fragmentation is observed in MALDI mass spectra.
49
 
The matrix - a small organic molecule with a strong UV absorption at the wavelength of the 
laser - is combined with the analyte on a MALDI plate to insulate the analyte molecules, 
absorb laser light and transfer the consequent excitation to the analyte.
51
  Molecules, such 
as 2,5-dihydroxybenzoic acid (DHB), α-cyano-4-hydroxycinnamic acid (CHCA) and 2’,4’,6’-
trihydroxyacetophenone monohydrate (THAP) are all typical MALDI matrices (Figure 1.6).  
CHCA and DHB are often used in the analysis of proteins and peptides, whereas THAP is 
often used for oligonucleotides.
52
  The sample and the matrix are each dissolved in a 
solvent.  Aliquots of the sample and the matrix solutions can be combined and spotted onto 
the MALDI plate.  Alternatively, the two solutions can be spotted separately onto the same 
well on the plate.  The well is dried (usually by leaving it to air-dry), causing a deposit on the 
surface of the plate of matrix and analyte crystals, which can then be analysed.   
 
Figure 1.6: Matrix molecules used for MALDI 
When the MALDI plate is in the mass spectrometer the crystals are subjected to a brief 
pulse of irradiation from a laser beam (Figure 1.7).   
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Figure 1.7: MALDI ionisation process 
The laser beam ablates portions of the solid deposit where it hits the surface of the sample 
spot.  There are many theories as to how the solid deposits on the surface of the MALDI 
plate generate the ions seen in the resulting mass spectrum.  In 1998, Zenobi and 
Knochenmuss stated that it is very probable that there is no one mechanism that can explain 
all of the ions observed in a MALDI mass spectrum.
53
   
In early publications, gas-phase photoionisation, ion-molecule reactions, disproportionation, 
excited-state proton transfer, energy pooling, thermal ionisation and desorption of preformed 
ions were all proposed as pathways for MALDI ion formation.
53
  It was proposed that there 
were two major processes which occur at the ionisation stage: generation of primary ions 
and subsequent conversion to more favourable secondary products.
54
  The primary ions are 
generated either during or shortly after the laser pulse, with the secondary ions (e.g. radical 
cations, protonated molecules and cationised molecules) being the commonly observed ions 
in positive ion mode.
54
  There are many proposed mechanisms for the formation of primary 
ions.  The most favoured by Zenobi and Knochenmuss for positive mode UV-MALDI were 
multiphoton ionisation, energy pooling and multicentre models and desorption of preformed 
ions.
53
  Primary ions go on to undergo further reactions to form the secondary products, 
which are observed in the mass spectrum.
54
  Conditions within the plume must be 
considered for secondary ionisation mechanisms.  Molecular dynamics simulations show 
that the plume can be described as being formed on very rapid, even explosive, solid-to-gas 
phase transition.
53
  The secondary ionisation mechanisms most favoured by Zenobi and 
Knochenmuss are gas-phase cationisation and electron transfer.
53
  Alkali cations, such as 
sodium and potassium, do not need to be added to the sample in order for [M+Na]
+ 
and 
[M+K]
+
 ions to be detected.  This is due to the fact that sodium and potassium are known to 
be ubiquitous contaminants observed in mass spectrometry.
53
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Two of the favoured ionisation mechanisms in MALDI-MS are the lucky survivors 
hypothesis
55
 and gas phase protonation
53
 model.   
The lucky survivors hypothesis was proposed by Karas et al. in 2000.
55
  It is based on the 
premise that the ions detected are pre-formed (i.e. they exist in the sample spot before 
ablation).  During ablation, most ions recombine with counterions, but a few (the lucky 
survivors) survive and go on to be detected.  The lucky survivors mechanism provides an 
alternative ionisation model to those proposed previously, but retains elements such as 
photoionisation.  As a result of laser desorption, small clusters of material are released from 
the surface of the sample spot, which consists of matrix, analyte and ionic species 
embedded in the matrix crystal.  The clusters have enough excess energy to 
evaporate/desolvate to molecular and ionic species.  Upon evaporation of the matrix 
molecules ion-ion and neutral-ion chemical reactions occur, driven by reaction enthalpy.  
Highly pre-charged analytes are neutralised, which is a strongly favoured reaction.  
However, a percentage of these analytes retain a single charge, and these analytes are 
known as the lucky survivors, which are observed in MALDI mass spectra.   
The gas phase protonation model was proposed in a paper by Ehring et al. in 1992.
56
  It is 
based on the hypothesis that neutral analytes are released into the gas phase after 
desorption/ablation, either through incorporation in the matrix crystals as uncharged species, 
or from charge recombination of a precharged analyte and its counterion.  It is also possible 
for neutral matrix molecules to be protonated in a similar manner.  The neutral analytes can 
undergo gas phase collisions with protonated or radical cation matrix species, to form 
charged, protonated analytes.   
Karas and Krüger published a paper in 2003 in which the cluster ionisation mechanism was 
discussed as a refinement to the lucky survivors mechanism.
57
  There is evidence to show 
that a mixture of matrix clusters and neutral evaporation are the fundamental ablation 
products.  These clusters then break down and react en route to the detector, and matrix 
and analyte ions are observed in the mass spectrum.  The presence of these clusters alters 
the MALDI ionisation process, with ionisation being linked to the occurrence of the clusters.
57
   
Jaskolla and Karas published a paper in 2011, in which they present evidence for both the 
lucky survivor model and the gas phase protonation model.
58
  They proposed that both of 
the models were valid pathways to protonation in MALDI-MS.  They also showed that one 
ionisation pathway can be more favourable than the other, depending on the conditions 
used.  For example, increasing the laser fluence favours the gas phase protonation model.  
Ultimately, a unified MALDI analyte protonation mechanism was proposed, which combines 
and connects elements of both ionisation models (Figure 1.8).   
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Figure 1.8: The unified MALDI analyte protonation mechanism restricted to positively 
precharged analyte ions such as peptides and proteins58 (where A = analyte, ma = matrix, X = 
counterion, H = proton) 
In 2012, a paper by Bae et al. discussing the degree of ionisation of peptides in MALDI-MS 
was published.
59
  The authors suggested that the current lucky survivor and gas phase 
protonation models were both valid to a degree for peptide ion formation, but both could be 
modified to describe gas-phase peptide ion formation.  The authors proposed, from 
experimental data, that laser ablation releases a peptide into the gas phase either as a free 
protonated peptide (Hypothesis 1), as a protonated peptide in a neutral ion pair (Hypothesis 
2) or as a neutral peptide (Hypothesis 3).  In Hypotheses 2 and 3, peptide ions were 
assumed to form via gas-phase reactions of peptide neutrals with matrix-derived cations.  In 
Hypothesis 1, the ion emission is assumed to occur only for preformed analyte ions which 
are dielectrically screened from counter anions by neutral matrix molecules in a solid 
sample, and hence are easily released into the gas phase.   
There is still uncertainty as to the exact MALDI mechanism, but the lucky survivor and gas 
phase protonation models seem to be accepted as the models which best explain the 
MALDI process.
58
  However, there is still no definitive explanation of the ionisation process, 
as can be seen from the fact that authors of papers in recent years have adopted aspects of 
both models, depending on what their experimental data showed.   
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1.2.2. Mass analysers 
The mass analyser separates the ions formed according to their m/z values.  The way in 
which ions are separated depends on the type of mass analyser used.  The time-of-flight 
(ToF) mass analyser and the Fourier transform ion cyclotron resonance (FT-ICR) mass 
analysers will be discussed, as these have been used in the work presented in this thesis.   
 
1.2.2.1. Time-of-flight (ToF) 
The ToF mass analyser was first described by Stephens in 1946,
60
 and the first commercial 
instrument was developed by Wiley and McLaren in the 1950s.
61
  The ToF mass analyser 
became a prominent tool in the field of mass spectrometry in the 1960s.
62
   
A ToF mass analyser works by measuring the time it takes the ions produced in the ion 
source to travel through a field-free region, known as the flight tube, and reach the detector.  
There are two types of ToF mass analyser: the linear
61
 and reflectron
63
 forms.   
As described by Wiley and McLaren, in the linear ToF (Figure 1.9), the ion packets travel 
from the ion source, through a flight tube, and hit a detector at the other end.
61
   
 
Figure 1.9: Linear ToF mass analyser in linear orientation 
Bundles of ions are expelled from the source and accelerated into a flight tube by a potential 
difference.  The ions separate in the flight tube based on their velocity (ν), which is 
proportional to their m/z value.  The kinetic energy (Ek) of an accelerated ion depends on its 
mass (m) and charge (𝑞 = 𝑧𝑒), but also on the accelerating potential (Vs) (Equation 1.1).
62
   
𝐸𝑘 =
𝑚𝜈2
2
= 𝑧𝑒𝑉𝑠 
Equation 1.1: Equation relating the kinetic energy of an accelerated ion to its velocity mass 
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The velocity of an ion can be found by rearrangement of Equation 1.1: 
𝜈 = (
2𝑧𝑒𝑉𝑠
𝑚
)
1
2
 
Equation 1.2: Rearrangement of Equation 1.1, to give velocity as the subject 
The time (t) taken for an ion to travel the length (L) of the flight tube is given by Equation 1.3.  
𝑡 =
𝐿
𝜈
 
Equation 1.3: Equation relating the time taken for an ion to travel the length of the flight tube 
to its velocity 
By replacing velocity in Equation 1.3 with the result of Equation 1.2, m/z values can be 
calculated from the time taken for different ions to travel the length of the flight tube:   
𝑡2 =
𝑚
𝑧
(
𝐿2
2𝑒𝑉𝑠
) 
Equation 1.4: Equation showing that m/z can be calculated from a measurement of the time 
taken to travel the length of the flight tube 
As the ions are accelerated into the flight tube, a spread of kinetic energies is possible for 
each m/z value.
63
  This is due to the fact that when the accelerating potential is applied, the 
distribution of the potential is not even.  This can mean that ions with the same m/z do not 
experience exactly the same potential, and subsequently do not have exactly the same 
kinetic energy.  The distribution of kinetic energies can be made worse by collisions within 
the plume, which can transfer energies between ions, and result in an uneven distribution of 
kinetic energies.
62
   
In a linear ToF, ions with the same kinetic energy can arrive at the detector at different 
times.  This spread in detection times can be caused by differences (prior to acceleration) in 
the position of the ions within the source, in the direction of travel of the ions and in the time 
at which ions of the same m/z are created.
62
  This means that ions of the same m/z can hit 
the detector at different times, which can result in peak broadening and reduced resolution in 
the resulting mass spectrum.   
The effects of kinetic energy spreads can be reduced using a reflectron, an idea which was 
introduced by Mamyrin et al. in 1973.
63
  In the reflectron ToF (Figure 1.10), the ions enter the 
flight tube and reach an ion mirror or reflectron - a series of rings of increasing potential.
63
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Figure 1.10: Reflectron ToF mass analyser (both ions have the same m/z, but the blue circles 
represent ions with less kinetic energy than the red circles) 
The ions which have the most kinetic energy will travel further into the ion mirror, whilst ions 
with less kinetic energy will travel less far into the ion mirror.  When the ions leave the 
reflectron, ions of the same m/z value should now arrive at the detector at the same time, 
creating a more uniform response at the detector, which should result in better resolution in 
the mass spectrum.  One of the additional benefits of the reflectron is that the ions 
essentially travel twice the length of the flight tube, which increases the resolution of the 
mass analyser when compared to a linear ToF.
63
   
ToF mass analysers are clearly very appropriate for use with pulsed ion sources (such as 
MALDI) because the pulsed ion source generates packets of ions.  These packets of ions 
have a short, precisely defined ionisation time, which generates defined packets of ions to 
be accelerated into the flight tube.  Therefore, a packet of ions can be accelerated into the 
flight tube and detected, before the next packet of ions is generated.  In the 1980s, Guilhaus 
and Dodonov ‘rediscovered’ orthogonal acceleration, which readily allows continuous ion 
sources (such as ESI) to be used with ToF mass analysers.
64,65
  The original work using an 
orthogonal geometry was attempted in the 1960s by O’Halloran, but the work was not 
published in the general scientific literature.
65
   
In orthogonal acceleration instruments (Figure 1.11), the continuous stream of ions 
generated in the ion source is focussed into a parallel beam which travels through an 
orthogonal accelerator.
64
  The orthogonal accelerator produces an injection pulse at regular 
time intervals, which is orthogonal to the ion beam.
65
  This raises the kinetic energy of the 
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ions in the direction orthogonal to the beam, and sends them towards the orthogonally 
placed flight tube.
64
  The accelerator has two modes: a fill-up mode and a push-out mode.
64–
66
  In the fill-up mode, the first stage of the accelerator must be field-free, to avoid ions in the 
ion beam being deflected from their trajectory, and causing a spatial spread of the ions.  The 
ion beam enters the orthogonal accelerator at a right angle to the entrance to the flight tube.  
If there is no field, the ions are able to continue in their parallel ion beam, which fills the 
orthogonal accelerator.  When the push-out pulse is applied, the ions in the orthogonal 
accelerator are pushed out of the accelerator, in an orthogonal direction to the ion beam.  
The ions then travel through the flight tube, towards the detector.   
 
Figure 1.11: Orthogonal acceleration reflectron ToF mass analyser (both ions have the same 
m/z, but the blue circles represent ions with less kinetic energy than the red circles) 
 
1.2.2.2. Fourier transform ion cyclotron resonance (FT-ICR) 
FT-ICR mass spectrometry was first described by Comisarow and Marshall in 1974.
67,68
  The 
FT-ICR mass analyser works on the basic principle that the trajectory of an ion can be 
controlled by a magnetic field; if an ion has a low velocity, but is in an intense magnetic field, 
it can be made to move in a circular motion, thus trapping it in a space.
52
   
The main components of an FT-ICR-MS are a magnet, an ICR cell, an ultra-high vacuum 
and a sophisticated data system.
69
  The magnet surrounds the ICR cell and is usually 
superconducting.  An ultra-high vacuum is needed to produce the high resolution associated 
with the FT-ICR mass analyser by minimising collisions within the cell, which subsequently 
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increases the mean free path of the ions.
69
  There are several stages (or sections) within the 
mass spectrometer, before the ions reach the ICR cell.  Each stage has a higher vacuum 
than the previous stage.
70
  The ICR cell is where the ions are stored, mass analysed and 
detected and is typically either cubic (Figure 1.12) or cylindrical in shape.   
The basic experimental sequence consists of four stages: quench, ionise, excite and 
detect.
69
  The quench step removes from the ICR cell ions remaining from a previous 
experiment, by applying a high potential difference across the trapping plates, which forces 
ions out of the cell axially.  Once the ions are in the cell, they are excited into a coherent 
motion, which allows the ions to be detected.   
 
Figure 1.12: An example of a cubic ICR cell, where B = magnetic field (trapping plates are 
coloured blue) 
The ICR cell consists of six plates, which are divided into three pairs.
71
  There are two plates 
(the plates with holes in them) which are known as the trapping plates, or end caps (Figure 
1.12), where the ions can enter and exit the cell.  Of the two remaining pairs of plates, one 
pair is known as the excitation plates, and the other pair is known as the detection plates.   
Ions enter the cell, with an incoherent motion, meaning that they simply spiral inside the cell, 
and are not detected.
72
  Once inside the cell, they undergo three types of ion motion: 
trapping motion, cyclotron motion and magnetron motion (Figure 1.13).
70
   
B 
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Figure 1.13: The three motions that ions undergo in the cell 
The trapping motion traps the ions in the cell in a path parallel to the magnetic field.  A 
voltage applied to the end caps, which are perpendicular to the magnetic field, traps the ions 
and causes them to undergo a harmonic oscillation.  The ions undergo cyclotron motion 
simultaneously to the trapping motion, causing them to perform a circular motion within the 
cell.  The magnetron motion experienced by ions comes from the combination of the 
magnetic field and electric field experienced by an ion.
70
  The electric field acts to drive ions 
away from the centre of the ICR cell, whilst the magnetic field stops the ions from being 
accelerated into the walls of the cell.  The passage of the ions within the ICR cell which is 
produced due to the combination of the three motions is summarised in Figure 1.14.   
  
Figure 1.14: The motion of an ion within the ICR cell as a result of trapping, cyclotron and 
magnetron motions 
The frequency with which an ion repeats its orbit within the ICR cell is called its cyclotron 
frequency.
71
  FT-ICR mass analysers determine the m/z value of ions based on their 
cyclotron frequency in a constant magnetic field.
71
  The cyclotron frequency (Equation 1.5) of 
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an ion is measured experimentally and subsequently converted to its m/z value.
72
  The 
frequency (fc) is inversely proportional to the m/z of the ion, and directly proportional to the 
strength of the applied magnetic field (B).  As the magnetic field remains constant, the only 
unknown quantity is the m/z value.  As can be seen in Equation 1.5, the lower the m/z value, 
the higher the cyclotron frequency.   
𝒇𝒄 =
𝒛𝑩
𝟐𝝅𝒎
 
Equation 1.5: Cyclotron frequency, and its dependence on mass, charge and magnetic field 
strength 
If all the ions enter the cell with the same kinetic energy, they are in a packet.  This packet 
then travels backwards and forwards within the cell (due to the trapping motion).  When the 
ions enter the cell, their cyclotron radius is too small to be detected.
71
  Ions at each m/z are 
excited by applying a sweeping radiofrequency (RF) pulse across the excitation plates, 
which excites all m/z values.
73
  This is a sinusoidal voltage, which increases the kinetic 
energy of the ions, and increases their radius when the RF is the same as the cyclotron 
frequency.
70
  When the two values are the same, the ions absorb energy from the RF and 
their cyclotron radius is increased.  The increase in radius allows the ions to be detected by 
the detector plates.
69
  As the packet of orbiting ions passes near each of the opposing pairs 
of detector plates, electrons are attracted first to one plate and then the other.  For example, 
if the instrument is operated in positive mode, the ion packet travelling towards the plate 
attracts electrons in the plate.  This creates a differential current between the two detection 
plates, forming a sinusoidal image current, which is then digitised by the computer 
software.
70
  The time domain sinusoidal curve undergoes Fourier transformation to produce 
a frequency spectrum, which is then converted to a mass spectrum.   
Over time, or if the ions do not all enter the cell with the same kinetic energy, a packet of 
ions with the same m/z may spread out along the axis of the cell.
74
  However, this does not 
necessarily affect the detection of the ions as they will still pass each of the detector plates 
at the same time, just at different points along the length of the cell.   
The high resolution achievable using FT-ICR-MS is a consequence of the length of time that 
the ions are detected (transient duration, T)
70
 and the cyclotron frequency: resolution 
increases as transient duration and cyclotron frequency increase (Equation 1.6).   
𝑹 =
𝒇𝒄𝑻
𝟐
 
Equation 1.6: Maximum resolution achievable in FT-ICR-MS 
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1.2.3. Tandem mass spectrometry 
Soft ionisation (such as ESI or MALDI) gives very few fragment ions, but for structure 
analysis fragments need to be generated.  Fragments can be generated by collisions with a 
neutral gas following ion acceleration.   
There can either be two mass analysers in line, with a collision cell in the middle to cause 
fragmentation (MS/MS ‘in-space’), or there can be one mass analyser which performs all the 
functions (MS/MS ‘in-time’).
75
  The typical set-up for an in-space tandem mass spectrometry 
experiment is shown in Figure 1.15, with the two mass analysers used for recording data 
referred to as MS1 and MS2.  The collision cell is where the ions from MS1 may be 
fragmented, before being passed through to the second mass analyser.   
 
Figure 1.15: Typical arrangement of an in-space tandem mass spectrometer 
There are four major MS/MS experiments: product ion, precursor ion, constant neutral loss 
and selected reaction monitoring experiments.
76
  In a product ion experiment, which is often 
used for sequencing peptides and oligosaccharides, and for analyte identification, the first 
mass analyser selects a specific precursor ion.
77
  This ion then undergoes fragmentation, 
and the product ions are analysed in the second mass analyser.  The resulting mass 
spectrum shows the ions which have been produced from the selected precursor.   
Fragmentation of ions can be achieved using different techniques, with the most commonly 
used technique being collision induced dissociation (CID).
78–81
  In CID, the ions are 
accelerated and then collided with a neutral gas (such as helium or nitrogen) in the collision 
cell.  The collisions increase the internal energy of the ions by converting some of their 
kinetic energy to internal energy, which causes subsequent fragmentation of the ions 
through bond breakage.
79
  The mass of the collision gas can influence the amount of energy 
that the ion receives, and therefore the maximum amount of kinetic energy which is 
converted to internal energy.
82
     
When a protein or peptide fragments (in most modern spectrometers, this is by low energy 
CID), it fragments in a well-defined way.
83
  All three bonds in the peptide backbone are 
susceptible to breaking to different extents.  When the bond in a singly-charged precursor 
breaks, the resulting charge can be left on either of the resulting fragments (Figure 1.16).  If 
the charge is on the peptide’s N-terminal portion, the fragment produced is termed an a-, b- 
or c-ion.
83
  If the charge is on the peptide’s C-terminal portion, the fragment is labelled either 
an x-, y- or z-ion.
83
  In addition to being labelled as an a-, b-, c-, x-, y- or z-ion, the fragment 
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is given a number.  The number is dependent on the number of amino acid residues in the 
fragment produced.  For example, if it is the second amino acid from the N-terminus, and the 
charge is on the N-terminal portion, either an a2-, b2- or c2-ion will be formed.   
 
Figure 1.16: The fragmentation which can occur in a peptide.  The different colours indicate 
the different types of bonds which can break.   
The amide (peptide) bond between the amino acids is the most likely to break as it has the 
lowest energy pathway.
84–86
  Identification and interpretation of sequence ions, 
predominantly the b- and y- ions, but also, less frequently with low energy CID, a-, c-, x- and 
z-ions, allows peptide amino acid sequences to be determined.  Immonium ions can be 
formed if double y/a-type cleavage occurs, which creates an ion derived from a single amino 
acid.
84
  These cleavages can identify amino acids present in a peptide, but they do not give 
information relating to where in the sequence these amino acids are.   
Computational methods are used to compare experimentally acquired mass spectra with 
known protein and gene sequences.  Search engines (for example Mascot
87
 and 
SEQUEST
77
) allow protein sequence databases to be queried using experimental data.  
Experimental mass values are compared with calculated peptide mass or fragment ion mass 
values, which are generated from predicted proteolytic digestion of proteins in the 
database.
88
  A database is often specified, to reduce the number of proteins being searched.  
The peptides from the theoretical fragments which have the ‘right’ mass are then pulled out, 
and theoretical spectra are generated for them.  These are then matched against the 
experimental spectra.  Mascot uses a probability-based matching algorithm to match the 
theoretically predicted fragments for all proteins in the database and the experimental 
fragments.
87
  The software produces a list of possible matches between the experimental 
results and the theoretical results, and scores them based on closeness of the match 
between the theoretical and experimental results.   
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1.3. Protein labelling strategies 
When discussing a protein labelling strategy, there are multiple ways the term can be 
understood.  The term protein labelling can refer to isotopic labelling (introduced with or 
without the use of a chemical label) and chemical labelling (which may or may not introduce 
an additional chemical moiety sometimes referred to as a tag) of proteins.  In the context of 
this thesis, protein labelling strategies have been used for the chemically-mediated isotopic 
labelling of proteins at the level of their tryptic peptides.   
The use of protein labelling strategies plays an important part in proteomics, in particular in 
quantitative proteomics as a means of being able to quantify differences in the levels of 
particular proteins in two (or more) different biological samples.
89
  However, protein labelling 
strategies have also been used for non-quantitative proteomics experiments (for example, 
proteins and peptides have been labelled to aid mass spectrometric identification).
90
   
Quantitative proteomics has been used to study subjects as diverse as biomarker discovery 
in pancreatic cancer
91
 and cold stress responses in petunia seedlings.
92
  In order to perform 
a quantitative proteomics experiment, there are a number of different routes which can be 
taken (Figure 1.17).  The different options can be broken down into four different generic 
strategies: metabolic labelling, chemical labelling, spiked peptides and label free.  Within 
each of these generic strategies, there are then a number of different experiments which can 
be performed (e.g. chemical labelling can be done using one of a range of different chemical 
labels). With each of the general strategies, the proteins must be extracted from the cells or 
tissue, prior to digestion to generate peptides.  The resulting peptides are then analysed by 
mass spectrometry, and the data interpreted.   
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Figure 1.17: Strategies for protein quantification, detailing the possible different stages 
involved and the potential stages at which experimental variation can occur.89 
Metabolic labelling strategies involve the incorporation of a label into proteins through the 
use of an isotopically labelled amino acid (e.g. deuterated leucine) during cell growth and 
division.  Two sets of cells are grown in cell medium.  One is grown using non-labelled 
amino acids.  The isotopically labelled amino acid is included in the cell culture medium for 
the other set of cells, and is incorporated into the proteins synthesised whilst in the cell 
culture medium.
93
  Labelling is at the protein level, with the protein extracts resulting from the 
different experimental conditions being combined prior to any subsequent purification, 
digestion and analysis.   
With a chemical labelling strategy, a label is usually introduced chemically or enzymatically 
into proteins or peptides.
89
  One example of an enzymatically-mediated labelling strategy is 
the incorporation of 
18
O during protein digestion.
94,95
  Chemical labelling strategies generally 
label peptides generated on protein digestion and the samples are not usually combined 
until a later stage.  The samples from the different experimental conditions are invariably 
extracted and/or fractionated as individual samples, prior to labelling.  Once the peptides 
have been generated and labelled, the samples from the different experimental conditions 
are combined.  A protein or peptide can be chemically labelled at the N-terminus, the C-
terminus or at a particular amino acid side chain within the sequence.  Chemical labelling 
can either introduce an isotopic label into a native component of the protein (such as a 
carbon, oxygen or nitrogen atom already present in the peptide structure) or introduce a new 
chemical moiety (such as an additional organic group).   
Chapter 1: Introduction 
49 
 
An alternative strategy is to spike synthetic peptides into a protein digest.
96
  After protein 
digestion, a known quantity of a stable isotopically-labelled peptide is added.  These 
peptides are synthetic versions of peptides produced during the digest, but incorporate 
stable isotopes to generate peptides with the same amino acid sequence as a peptide from 
the digest.  The spiked digest is then analysed mass spectrometrically, where precise and 
absolute quantitative determination of the non-labelled peptides can be carried out.  Such 
labelled peptides for spiking can be synthesised, but QconCAT is an alternative strategy for 
producing labelled peptides, and uses genes to express artificial proteins.
97,98
  A synthetic 
gene (which encodes for all the required peptides) is designed, inserted into a vector and 
expressed in E. coli.  The cell medium is isotopically enriched to ensure that the expressed 
peptides are isotopically labelled.  The artificial protein may be spiked into the samples 
before digestion, releasing its isotopically labelled peptides when the samples are digested.   
Label-free strategies involve the two experimental conditions being kept separate throughout 
the analysis, until after the data have been acquired.  In a shotgun proteomics experiment, 
label-free peptide quantification is achieved by either measuring mass spectral peak 
intensities or by spectral counting.
99
  Measuring mass spectral peak intensities of peptide 
ions has been shown to provide relative quantification data.
100
  Spectral counting involves 
comparing the number of tandem mass spectra assigned to each protein, and using these to 
compare the relative abundances of these proteins in different samples.  It has been 
demonstrated that the number of times a peptide is selected for fragmentation directly 
reflects its relative abundance (and thus the relative abundance of its parent protein(s)) in 
the sample.
101
   
Within all quantification strategies there are stages where experimental variation can occur 
(Figure 1.17), and so lead to quantification errors.  This variation includes the fact that the 
amount of protein/peptide recovered from one experimental condition may not be exactly the 
same as that from another.  Therefore, two experiments which may have started with similar 
amounts of protein may end up having differing amounts by the time the samples are 
combined, leading to errors in the quantification.   
Metabolic labelling strategies incorporate the label within the proteins from the very earliest 
stage (during cell growth and division), which is a huge advantage of the metabolic labelling 
strategy compared to the other three strategies.
93
  This is because pooling of samples can 
occur immediately after labelling, and so the possible experimental variation is dramatically 
reduced.  As the labelled proteins are combined at the level of intact cells, this reduces 
sources of quantification error.  With chemical labelling strategies, experimental variation 
can occur at any of the stages in the analysis that take place before samples are combined, 
as the individual samples undergo separate procedures (e.g. sample clean-up as well as 
labelling) before they are combined.  Sample could be lost during these stages, or labelling 
efficiencies may vary, which would not be accounted for as the samples are handled 
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separately.  The spiked peptides strategy can be subject to experimental variation, 
particularly if the spiking does not occur until protein digestion (as depicted in Figure 1.17).  
Like with the chemical labelling strategies, sample could be lost from, for example, sample 
clean-up or fractionation.  With label-free strategies, there is the chance for experimental 
variation to occur at all of the different stages between generating the samples, obtaining the 
proteins and acquiring the data.   
There are a number of criteria which should be met when considering the use of a label.  
These include the fact that the labelling strategy should label all proteins or peptides present 
in a sample in very high yield, and there should be minimal treatment of the sample to add 
the label.
102
  Mass spectrometric analysis is generally used to analyse labelled peptides and 
proteins.  There are many tags which are commonly used in the world of bio-molecule 
analysis.   
 
1.3.1. Stable isotope labelling by amino acids 
Stable isotope labelling by amino acids in cell culture (SILAC) is an in vivo metabolic 
labelling strategy first introduced in 2002 to monitor the relative abundance of proteins when 
cells are grown in different culture media.
93
  One culture medium contains standard amino 
acids (‘light’), whilst the other(s) contains isotopically-modified amino acids (‘heavy’).
93
  
When the technique was first introduced by Ong et al. in 2002,
93
 the group used deuterated 
leucine as the isotopically-modified amino acid to investigate the relative quantification 
changes in protein expression during muscle cell differentiation.  Other isotopically-modified 
amino acids commonly used are lysine and arginine where (usually) 
13
C and 
15
N are 
incorporated into the amino acids.
103
  These amino acids are incorporated into the proteins 
synthesised by the cells or organism grown in the ‘light’ or ‘heavy’ media.  Enough cycles of 
cell growth must be completed to ensure that the isotopically-modified amino acids are fully 
incorporated into the proteins growing in the modified medium.
103
  The different experimental 
conditions are combined and processed as a single sample. The resulting peptides are 
subjected to mass spectrometric analysis (Figure 1.18), with quantification carried out at the 
peptide level.   
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Figure 1.18: Schematic of SILAC labelling strategy (where blue and red colours represent the 
two different cell cultures) 
When SILAC was first introduced as a labelling strategy, it was as a duplex experiment.
93
  
However, it is possible to perform a triplex experiment by use of ‘light’, ‘medium’ and ‘heavy’ 
labels.
104
  In a standard duplex experiment, pairs of peptides which differ by a set mass 
difference, as determined by the number of heavier isotopes incorporated into the modified 
amino acids and the number of those amino acid in the peptides, can then be identified.   
 
1.3.2. Isotope-coded affinity tag 
The isotope-coded affinity tag (ICAT) was introduced as a chemical label for quantitative 
proteomics in 1999.
105
  It contains a biotin affinity tag, linker region and cysteine-reactive 
group (Figure 1.19).  ICAT is an example of a residue-specific chemical label, as it only 
reacts with cysteine side-chains (through the cysteine-reactive group).  The biotin affinity tag 
is used as a way of isolating the ICAT-tagged peptides through avidin affinity 
chromatography.
105
  The linker region contains the stable isotopes (either hydrogen or 
deuterium).   
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Figure 1.19: ICAT reagent, consisting of three regions: a biotin region to isolate ICAT-labelled 
peptides, a linker region which incorporates the stable isotopes and a reactive group which 
reacts with thiols (X = H (light) or X=D (heavy)) 
One sample is treated with the heavy ICAT reagent, whilst the other is treated with the light 
ICAT reagent (Figure 1.20).
105
  The two samples are then combined, and enzymatically 
digested.  The ICAT-labelled peptides (which must contain a cysteine residue) are isolated 
using biotin/avidin affinity chromatography, and analysed by mass spectrometry.  Peptide 
pairs are identified by the presence of two peaks in the mass spectrum which differ by one 
eight mass unit increment for each ICAT moiety incorporated, and which appear in the same 
peak in the chromatogram.
105
  They are then isolated for further analysis, in which their 
sequence is determined.  Quantification of peptides occurs at the MS level by comparing the 
relative signal intensities of the peaks for the peptide ion pairs.   
 
Figure 1.20: The ICAT strategy for quantifying differential protein expression 
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Gygi and co-workers initially looked at the applicability of the ICAT labelling strategy through 
the use of a standard protein mixture.
105
  Two mixtures consisting of the same proteins, but 
present at different concentrations were labelled (one with the light ICAT label, and the other 
with the heavy ICAT label) and treated as schematically illustrated in Figure 1.20.  All six 
proteins were identified and quantified (an example mass spectrum, which was obtained at 
19.76 minutes is shown in Figure 1.21).  The group then went on to compare protein 
expression in the yeast Saccharomyces cerevisiae using either ethanol or galactose as a 
carbon source.
105
   
 
Figure 1.21: ICAT analysis of a protein from a standard protein mixture.  Full scan mass 
spectrum at time 19.76 minutes of the LC-MS analysis (expanded m/z region to illustrate m/z 
difference between light and heavy labelled doubly charged peptide ions).  At least four 
different peptide doublets were identified.105 
There are limitations to the ICAT technology.  For example, the protein must have at least 
one cysteine residue in order to be represented in the peptides analysed.  Another concern 
is that although the heavy and light versions of the peptides should co-elute in the HPLC, 
there is a chance that they may have slightly different retention times due to the presence of 
deuterium, which can affect the chromatography and thus the quantification.
106
  Post-
translational modifications may not be seen, as they would need to occur on the peptides 
containing cysteine.
107
  There is also the possibility that the avidin affinity stage could suffer 
from non-specific binding.
107
 
There have been variations on the original ICAT molecule, such as the acid-cleavable 
ICAT.
106
  This uses 
12
C and 
13
C isotopes instead of H and D, which avoids D/H 
chromatographic separation.  It is called ‘cleavable’ because the linker group can be cleaved 
under acidic conditions, to remove the biotin.
107
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1.3.3. Tandem mass tags 
Tandem mass tags (TMTs) were proposed as an N-terminal labelling strategy by Thompson 
et al.in 2003.
108
  The tag consists of an amine-reactive NHS group, a mass normaliser group 
and a mass reporter group.  The tandem mass tags are a set of isobaric tags, meaning that 
each of the tags has the same overall mass.  However, when the tagged peptides are 
fragmented in the mass spectrometer, ions of different m/z values are produced for each of 
the different isobaric tags.  TMT labelling is a peptide quantification method which uses an 
MS/MS based analysis method.  This technique allows for both the simultaneous 
determination of the identity and relative abundances of peptide pairs using CID.  There 
have been different generations of the tandem mass tag.  The first generation (duplex) TMT 
is shown in Figure 1.22, whilst the current Pierce
TM
 Amine-Reactive TMT
0
 is shown in Figure 
1.23.   
 
Figure 1.22: First generation of the TMT tag (R = protein reactive functionality, X = H/D) 
The first generation of the TMT tag, as shown in Figure 1.22, comprises several different 
regions: sensitisation group, mass differentiated group, mass normalisation group and a 
reactive functionality.
108
  The combination of the sensitisation group and mass differentiated 
group make up the TMT fragment that is generated upon tandem mass spectrometric 
analysis.  The tag consists of a series of amide bonds in the backbone, connected to the 
sensitisation group, with the mass differentiated group and mass normalisation group being 
methionine residues.  The sensitisation group is a guanidino functionality.  Guanidination of 
lysine residues from a tryptic digest has been shown to improve the signal response of C-
terminal lysine fragments upon tandem mass spectrometric analysis.
109
   
In 2008, Dayon et al. published a 6-plex TMT strategy which was used for proof of principle 
studies using standard protein mixtures and also to investigate proteins in human 
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cerebrospinal fluids.
110
  This has essentially gone on to become the Pierce
TM
 TMT reagent 
(Figure 1.23), where a combination of carbon and nitrogen isotopes are used instead of the 
hydrogen and deuterium used in the first generation TMT, to ensure chromatographic co-
elution.   
 
Figure 1.23: PierceTM TMT reagent (TMT0 shown) (* indicates isotope position) 
The current Pierce
TM
 TMT reagent (Figure 1.23) bears little resemblance to the first 
generation TMT reagent devised by Thompson et al..  The element of the peptide/reactive 
functionality denoted ‘R’ in Figure 1.22, has been retained in the form of the NHS ester of 
the Pierce
TM
 TMT reagent.  However, the mass normaliser region no longer contains 
deuterium/hydrogen combinations, whilst the mass reporter part of the reagent is also 
significantly different from that in the first generation TMT.   
The Dayon et al. paper first discussed the relative quantification ability of the 6-plex TMTs 
with a model four-protein mixture with protein abundances at six different concentrations.
110
  
Six mixtures were prepared of a model protein mixture (with each mixture containing the 
same standard proteins), with varying ratios of tryptic peptides from the standard proteins.  
Each of the model protein mixtures was labelled with a different TMT label, and then aliquots 
of the six mixtures were combined.  An example product ion spectrum obtained for a single 
peptide from the model protein mixture is shown in Figure 1.24, showing the detail of the 
reporter ion region used for relative quantification.  Quantification is based on the ratios 
between the intensities of the reporter group ions in the tandem mass spectra.   
* * * * * 
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Figure 1.24: (a) Tandem mass spectrum of the peptide LSFNPTQLEEQCHI of β-lactoglobulin 
(m/z 1944.902), labelled with TMT and iodoacetamide.  (b) Expanded depiction of the 
reporter ion region providing peptide relative quantification in a model four-protein mixture 
at six different relative concentrations (1:2:3:3:5:10) through the abundance of the reporter 
ions at m/z = 126.1, 127.1, 128.1, 129.1, 130.1 and 131.1.110   
Cerebrospinal fluid proteins from ante-mortem and post-mortem samples were then 
interrogated using TMT labelling.  Through the TMT labelling, the authors were able to 
identify a number of proteins with expression differing between the ante-mortem and post-
mortem cerebrospinal fluid samples.  The results for several of these proteins (glial fibrillary 
acidic protein, protein DJ-1 and protein S100B) were validated by additional methods.
110
   
The advantages of the TMT labelling strategy, reported by Thompson et al. include the fact 
that the isobaric tagged peptides co-migrate in chromatographic separation.
108
  Another 
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advantage is the use of CID for quantification, which allows untagged material to be 
ignored.
108
  However, the precursor peptide must be isolated exclusively, but this is not 
always achieved.
111
  If multiple precursor peptides are isolated at the same time, then this 
can skew the ratios produced.   
 
1.3.4. Isobaric tag for relative and absolute quantification 
The isobaric tag for relative and absolute quantification (iTRAQ) (Figure 1.25) was proposed 
in 2004 as a multiplexing quantification technique.
112
  As with TMT, the iTRAQ label contains 
a reporter group and a balancer group and reacts with primary amines.     
 
Figure 1.25: iTRAQ label consisting of three regions: a reporter group, a balancer group and a 
reactive group which targets primary amines.  Table shows combinations of isotopes used to 
create each reporter group with the relevant balancer group, to make isobaric tags 102,113 
iTRAQ is used as a label after protein digestion, at the peptide level.  Proteins are 
enzymatically digested, and the peptides produced are labelled at the N-terminus (meaning 
all peptides are labelled), with each digest being labelled with a different version of the 
iTRAQ reagent (Figure 1.26).   
Reporter group Balancer group 
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Figure 1.26: iTRAQ strategy for quantitative analysis 
There were four versions of the original iTRAQ reagent allowing the comparison of four 
samples.  As with TMT tags, the iTRAQ labels are isobaric, meaning that they have the 
same overall mass but different combinations of the reporter group and balancer group.  
Each sample is labelled with a different iTRAQ label.  After labelling of the peptides with 
iTRAQ, the solutions are then combined and analysed by LC-MS.  When subjected to 
MS/MS analysis, the reporter group fragments from the peptide to give rise to an ion at m/z 
114-117, depending on the combinations of carbon and nitrogen isotopes used in the 
reporter group.  Quantification is based on the reporter group ions produced on MS/MS (i.e. 
the intensities of the peaks at m/z 114-117), and the peptide is identified through the 
fragment ions also observed in the tandem mass spectrum.
112
   
In 2004, Ross et al. published a paper in which they used iTRAQ labelling to examine the 
global protein expression of a wild-type yeast strain and mutant strains (upf1Δ and xrn1Δ).  
An example tandem mass spectrum is shown in Figure 1.27.   
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Figure 1.27: Example tandem mass spectrum of the peptide TPHPALTEAK from a protein 
digest mixture prepared by labelling four separate digests with each of the four iTRAQ 
reagents and combining the reaction mixtures in a 1:1:1:1 ratio.  (i) isotopic distribution of the 
precursor ([M+H]+, m/z 1352.84), (ii) low mass region showing signature iTRAQ ions used for 
quantification, (iii) isotopic distribution of the b6-ion, and (iv) isotopic distribution of the y7-
ion.  The peptide is labelled at both the N-terminus and C-terminus (lysine side-chain).  The 
precursor ion and all internal fragment ions (e.g. b- and y-ions) contain all four members of 
the tag set, but remain isobaric.112   
The group found that with both of the mutant strains, there was an increase in expression of 
a common set of proteins which are involved in amino acid biosynthesis and general 
nitrogen metabolism.  However, they found that there were differences between the two 
mutant strains in terms of protein down-regulation: the upf1∆ strain showed down-regulation 
of proteins involved in DNA replication and RNA transcription, whereas the xrn1∆ strain 
showed down-regulation of proteins involved in the translation process (e.g. ribosomal 
proteins).
112
   
An 8-plex version of the iTRAQ reagent (Figure 1.28) has also been developed (and is 
commercially available) where eight samples can be analysed in a single experiment.
114
  
The reporter group masses are 113-119 Da and 121 Da (there is no reporter group mass at 
120 Da due to potential contamination from phenylalanine immonium ions in the MS/MS 
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spectrum).
114
  Pierce et al. published a paper in 2008 detailing the 8-plex iTRAQ reagents, 
and demonstrated their use by comparing the activity of six oncogenes - all leukemogenic 
tyrosine kinases.
114
  Initially, the group used a defined mixture to show that the 8-plex 
reagent was capable of detecting differences in peptide levels between two samples, in line 
with the 4-plex strategy.  They then went on to analyse the six oncogenes by several 
methods: iTRAQ, exon array, QTPCR and western blotting.  There was good agreement 
between the results of the different analytical methods.   
8-plex iTRAQ was also used by Ow et al. in 2008 for a shotgun proteomics experiment 
investigating enriched heterocysts from Nostoc sp. PCC 7120.
115
  They used the 8-plex 
iTRAQ strategy to simultaneously analyse four replicate phenotypical families in one 
experiment, rather than having to use multiple 4-plex reagent kits, which is highlighted in the 
paper as allowing an increase in throughput and reduction in experimental and mass 
spectrometry analysis time.
115
   
 
Figure 1.28: 8-plex iTRAQ label consisting of three regions: a reporter group, a balancer group 
and a reactive group which targets primary amines 
The fact that multiple samples can be analysed at the same time is a great advantage of 
iTRAQ and TMT.  There is also the advantage that all peptides are labelled at the N-
terminus, which means that iTRAQ and TMT are less of a specific labelling strategy than 
ICAT, which only labels cysteine residues.  This means that greater coverage of the peptide 
can be observed, and can also lead to several peptides being used to generate a 
quantification ratio for one protein, which can improve quantification accuracy.   
The iTRAQ and TMT reagents are quite expensive, and it is difficult to detect PTMs and 
protein degradation, due to analysis occurring at the peptide level.
102
  An additional concern 
is the fact that the tags are not suitable for analysis on all mass spectrometers.  For 
example, the signature masses for iTRAQ at 114 to 117 Da can lie out of the range of the 
instrument, as can happen with an ion trap instrument when operated in MS/MS mode.
102
  
There has been much information published on ratio under-representation of fold change 
observed when using iTRAQ.
116,117
  Isotopic impurities, interference of immonium ions 
derived from peptide fragmentation and peptide co-fragmentation due to mixed MS/MS on 
Reporter 
group 
Amine reactive 
group 
Balancer group 
Chapter 1: Introduction 
61 
 
fold change were evaluated by Ow et al. as possible reasons for underrepresentation of fold 
change.
116
  The problem of co-isolation with the isobaric-reagent labelled peptide ion was 
discussed by Christoforou and Lilley in 2011.
118
  Here they presented the strategies 
developed by two groups to counter this issue.  Ting et al. almost completely eliminated ratio 
distortion due to co-isolation through the use of MS
3
.
119
  The group used 6-plex TMT 
reagents to model a two-proteome peptide mixture sample.  Yeast peptides were labelled 
with all six TMT reagents, and combined to give a range of ratios between 2.5:1 and 10:1, 
whilst HeLa peptides were labelled with three of the TMT reagents and combined to give a 
1:1:1 ratio.  A variety of methods to try and reduce interference were investigated: estimation 
of the extent of interference based on data from full scan spectra; sample fractionation; 
reduction of the precursor ion isolation width; and MS
3
 data acquisition.
119
  They found that 
the best method to reduce interference was to perform an MS
3
 analysis, and that even 
though fewer peptide and protein identifications were made compared with MS
2
 analysis, the 
quality of the quantification data justified this loss in analytical depth.  A target ion was 
selected for CID MS
2
 analysis, with the resulting data used for peptide-ion identification.  
The most intense MS
2
 fragment ion was then selected for MS
3
 analysis to yield the 
quantification data in the resulting spectrum.  This MS
3
 strategy was found to reduce 
interference with the TMT reporter ions when performing quantification.   
Wenger et al. published an alternative approach to address the issue of co-isolation: 
‘QuantMode’.
120
  Here, a variety of methods was also investigated to reduce the problem of 
co-isolation interference: narrowing the precursor ion selection width; data filtering after 
acquisition; and a real-time filtering approach to ensure suitably uncontaminated ions were 
analysed.
120
  Ultimately, the group decided upon a method whereupon once a precursor ion 
is selected, it undergoes charge reduction through proton-transfer ion-ion reactions.  If there 
were two precursor ions at m/z 500 (with different charge states (e.g. one with +2 and the 
other with +3)), then through proton-transfer ion-ion reactions these would become m/z 999 
(now +1 charge state) and m/z 749.5 (now +2 charge state).
120
  The two ions now have 
different m/z values, and therefore isolation of m/z 999 would result in isolation of only one of 
the original two precursors.  The group devised the ‘QuantMode’ scan function in order to 
implement this process.  Of the two approaches suggested by Ting et al. and Wenger et al., 
Christoforou and Lilley summarise that the approach presented by Ting et al. is perhaps the 
most intuitive and (currently) easier of the two to implement.
118
   
 
1.3.5. Acid-labile isotope-coded extractants 
The acid-labile isotope-coded extractants (ALICE) tag was described by Qui et al. in 2002 
(Figure 1.29) and is a tag (which reacts with cysteine-containing peptides) attached to a non-
biological polymer bead.
121
  Capture of the peptides on the resin takes place at a neutral pH 
(pH 7.0-7.5), before cleaving the peptide and ALICE tag from the resin using a mild 
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acidolysis reaction.
107
  The tag itself consists of a thiol-reactive group which reacts with the 
cysteine side chain, a linker chain which contains the chemical label element of the tag, and 
an acid-labile group which connects the tag to the cross-linked polymer bead.   
 
Figure 1.29: ALICE chemical structure (X=H (light), X=D (heavy)) with three regions: reactive 
group, linker chain and acid-labile functionality  
Two aliquots of a protein mixture are digested; one is reacted with the light ALICE tag and 
the other with the heavy ALICE tag.  The two ALICE-tagged digests are then mixed.  The 
tagged peptides can be extensively washed, in order to remove untagged peptides, and then 
cleaved from the resin by mild acid-catalysed elution and subjected to LC-MS.  Relative 
quantification is possible with the ALICE tag by calculating the relative peak heights of 
peptides labelled with the heavy and light tags.
121
  An example CID spectrum of a peptide 
containing three cysteine residues labelled by ALICE is shown in Figure 1.30.   
 
Figure 1.30: Example tandem mass spectrum of a BSA peptide with three cysteine residues 
(CCAADDKEACFAVEGPK) labelled with the light ALICE label121 
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One of the main advantages of the ALICE tag is the fact that only derivatised peptides are 
present in the mass spectrometric analysis.  Peptides that have not been labelled are 
washed away prior to cleaving of the tagged peptides from the resin, which should simplify 
the mass spectrum obtained.   
However, the cysteine-specific nature of the tag means that a small subset of peptides from 
the protein are analysed, which can hinder the identification of the protein.  This may be the 
reason that there is little evidence to suggest that the ALICE labelling strategy has been 
adopted by the proteomics community for routine use.   
 
1.3.6. Dimethyl labelling 
Dimethyl labelling uses reductive amination to label the primary amino group at the N-
terminus of the peptides and in the side chain of lysine residues.  It was first proposed by 
Hsu et al. in 2003 as a global labelling strategy and is described as a reliable, cost-effective 
and undemanding labelling strategy.
122,123
  The labelling process increases the peptide mass 
by 28 Da from the unlabelled peptide when formaldehyde is used (light), and by 32 Da when 
deuterated formaldehyde is used (heavy) (Figure 1.31).  The method is described as a 
relative quantification method, as the ratio between the intensities of the peaks for the light- 
and heavy-labelled peptide pairs can be compared.  Hsu et al. performed dimethyl labelling 
on a standard protein mixture containing ovalbumin, bovine serum albumin and myoglobin to 
demonstrate the method was applicable for quantitative proteomics.  Solutions of the three 
peptides were labelled with either the light or heavy formaldehyde labels and combined to 
give heavy/light ratios of 2.5:1 (ovalbumin), 1:1 (bovine serum albumin) and 0.25:1 
(myoglobin) for LC-MS analysis.  The experimental results were in good correlation with the 
prepared ratios.   
 
Figure 1.31: Dimethyl labelling strategy developed by Hsu et al. (X = H (light) or D (heavy))122 
In 2009, a paper by Boersema et al. described a multiplex dimethyl labelling strategy, which 
introduced another version of the dimethyl label including 
13
C and D in the formaldehyde, 
and D in the sodium cyanoborohydride (Figure 1.32).
123
  They described a number of 
strategies which could be used for labelling: in-solution, online and on-column.  In each of 
the strategies, the labelling was complete within 60-90 minutes.   
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Figure 1.32: Labelling schemes for triplex isotope dimethyl labelling (R = remainder of 
peptide) 
In 2014, Wu et al. published a paper which proposes a five-plex isotope dimethyl labelling 
system, with a mass difference of 2 Da between the different isotopic labels (Table 1.1).
124
   
Table 1.1: The combination of different isotopic reagents used for the five-plex dimethyl 
labelling system 
Label 1 2 3 4 5 
Formaldehyde isotope H2CO H2CO D2CO D2CO D2
13
CO 
Cyanoborohydride isotope NaBH3CN NaBD3CN NaBH3CN NaBD3CN NaBD3CN 
∆Mass (Da, one active site) 28.0313 30.0439 32.0564 34.0690 36.0757 
 
The group demonstrated the feasibility of the five-plex strategy in proteome and 
phosphoproteome quantification of HeLa cell samples.  They showed that high quantification 
accuracy could be obtained, although the quantification rates (quantified number/identified 
number) were lower for the five-plex labelling strategy (~78%) than the conventional 
dimethyl labelling strategies (>90%).
124
  However, the authors contend that it is still better to 
run one five-plex experiment than two or three conventional experiments.   
Dimethyl labelling has the advantages of being relatively quick and of using cheap reagents.  
The N-terminus of every peptide will theoretically be labelled, which can increase the 
sequence coverage
125
 when compared with a labelling strategy such as ICAT which only 
targets cysteine-containing peptides.  There is also the fact that multiple labels can be added 
if the peptide contains a lysine residue, which creates a larger mass difference between the 
Chapter 1: Introduction 
65 
 
light and heavy labelled peptides, which in turn reduces the chance of isotopic envelopes 
overlapping in the mass spectrum.   
A disadvantage to the dimethyl labelling strategy is the fact that separation of deuterated 
and non-deuterated forms of isotopically substituted compounds on chromatography is well-
known to occur.  This could be problematic when the samples are analysed by LC-MS, as a 
slight difference in retention times for the light formaldehyde and heavy formaldehyde 
labelled peptides is likely to be seen, which could affect the ability to perform quantification.  
Hsu et al. noted a negligible retention time shift when the authors first proposed the idea of 
dimethyl labelling; however they only looked at one labelled tryptic peptide from a BSA 
digest, which may not have been representative of all the peptides analysed in their 
experiment.
122
  Boersema et al. proposed that the reason for chromatographic separation of 
hydrogen and deuterium containing peptides may be due to the higher hydrophilicity of 
deuterium over hydrogen, meaning that the deuterium-labelled peptides travel through the 
column faster than the hydrogen-labelled peptides (if reversed phase LC is used).
123
  
Boutilier et al. have also studied the chromatographic behaviour of peptides following 
dimethylation with light and heavy formaldehyde.
126
  The authors observed a statistically 
significant separation of dimethylated peptides, with the deuterium-labelled peptides eluting 
before the hydrogen-labelled peptides.  However, they concluded that the separation was 
inconsequential in relation to peptide quantification in terms of point measurements, and that 
the dimethyl labelling strategy is suitable for quantitative proteomics.   
 
1.3.7. N,N-Dimethyl leucine 
N,N-Dimethyl leucine (DiLeu) labelling involves the labelling of peptide amine groups (i.e. 
the N-terminus and lysine residues).  It was first proposed as a 4-plex chemical labelling 
strategy by Xiang et al. in 2010.
127
  The tag consists of an amine reactive group, a balance 
group and a reporter group (Figure 1.33).   
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Figure 1.33: General structure of the DiLeu chemical label (* indicate labels in the 115 
(smallest) label) 
Quantification is based on the relative intensities of the reporter ions (m/z 115 – 118) in the 
tandem mass spectra.  Xiang et al. compared the labelling efficiency and quantification 
capabilities of DiLeu labelling with those of the commercially available isobaric tag iTRAQ.
127
  
Their work showed that the DiLeu labelling strategy produces a comparable performance to 
iTRAQ.   
The advantages of the labelling strategy are the fact that the labels are synthetically simple, 
there is high labelling efficiency and improved fragmentation efficiency.
127
  Another big 
advantage of the DiLeu label over the commercially available isobaric tags iTRAQ and TMT 
is the fact that it is much cheaper to perform a quantification experiment with DiLeu than with 
iTRAQ or TMT.
127
  The group have also developed 8-plex
128
 and 12-plex
129
 versions of the 
DiLeu labels.   
 
1.3.8. 18O oxygen incorporation 
18
O can be incorporated into peptides at the carboxyl terminus by enzymatic digestion of the 
protein in the presence of H2
18
O (Figure 1.34).  One protein mixture is digested in the 
presence of normal 
16
O-water, and another is digested in the presence of 
18
O-water.  The 
two samples are then combined for mass spectrometric analysis.  The addition of the 
18
O 
leads to an increase of either 2 or 4 Da (one or two 
18
O).
102
   
* * 
* 
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Figure 1.34: Reaction scheme for the incorporation of 18O during proteolytic digestion using 
labelled water  
The small mass difference can lead to a quantification issue as the mass of the peptides 
increases: the larger the mass of the peptide, the more complicated the isotopic distribution 
becomes, and so an overlap can occur between the isotopic envelopes of the light- and 
heavy-labelled peptides.  An algorithm can be used to identify the proportions of the peaks 
which belong to the light- and heavy-labelled peptides when overlapping isotopic 
distributions are observed in the mass spectrum.  The main advantage of this technique is 
that the two versions of the peptide do not suffer any of the effects previously mentioned 
upon chromatographic separation, such as retention time shifts.  The labelling procedure 
itself is fairly straightforward, which also promotes its use as a labelling strategy.   
However, there is the possibility of incomplete labelling, or back-exchange of 
16
O and 
18
O, 
which affect the quantification accuracy.
102,107
  Additionally, H2
18
O is an expensive reagent.   
 
1.3.9. Bromine incorporation 
A protein and peptide labelling strategy which is a qualitative, rather than a quantitative one, 
is the incorporation of bromine into proteins and peptides.  The two isotopes of bromine (
79
Br 
and 
81
Br) can be simultaneously incorporated into tags for protein analysis, and proves 
useful due to its characteristic isotopic signature when analysed by mass spectrometry.  The 
incorporation of bromine allows easy identification of bromine-containing species in a mass 
spectrum that can have a very high background from other components.  The incorporation 
of a chemical group or tag can also help improve mass spectrometric response of peptides, 
especially in the presence of impurities that may be present in some ‘real’ samples.  Finally, 
a tag can also help direct fragmentation on CID, or facilitate interpretation of fragmentation 
data from tagged peptides.  Consequently, it has been included in this overview of labelling 
strategies, and also because this work is a very relevant precursor to the new work 
presented in this thesis.
90
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Hudson et al. published a paper in 2012 detailing the preparation and use of two bromine-
containing solid-support N-terminal tagging strategies (Figure 1.35).
90
  Unlike most solid 
support labelling strategies, the authors looked to perform labelling and cleavage of the 
tagged peptide in a single step.  This simplifies the workflow for peptide tagging, which is an 
advantage of the technique, as it reduces the number of stages required in order to obtain 
tagged peptide, and therefore possible sample loss etc..  The tagging construct consists of a 
divinylbenzene cross-linked polystyrene solid-support, a linker and the analytical tag.  The 
main advantage of this technique is the fact that unreacted tag and by-products bound to the 
resin are removed by filtration, resulting in simple preparation for analysis by mass 
spectrometry.
90
  However, there was an issue with the sensitivity of the approach, as the 
lower limits of detection (approximately 4 µg of single peptide, in this instance leucine 
enkephalin)
90
 are well above the amount of each peptide which would typically be available 
in a proteomic digest, which could be expected to contain nanograms to milligrams total 
protein.
3
   
 
Figure 1.35: Bromine-containing solid-support N-terminal tags  
In 2012, Song and Kim described the N-terminal bromoacetylation of peptides, and the 
subsequent sequencing by MALDI-MS, by reacting the N-terminus with bromoacetic 
anhydride.
130
  The authors were able to selectively label the N-terminus over the lysine side 
chains by controlling the pH of the reaction.  They found that the b-ions contained the 
bromine tag, but not the y-ions, which facilitated de novo sequencing of peptides (Figure 
1.36).   
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Figure 1.36: Tandem MALDI mass spectra from the peptide WHWLQLKPGQPMY (a) before 
bromoacetylation and (b) after bromoacetylation.  The Br-tag was only observed in the b-ion 
series.130 
 
1.3.10. Summary  
There are many different labelling strategies possible for proteomics work, most, but not all, 
of which have been designed to enable relative or absolute quantification.  Each has its own 
advantages and disadvantages, which have been summarised in Table 1.2.  The 
commercially available chemical labels, such as iTRAQ and TMT, are well established for 
quantitative proteomics analyses.  Labelling strategies which are not commercialised, such 
as dimethyl labelling, are discussed as part of the development of the work in this thesis 
(see Chapter 5 for further discussion).   
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Table 1.2: Summary of labelling methods, developed from the table by Boersema et al.123 
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1.4. Self-assembled monolayers  
In 1946, a paper published by Zisman, Pickett and Bigelow described the formation of a film 
on a clean metal surface by adsorption.
131
  However, the importance of this discovery was 
not recognised for many years.  In the 1980s, research into self-assembled monolayers 
(SAMs) accelerated, and discoveries in the next 15 years resulted in the use of many SAMs 
in varying applications.
132
  The following section is thus not a comprehensive review of SAM 
chemistry, but instead focuses on the biological and analytical applications of SAMs   
In its simplest embodiment, a self-assembled monolayer is an organised layer of molecules, 
and arises by the spontaneous arrangement of molecules on a surface by adsorption.
133
  
The composition of the molecules used means that SAMs have a unique combination of 
physical and chemical properties.  Each molecule in a SAM contains a head group, a spacer 
group and a terminal group (Figure 1.37).   
 
Figure 1.37: Generic structure of a SAM 
The head group has a high affinity for the solid surface substrate (e.g. sulfur has a strong 
affinity for gold
134
).  The initial part of the self-assembly is the rapid reaction between the 
head group and the substrate, forming a bond between the two.  The organisation of the 
terminal groups then follows over a slower period of time.  This self-ordering of the terminal 
functional groups creates a high degree of organisation in SAMs.  The degree of order within 
the SAM is due to factors such as electrostatic and dipole-dipole interactions, and affinity of 
the head group for the substrate.
133
  The terminal group extends beyond the spacer groups, 
and therefore plays a large part in how the SAM reacts with the external environment.  The 
terminal groups do not need to be solvated in order to react.
133
  This is unusual, and means 
that the terminal groups can be reacted either with a solution or a gas-phase reagent.
133
  
The first reported example of a gas-phase reagent reacting with a SAM was published by 
Sun et al. in 1991, where they reported the reaction between surface-confined 4-
Terminal group 
Spacer group 
Head group 
Substrate 
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hydroxythiophenol and 4-aminothiophenol with gaseous dimethyloctylchlorosilane (Figure 
1.38).
135
   
 
Figure 1.38: Gas-phase reagent reacting with a SAM135 
There are many advantages to using SAMs; they are easy to prepare; they can be used as 
building blocks for a more complex structure (usually confined to the solid surface); and the 
surface properties can be changed by modification of the molecular structure.
136
  The most 
commonly used terminal groups for surface reactions are carboxyl, amino or hydroxyl 
groups.
133
   
Defects and pinholes can arise within a SAM structure, which have a detrimental effect on 
the SAM.  These defects can arise from SAM formation on a surface with defects, the length 
of the spacer group and the conditions used to prepare the SAM.
137
  It is also possible for 
reagents or by-products to adhere to the substrate, causing defects. 
The field of self-assembled monolayers is vast, with many different applications.  These 
include electrochemistry
138
, DNA binding
138,139
 and chemical sensing
139,140
.  Due to the 
nature of the work discussed in this thesis, the applications focus for this introduction to self-
assembled monolayers is on SAMs in relation to biological applications.   
SAMs have been used for many years to provide a model system for studying protein 
interaction with organic surfaces.  One such example was published in 1991 by Prime and 
Whitesides, in which they used combinations of five alkanethiols, and monitored the 
adsorption of five proteins (ribonuclease A, pyruvate kinase, fibrinogen, lysozyme and 
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chymotrypsinogen) on prepared SAMs.
141
  The five structures used were a mixture of 
hydrophilic and hydrophobic alkanethiols, thus allowing the formation of mixed SAMs.  They 
found that protein adsorption was lowest for SAMs which contained high concentrations of 
the hydrophilic alkanethiols.   
SAMs have been used to capture peptides and can be engineered to prevent the non-
specific adsorption of peptides or proteins on surfaces.
142
  This is through the inclusion of 
polyethylene glycol (or oligoethylene glycol) in the spacer groups.  There are several 
theories which have been proposed to explain why polyethylene glycol groups prevent 
protein adsorption.  Jeon et al. theorised that as a protein approaches the polyethylene 
glycol groups by diffusion, van der Waals attraction between the polyethylene glycol groups 
and protein dominates.
143,144
  As the protein further approaches the polyethylene glycol 
layer, the polyethylene glycol chains compress, which increases the surface density of the 
polyethylene glycol layer leading to repulsion of the protein.
144
  The more polyethylene glycol 
groups there are in the polymer (at least three), the greater the ability to resist protein 
adsorption.
145
  In 1991, Jeon et al. studied the in silico theoretical experimental interaction 
between a model polyethylene glycol with a hypothetical ‘protein’ of infinite size (with the 
SAM substrate being in water).
143,144
  The group theorised that as a protein approaches the 
terminal polyethylene glycol chains, the protein is prevented from reaching the substrate 
surface due to a combination of steric repulsion, van der Waals forces and hydrophobic 
interaction.  The polyethylene glycol chains compress (proposed to be due to the 
approaching protein causing the chains to start to flatten) causing a loss of entropy due to 
the limited configurations accessible to polyethylene glycol.  This loss of entropy means that 
compression is disfavoured and steric repulsion occurs, so hindering protein adsorption.  
Ultimately, the theory summarises that surface-bound polyethylene glycol groups prevent 
protein adsorption due to the high conformational freedom of the chains and the entropy of 
the solvated PEG chain at the surface.  The group summarised that the higher the surface 
density and the longer the chain length of the polyethylene glycol groups, the better 
resistance to protein adsorption was observed.
144
  These findings have been corroborated 
by others, such as Michel et al. who published a paper in 2005 detailing the influence of 
polyethylene glycol architecture on protein adsorption and conformation.
146
    
Whitesides et al. surmised that there is a tightly bound layer of water at the interface 
between the SAM and the surrounding solution.
147,148
  Functionalities which can act as 
hydrogen bond acceptors (such as polyethylene glycol) are efficient at resisting protein 
adsorption, which is thought to be due to their ability to bind water molecules.
148
  In contact 
with water, ethylene oxide chains are self-avoiding.
149
  Prime and Whitesides concluded that 
any chain length for the polyethylene glycol groups (even as small as one unit) is enough to 
prevent protein adsorption, but that the longer the chain, the more effectively the surface can 
be covered, and therefore the less dense the polyethylene glycol chains need to be.
147
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The biological applications of SAMs include the use of SAMs for enzyme-substrate 
reactions
150,151
, carbohydrate chemistry
152,153
 and biomolecule immobilisation
154
.   
There have many been publications which have looked at enzyme-substrate reactions, with 
the incorporation of SAMs.  Halling et al. reviewed the understanding of enzyme action on 
immobilised substrates (although there are also examples of enzymes being immobilised on 
a solid phase, and the substrate being in solution).
151
  Substrates are attached to a solid 
phase, meaning that the enzyme must migrate to the substrate sites.  The paper discusses 
an increasing interest in automated synthesis and screening protocols, solid supported 
chemistry (with enzymes potentially being used for selected steps in a solid-phase 
synthesis) and biochemistry as potential reasons for the increased interest in studying these 
types of systems.   
In the most cited example of carbohydrate-based SAM technology, Houseman and Mrksich 
detailed a chemical strategy for preparing carbohydrate arrays and the use of these in 
subsequent substrate-protein interaction studies.
152
  The authors prepared chips containing 
carbohydrate arrays, which were then used to study the interaction of the carbohydrates with 
proteins and enzymes.  The arrays were incubated with bovine β-1,4-galactosyltransferase.  
The substrates were then incubated with rhodamine-labelled lectins from either E. cristagalli 
or B. simplicifolia I.  Fluorescence imaging of the arrays revealed substrate specificity of the 
enzyme, and demonstrated the use of carbohydrate arrays for characterising enzymatic 
activities towards carbohydrate substrates.  The advantages of this technology were 
described as the ability to immobilise carbohydrates on a chip in order to participate in 
binding interactions with proteins and enzymes, the prevention of non-specific adsorption of 
proteins on the SAM substrate, and the high yields and excellent selectivity of the arrays 
towards immobilisation.
152
  Houseman et al. published a paper in 2003 detailing the use of 
maleimide-functionalised SAMs for the preparation of peptide and carbohydrate biochips.
153
  
In 2012, Tantakitti et al. published a paper in which the authors created a variety of SAMs 
featuring carbohydrate thiols and oligoethylene glycol thiols.
155
  Pure and mixed SAMs were 
formed, with the resulting SAMs monitored over a period of time.  The authors concluded 
that the components of the mixed SAM segregated into increasingly pure and ordered 
domains over time.   
Wagner et al. published a paper which looked at the covalent immobilisation of native 
biomolecules on SAMs, with the purpose of capturing amino group-containing biomolecules 
on surfaces via functionalised SAMs.
154
  A variety of molecules including amino acids and 
model proteins were captured on the SAM.  The group studied the resulting products by 
scanning tunnelling microscopy (STM) and atomic force microscopy (AFM), and found that 
SAMs on gold surfaces could provide tools in a number of nanotechnological applications 
(e.g. biosensing).   
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Houseman et al. published a paper detailing the use of peptide chips for the quantitative 
evaluation of protein kinase activity.
156
  A kinase substrate (AcIYGEFKKKC-NH2) was 
immobilised on an alkanethiolate-derived SAM, to reduce the need for blocking procedures 
used for peptide and protein chip assays.  Phosphorylation of the peptide by c-Src kinase 
was monitored using phosphorimaging.  SAMs have also been used as a means of 
immobilising antimicrobial peptides for study.
157,158
  Humblot et al. published a paper 
detailing the immobilisation of antimicrobial peptide amines on activated carboxylic acid 
groups on the SAM, with the aim to demonstrate antimicrobial peptides as an alternative 
antibacterial coating to conventional antibiotics.
158
  The authors found that the inclusion of 
the antibacterial peptides on the SAM reduced the adhesion of three Gram-positive bacteria 
at the surface, whilst the peptides were also still able to kill over 50% of the bacterial cells.   
Gold is often used as a surface for SAM formation due to its limited reactivity, but high 
affinity for sulfur.  Molecules which have a sulfur head group, such as alkanethiols, dialkyl 
sulfides or alkyl xanthates, have been used for the formation of SAMs on gold surfaces.
132
  
One of the first such uses of gold was reported in 1983 by Nuzzo and Allara.
159
  The authors 
experimented with preparing, and structurally characterising, orientated monolayers of 
disulfide-terminated polyfunctional organic molecules with a variety of molecular structures 
on to a zerovalent gold substrate.
159
   
SAMs formed from sulfur head groups can be formed using either thiols or disulfides.  In 
1989, Bain et al. published a paper detailing their study of the formation of SAMs on gold 
using thiols and disulfides.
160
  X-ray photoelectron spectroscopy (XPS) was used to 
determine the composition of the SAM formed.  The XPS spectra of the sulfur bound to the 
surface suggested that both thiol and disulfide species yielded the same species on the 
surface, most probably in the form of a gold thiolate.
160
  The authors found that, although 
there was a preference for the thiol to adsorb to the surface of the gold over the disulfide 
when thiols and disulfides are used simultaneously to form a SAM, there was little difference 
between the SAMs formed from pure thiols or disulfides.  The preference for thiol adsorption 
over disulfide adsorption was summarised to be due to a kinetic phenomenon.
160
  The 
conclusion that there is little difference in the SAMs formed from pure thiols and disulfides 
was due to the fact that the same species were formed on the substrate surface (observed 
by XPS), and the fact the contact angles recorded for the SAMs was largely independent of 
the precursor species used (i.e. a thiol or a disulfide).  In 1994, Biebuyck et al. released a 
further paper which looked at formation of a SAM using solutions containing dialkyl disulfides 
and alkanethiols.
161
  It was found that the SAMs formed were indistinguishable in many ways 
from the two starting materials.  However, they found that a SAM made only from disulfides 
had a lower contact angle than a SAM formed from alkanethiols.  This meant that, due to the 
hydrophobic nature of the SAM, there may have been incomplete SAM formation when the 
disulfide was used, which would increase the hydrophilicity of the surface, and therefore 
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reduce the contact angle.  When the surface with the dialkyl disulfide SAM formed on it was 
submerged in a solution of only alkanethiol, and the contact angle retested, the contact 
angle was indistinguishable from that for the SAM formed from the alkanethiol only.  This 
suggests that a SAM formed from disulfides is not as tightly packed as a SAM formed from 
thiols.   
In 2009, a paper was published investigating the surface processes involved in the 
generation of ions from MALDI-MS analysis of alkanethiolates on a gold surface.
162
  It has 
long been observed that intact, characteristic ions (usually disulfides) are seen in the 
resulting mass spectra.
162
  In this paper, it was proposed that the matrix solution dissolves 
alkanethiols from the SAM, which form disulfide species in solution.  These then co-
crystallise with matrix molecules, and are detected when analysed by MALDI-MS.  Previous 
to the paper, it had been found that direct desorption of alkanethiolate SAM molecules from 
the gold surface led to formation of disulfides in the mass spectrometer vacuum.
162
  The 
topic of gold-immobilised SAMs is discussed in more detail in Chapters 2 and 3.   
 
1.5. Aims of this thesis 
Most proteomic chemical labelling strategies, such as iTRAQ
112
 and TMT
108
, are carried out 
in solution.  It is also possible to label peptides using a labelled solid-support,
121,163,164
 
although this approach has been less well explored.  This is likely to be due to the numerous 
steps required to obtain labelled peptides: immobilisation of a label on the solid phase, 
capture and subsequent cleavage of the derivatised peptides from the solid phase.  Work by 
Hudson et al. showed a labelling strategy using a solid phase, whereby the peptide cleaved 
the label from the solid phase during the labelling step.
90
  The overall aim of the work in this 
thesis was to work towards developing a relative quantification proteomics technique for 
application to single protein digests; through the miniaturisation and localisation of a bottom-
up proteomics workflow, so that everything except protein digestion takes place on a gold-
coated MALDI chip.  The gold-coated MALDI chips can be reused for a number of 
experiments, after cleaning.  The strategy aims to provide simultaneous peptide capture and 
labelling with minimal sample manipulation and in situ mass spectrometric analysis.   
This project aimed to investigate a new chemical labelling strategy, initially based on work by 
Hudson et al. using a bromine-containing chemical label,
90
 and work by Flitsch and co-
workers.
150,165,166
  The Flitsch group work involved the synthesis of carbohydrates and 
peptides on self-assembled monolayers and monitoring by MALDI-MS analysis.     
The work may be divided into two strands which are brought together at the very end of the 
thesis: work involving the use of SAMs and work using in-solution dimethyl labelling.   
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The SAM-based work can be broken down further into peptide capture on SAMs on gold-
coated MALDI chips and the subsequent removal of SAMs from the gold-coated MALDI 
chips.  The aim of the peptide capture work was to develop a generic, flexible labelling 
strategy to capture, chemically derivatise and analyse protein digests directly on gold-coated 
MALDI chips.   
In-solution dimethyl labelling was investigated to establish whether quantitative results could 
be obtained, with the ultimate aim being to attempt to adapt the dimethyl label for 
incorporation into the SAM technology.   
Chapter 2 describes the capture of a variety of peptides on a thiol-derived SAM, with and 
without the use of a chemical tag, 4-bromophenylalanine.   
Chapter 3 describes the capture of a variety of peptides, 4-bromophenylalanine and 
phenylalanine on a disulfide-derived SAM.   The aim of the work in Chapter 3 was to 
improve the peptide capture efficiency from that seen in Chapter 2.  Additionally, an 
investigation was undertaken to determine whether the presence of Phe at the N-terminus of 
the peptide reacting with the SAM reduced capture efficiency.   
Chapter 4 describes the use of an alternative technique (plasma treatment) for cleaning 
gold-coated MALDI chips.  The aim of this work was to determine whether treating the wells 
with plasma effluent was an alternative, less corrosive technique which could be used for 
cleaning the gold-coated MALDI chips.   
Chapter 5 describes the application of Boersema’s in-solution dimethyl labelling strategy
123
 
to a set of standard solutions for validation and then it was used to analyse a set of muscle 
protein samples.   
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Throughout Chapter 2, the following terminology will be used to describe the SAM at the 
different stages of the method. 
Terminology Structure 
SAM 
 
Activated SAM 
 
  
 
 
 
 
 
4-BrPhe-tagged SAM 
 
Activated 4-BrPhe-tagged SAM 
 
 
 
 
 
 
  
R = 
 
  
R = 
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Peptide captured on the 
activated SAM 
 
Peptide captured on the 
activated 4-BrPhe-tagged SAM 
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2.1. Introduction  
The capture of peptides on a gold surface for matrix-assisted laser desorption/ionisation 
mass spectrometry (MALDI-MS) analysis is being investigated with the potential specific 
intention of development for application to analysis of single protein digests, for example 
collagen in species identification studies.
167
  The process involved creating a SAM on the 
surface of a gold-coated MALDI chip (Figure 2.1).  This gold-immobilised SAM was modified 
to introduce a chemical tag, on which peptides were captured, and then desorbed and 
analysed when the gold-coated MALDI chip was placed in the MALDI source.   
 
Figure 2.1: 64 well gold-coated MALDI-MS chip 
The Flitsch group has investigated the use of SAMs on gold-coated MALDI chips for the 
SPOT synthesis (synthesis of large numbers of peptides on membrane sheets) of peptide 
libraries
166
 and their evaluation as enzyme substrates.
165,168
  In that work, the thiol-derived 
SAM consisted of two components which terminated in either an alcohol group or a 
carboxylic acid group (HS(CH2)17(OCH2CH2)3OH or HS(CH2)17(OCH2CH2)6OCH2COOH).  
Their SPOT synthesis of peptides on the surface of a gold-coated MALDI chip is 
summarised in Figure 2.2.  Having formed the SAM on the gold-coated MALDI chip, the 
carboxylic acid groups were activated using N-hydroxysuccinimide (NHS) prior to reaction 
with N-Fmoc diaminobutane.  The subsequent removal of the Fmoc protecting group 
revealed the amine functionalised surface, which could be further reacted with Fmoc-
protected amino acids to build a peptide on the surface of the SAM.   
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Figure 2.2: SPOT synthesis of a peptide library using Fmoc-protected amino acids.   
Reagents and conditions: (a) NHS/EDC in DMF (1 h, ambient temperature); (b) 
H2N(CH2)4NHFmoc in DMF (16 h, ambient temperature); (c) 20% piperidine in DMF (10 min, 
ambient temperature); (d) (i) SPOT synthesis (Fmoc-amino acid, PyBOP, DIPEA in DMF then 
20% piperidine in DMF) (ii) 50% TFA, DCM (side-chain deprotection if required) 
The success of the SAM formation, and each subsequent reaction, was monitored by 
MALDI-MS.  The advantage of the on-chip synthesis is that the product does not need to be 
removed from the surface of the gold-coated MALDI chip prior to analysis, as the MALDI 
laser cleaves the immobilised material from the gold surface.  The group synthesised a 
peptide library containing 56 tripeptides (all built on the surface of the SAM), which they 
used to probe the specificity of the protease thermolysin (a protease with a preference for 
cleaving at the N-terminus of hydrophobic residues).  The gold-coated MALDI chip was 
incubated overnight in a solution of the enzyme, to assess whether there was a preference 
for a particular type of peptide, and then analysed by MALDI-MS.  For some of the 
tripeptides, the terminal amino acid residue was cleaved by thermolysin (e.g. GFS, which 
was cleaved to FS).  For other tripeptides, a dipeptide was cleaved by the thermolysin (e.g. 
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SAL was cleaved to L).  Other tripeptides were unaffected by the presence of the 
thermolysin (e.g. GPS).  The results showed the enzyme has a preference for hydrophobic 
and/or aromatic residues.  The major benefits of the work were described as the in situ mass 
spectrometric analysis, the simple workflow with reduced sample manipulation, the 
possibility of multiplexing due to the 64 wells of the gold-coated MALDI chip and the fact that 
the gold-coated MALDI chip can be reused until the gold coating deteriorates.   
This SAM-based technology could have many applications, as has been initially proven by 
the Flitsch group who have demonstrated applications in addition to SPOT synthesis.
165,168
  
One such alternative application would be to adapt the SAM, and incorporate a chemical tag 
for quantitative or qualitative proteomics work.  The use of chemical tags has long been 
established in proteomics work, and there are many variations which can be used, including 
labels for both quantitative and qualitative work.  Collaborative work in the Flitsch and 
Routledge/Thomas-Oates groups identified bromine as a useful chemical label for 
incorporation into a tag for this application (theses
169,170
 and unpublished observations
i,ii
). 
 
                                                          
i
 S. Hudson, University of York 
ii
 R. Castangia, Manchester Interdisciplinary Biocentre, The University of Manchester 
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2.1.1. Aims and overview 
The aim of the work presented in this chapter was to capture a variety of peptides on the 
Flitsch group’s thiol-derived SAM, using an immobilised chemical tag to enable easy mass 
spectrometric identification of peaks associated with peptide captured on the SAM.  A SAM 
was formed on the gold surface, with the carboxylic acid groups subsequently being 
activated for reaction with the chemical tag, 4-bromophenylalanine (4-BrPhe).  The 
carboxylic acid groups then present on the tagged SAM were activated prior to reaction of 
the tagged SAM with a peptide (Figure 2.3).  The activating agents NHS, 2,3,4,5,6-
pentafluorophenol (PFP) and N-hydroxysulfosuccinimide (NHSS) have been tested for 
activating the carboxylic acid group.   
 
Figure 2.3: Schematic representation of the capture of peptides on 4-bromophenylalanine 
tagged thiol-derived SAM 
An investigation into SAM activation inefficiency (and subsequent poor coupling) was 
undertaken using light and heavy labelled buffers.   
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2.2. Formation of a thiol-derived SAM 
A gold-coated MALDI chip was cleaned with piranha solution (3:1 v/v conc. H2SO4:35% 
H2O2) prior to a SAM being formed on its surface.  The two SAM components are alkane 
thiols containing PEG spacers and either a carboxylic acid 
(HS(CH2)17(OCH2CH2)6OCH2COOH) or alcohol (HS(CH2)17(OCH2CH2)3OH) as their head 
group.  The SAM components were each dissolved in DMSO at a concentration of 0.1 
mg/mL, and a 1:4 molar ratio of carboxyl:alcohol terminated groups was created from these 
stock solutions.   
Collaborators investigated the optimum ratio for the carboxylic acid groups to alcohol groups 
for capture of 4-BrPhe and Leu-Enk on the surface of the SAM.
170
  A range of ratios was 
investigated ranging from a SAM being comprised solely of the carboxylic acid component, 
to a SAM being comprised of the carboxylic acid groups diluted 1:10 with the alcohol groups.  
For the 4-BrPhe coupling to the surface of the SAM, it was found that for a SAM composed 
solely of the carboxylic acid component, 4-BrPhe coupling was less effective than when the 
SAM was composed of both the carboxylic acid and alcohol groups.  The optimum ratio was 
found to be between 1:2 and 1:4 (carboxylic acid groups:alcohol groups).  Leu-Enk capture 
on SAM and 4-BrPhe-tagged SAM was also investigated, using the same SAM component 
ratios as for the 4-BrPhe coupling.  In agreement with the results obtained for 4-BrPhe 
coupling to the SAM, the optimum ratio for the carboxylic acid groups and alcohol groups 
was found to be between 1:2 and 1:4.  Capture of Leu-Enk on the 4-BrPhe-tagged SAM was 
found to be improved over the capture of Leu-Enk on the SAM.  This was thought to be due 
to the hydrophobicity of the 4-BrPhe and the Leu-Enk possibly leading to an association of 
the 4-BrPhe and Leu-Enk in solution, increasing the likelihood of a reaction.   
Based on the SAM ratio data, there is an indication that an element of steric hindrance 
occurs for both the 4-BrPhe and the Leu-Enk.  The results show the importance of having a 
mixed SAM, containing both the carboxylic acid groups and the alcohol groups.  The 
presence of the alcohol groups, creating the mixed SAM, increased the percentage of 4-
BrPhe coupled to the SAM compared with starting material when analysed mass 
spectrometrically.  Using this information, it is less likely that with the 1:4 ratio of carboxylic 
acid groups:alcohol groups, the coupling of one 4-BrPhe to the SAM would inhibit the 
coupling of another 4-BrPhe to the SAM.   
Aliquots (0.4 µL) of the 1:4 molar ratio of carboxyl:alcohol terminated groups solution were 
spotted onto the wells on the gold-coated MALDI chip and the SAM was left to assemble 
overnight at ambient temperature (Figure 2.4).  The gold-coated MALDI chip was washed 
with acetonitrile and dried under a stream of nitrogen.   
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Figure 2.4: Formation of the thiol-derived SAM 
The success of the formation of the SAM was assessed by MALDI-MS.  Aliquots (0.3 µL) of 
THAP matrix solution were spotted on wells prior to mass spectrometric analysis.  A typical 
MALDI mass spectrum is shown in Figure 2.5 (peak assignments shown in Table 2.1).   
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Figure 2.5: MALDI mass spectrum of the thiol-derived SAM formed on a gold-coated MALDI 
chip  
As can be seen in Figure 2.5, peaks are observed for a disulfide having two alcohol termini, 
and also for a mixed disulfide having one alcohol terminus and one carboxylic acid terminus 
(Table 2.1).  No peaks were observed for free thiols (data not shown), although there are 
many papers showing that upon MALDI-MS analysis, a combination of thiols and disulfides 
are formed before subsequent detection.
171–175
  In 1998, Trevor et al. published a paper 
detailing an investigation using two-laser mass spectrometry on thiolate, disulfide and sulfide 
SAMs.
171
  SAMs were formed on gold, and studied by nitrogen laser desorption followed by 
vacuum ultraviolet photoionisation of secondary neutrals on a ToF-MS.  The authors found 
that dimers (RSSR
+
) and disulfide ions were the predominant species observed in the mass 
spectra for all alkanethiolates and disulfides studied.  The group found that no monomer ions 
(RS
+
) were formed for linear thiolates.  The group surmised from the data that dimerization 
occurred as a result of the recombination of nearest-neighbour thiolates on the surface, 
followed by intact dimer desorption, rather than recombination in the gas phase.  In 2009, Ha 
et al. published a paper further investigating the MALDI process and SAMs.
162
  SAMs 
decorated with peptides and THAP matrix were subjected to two-laser mass spectrometry.  
The authors proposed that the matrix solution dissolves alkanethiolate molecules from 
SAMs, which results in formation of disulfide species in solution.  The disulfides are then co-
crystallised with matrix molecules and subsequently detected by MALDI-MS.  The group 
found that when methanol was dropped onto a SAM surface, and re-collected after a few 
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seconds, the resulting mass spectrum was almost the same as one recorded directly from 
the SAM, when both areas were spotted with aliquots of matrix solution.  Peaks associated 
with disulfide ions were observed from spectra obtained in both instances, indicating that the 
formation of these characteristic disulfide ions does not occur after laser irradiation.
162
   
Table 2.1: Peak assignment for mass spectrum of thiol-derived SAM formation on a gold-
coated MALDI chip 
Nominal m/z value Assignment 
839 [M+H]
+
 - 2 alcohol termini 
861 [M+Na]
+
 - 2 alcohol termini 
877 [M+K]
+
 - 2 alcohol termini 
1051 [M+Na]
+
 - 1 alcohol terminus, 1 carboxyl terminus 
1067 [M+K]
+
 - 1 alcohol terminus, 1 carboxyl terminus 
1073 [M+2Na-H]
+
 - 1 alcohol terminus, 1 carboxyl terminus 
1089 [M+Na+K-H]
+
 - 1 alcohol terminus, 1 carboxyl terminus 
 
2.3. Investigation into the most suitable matrix 
THAP was used as a MALDI matrix for the experiments described above on the basis of 
work done by others using the same SAM components (S. Hudson
iii
 and R. Castangia
iv
).  An 
independent study was undertaken with non-nucleophilic solvents, and a range of matrices 
(Figure 2.6) to assess whether the optimum matrix was being used for the SAM work.   
A SAM was formed on a gold-coated MALDI chip.  Two separate solutions for the matrix 
molecules, THAP, DHB, CHCA and dithranol (DIT) were prepared, one in acetonitrile and 
one in acetone, with both prepared at concentrations of 15 mg/mL.   
OH
CN
OHO
CHCA
OH
OH
OHO
DHB
CH3O
OHOH
OH
THAP
OH O OH
DIT
 
Figure 2.6: Structures of matrix molecules used for the investigation 
                                                          
iii
 The University of York 
iv
 Manchester Interdisciplinary Biocentre, The University of Manchester 
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Aliquots of each matrix solution were spotted on wells of the gold-coated MALDI chip with 
the SAM formed on them, and the gold-coated MALDI chip was analysed by MALDI-MS.  
The S/N of the peak due to [M+Na]
+
 for a disulfide having two alcohol termini (m/z 861) was 
extracted from each mass spectrum.   
S/N is often used as a general indicator of the quality of a mass spectrum and enables 
comparison between samples prepared in different manners in which the absolute response 
may be affected by the chemical background: a high S/N is indicative of a ‘high quality’ mass 
spectrum (usually in combination with a large number of signals and narrow peaks).
101
  In 
2012, Toh-Boyo et al. published a paper comparing sample preparation methods and 
evaluating intra- and intersample variability in MALDI-MS profiling.
101
  Multiple mass spectra 
were obtained from a MALDI spot containing an E. coli suspension.  Data for absolute signal 
intensity (peak area), S/N and peak resolution from these spectra were extracted.  It was 
found that the overall trends seen when using peak areas and S/N were similar. 
The aim of comparing the different matrices and solvents analysed was to determine the 
appropriateness of each matrix and each solvent.  In order to determine which matrix (and 
which solvent) was most appropriate for the SAM work, a measure which could be 
compared across the differently acquired spectra was needed, as different matrices have a 
particularly dramatic effect on spectral appearance which is why a means of comparing data 
was required.  The S/N of the peak due to [M+Na]
+
 ions was used to give an indication of the 
quality of data generated using the different matrix and solvent combinations for the SAM 
work.   
The mean S/N of the resulting peak in the spectra from eight wells analysed with the same 
matrix and solvent were calculated, and the results summarised in Table 2.2.   
Table 2.2: Matrices and solvents used for the investigation (number of replicates = 8) 
Matrix Solvent Mean S/N of peak 
at m/z 861  
Standard 
deviation 
Coefficient 
of Variation 
/ %  
Matrix 
clusters 
observed 
THAP Acetonitrile 3904.0 1304.42 33.4 No 
Acetone 5311.5 2309.9 43.5 No 
DHB Acetonitrile 286.8 140.9 49.1 No 
Acetone 427.3 273.5 64.0 No 
CHCA Acetonitrile 39.0 25.4 65.2 Yes 
Acetone 41.2 20.8 50.5 Yes 
DIT Acetonitrile 21.7 10.5 48.1 Yes 
Acetone 11.1 4.4 39.8 Yes 
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The term ‘matrix clusters observed’ has been used to refer to when a mass spectrum is 
dominated by a series of peaks due to clusters of matrix molecules, which usually include 
signals from a variety of ionised species (e.g. [M+H]
+
 and [M+Na]
+
).  A repeating pattern is 
observed in the mass spectrum.  These dominant matrix cluster peaks can interfere with the 
signals from peaks associated with the analyte.   
It can be seen that THAP gave a higher average S/N value than the other matrices tested.  
DHB gave a lower average S/N value than THAP.  CHCA and DIT both showed matrix 
clusters, making them unsuitable for use with this work.  This indicates that the most suitable 
matrix to use is THAP.  Either of the solvents could be used with THAP, although acetonitrile 
gave S/N values with a smaller standard deviation and coefficient of variation than acetone.  
Therefore THAP prepared in acetonitrile was used for all further work.  Although the 
standard deviation and coefficient of variation for THAP are large (which may, in part, be due 
to the innate variability observed with MALDI
176
) THAP seems to be the ‘least worst’ option 
in terms of matrix to be used.   
Having determined that THAP was the matrix to be used in future work, different THAP 
concentrations (with acetonitrile as the solvent) and volumes of matrix solution spotted on 
the wells were investigated to determine the impact on the quality of the data obtained by 
MALDI-MS.  A mixed SAM containing the carboxylic:alcohol terminated groups at a 1:4 
molar ratio was formed on the wells of a gold-coated MALDI chip.  The S/N of the peak due 
to [M+Na]
+
 ions (m/z 861) was used to give an indication of the quality of data generated 
using the different concentrations and volumes of matrix solutions.  The mean S/N of the 
resulting peak in the spectra from three replicate wells was calculated, and the results 
summarised in Table 2.3.   
Table 2.3: THAP concentrations and volumes spotted on wells (number of replicates = 3) 
THAP concentration 
/ mg/mL 
Volume / µL 
Mean S/N of 
peak at m/z 861 
Standard 
deviation 
Coefficient of 
variation / % 
5 
1 461.5 76.4 16.6 
0.5 676.0 352.7 52.2 
0.3 283.6 55.5 19.6 
10 
1 285.4 127.7 44.7 
0.5 387.2 149.0 38.5 
0.3 726.2 111.8 15.4 
 
As can be seen in Table 2.3, there is a difference observed, not only between the different 
THAP concentrations, but also between the volumes spotted on the wells.  For 5 mg/mL 
THAP in acetonitrile, the mean S/N was lowest when 0.5 µL of THAP solution was used.  
However, this produced the largest standard deviation and coefficient of variation.  For both 
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1 µL and 0.3 µL volumes of THAP solution, the standard deviations and coefficients of 
variation are much smaller than with 0.5 µL volumes of matrix solution.  For 10 mg/mL THAP 
in acetonitrile, the mean S/N increases as the volume of matrix solution decreases, and the 
standard deviation and coefficient of variation decrease.  Therefore, THAP in acetonitrile at 
10 mg/mL was used for all further work.  A 0.3 µL volume of matrix solution was also used, 
as this gave the best results in terms of mean S/N, standard deviation and coefficient of 
variation compared to 1 µL and 0.5 µL aliquots of matrix solution.   
 
2.4. Peptide capture on a 4-bromophenylalanine tagged SAM 
There are many advantages to the incorporation of a chemical tag.  In the case of 4-BrPhe 
(Figure 2.7), the two isotopes of bromine (
79
Br and 
81
Br) occur in nature in a ratio that is 
roughly 50:50.  The incorporation of bromine (e.g. 4-BrPhe) gives a characteristic isotopic 
distribution when brominated species are analysed by mass spectrometry.   
 
Figure 2.7: L-4-bromophenylalanine 
The isotopic distribution of peaks associated with the SAM species containing one 4-BrPhe 
(i.e. one alcohol terminus and one carboxyl terminus carrying the 4-BrPhe tag) can be seen 
in Figure 2.8.   
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Figure 2.8: Simulated isotopic distribution of peaks associated with [M+Na]+ mixed disulfide 
having one alcohol terminus and one carboxylic acid terminus on which the 4-BrPhe chemical 
tag is incorporated 
As can be seen in Figure 2.8, a very distinctive isotopic distribution is observed following 
incorporation of 4-BrPhe on the SAM.  Therefore, it should be easy to identify signals due to 
bromine-containing tagged peptides produced following capture on the tagged SAM.   
 
2.4.1. Activation of SAM carboxylic acid groups 
Having determined the SAM had formed successfully on the surface of the gold-coated 
MALDI chip, the carboxylic acid groups were activated toward nucleophilic attack by an 
amine.  This was achieved using either PFP and 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) (each at 180 mM), or NHS and EDC (at 25 mM and 100 mM 
respectively), with both sets of reagents being prepared in anhydrous dimethylformamide 
(DMF) (NHS/EDC activation shown in Figure 2.9).  Aliquots (1 µL) (for PFP/EDC: 180 nmol 
of each spotted on a well, for NHS/EDC: 25 nmol of NHS and 100 nmol of EDC spotted on a 
well) of these solutions were left on the wells for an hour before washing the gold-coated 
MALDI chip with acetonitrile and drying it under a stream of nitrogen.   
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Figure 2.9: NHS/EDC activation of the thiol-derived SAM 
 
2.4.2. Coupling of 4-bromophenylalanine to activated SAM  
A 50 mM solution of 4-BrPhe was prepared in DMF:phosphate buffered saline (PBS) (50:50 
v/v), and aliquots (1 µL, 50 nmol of 4-BrPhe) were spotted onto the activated SAM.  The 
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solution was left to react overnight at ambient temperature (Figure 2.10).  The gold-coated 
MALDI chip was washed with acetonitrile and dried under a stream of nitrogen.   
 
Figure 2.10: 4-Bromophenylalanine coupling to the NHS-activated carboxylic acid group 
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The gold-coated MALDI chip was subjected to mass spectrometric analysis to determine 
whether 4-BrPhe had been coupled to the activated SAM.  Aliquots (0.3 µL) of THAP matrix 
solution were spotted on wells prior to mass spectrometric analysis.  A representative mass 
spectrum showing the results of spotting 4-BrPhe on NHS-activated SAM is shown in Figure 
2.11 (peak assignments shown in Table 2.4).   
 
Figure 2.11: MALDI mass spectrum of 4-BrPhe coupled to the NHS-activated SAM 
Peaks were observed at m/z 1276/1278 and 1298/1300, which correspond to a mixed 
disulfide having one alcohol terminus and one carboxylic acid terminus with 4-BrPhe 
coupled to it (Table 2.4).  However, there is incomplete reaction of the 4-BrPhe with the 
SAM, as can be seen by the presence of peaks at m/z 1051 and 1073, which correspond to 
a mixed disulfide having one alcohol terminus and one carboxylic acid terminus (unreacted 
SAM).   
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Table 2.4: Peak assignment for mass spectrum of 4-bromophenylalanine tagged SAM 
Nominal m/z value Assignment 
861 [M+Na]
+
 - 2 alcohol termini 
877 [M+K]
+
 - 2 alcohol termini 
1051 [M+Na]
+
 - 1 alcohol terminus, 1 carboxyl terminus  
1073 [M+2Na-H]
+
 - 1 alcohol terminus, 1 carboxyl terminus 
1276/1278 [M+Na]
+
 - 1 alcohol terminus, 1 CO-4-BrPhe terminus 
1298/1300 [M+2Na-H]
+
 - 1 alcohol terminus, 1 CO-4-BrPhe terminus 
1314/1316 [M+Na+K-H]
+
 - 1 alcohol terminus, 1 CO-4-BrPhe terminus 
 
2.4.3. Activation of 4-BrPhe-tagged SAM carboxylic acid groups 
The carboxylic acid groups on the 4-BrPhe-tagged SAM were activated using PFP/EDC 
(180 mM/180 mM) or NHS/EDC (25 mM/100 mM) in anhydrous DMF for one hour 
(NHS/EDC activation shown in Figure 2.12).  Aliquots (1 µL) of these solutions (for 
PFP/EDC: 180 nmol of each spotted on a well, for NHS/EDC: 25 nmol of NHS and 100 nmol 
of EDC spotted on a well) were left on the wells for an hour at ambient temperature before 
washing the gold-coated MALDI chip with acetonitrile and drying it under a stream of 
nitrogen.   
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Figure 2.12: NHS/EDC activation of the 4-BrPhe-tagged SAM 
  
Chapter 2: Thiol-derived SAM 
100 
 
2.4.4. Capture of single peptides on activated 4-BrPhe-tagged SAM 
Capture of the peptides Leu-Gly-Gly and Gly-Gly-Val was attempted on the activated 4-
BrPhe-tagged SAM (generic reaction shown in Figure 2.13).  Stock solutions of the peptides 
Leu-Gly-Gly and Gly-Gly-Val were prepared at 50 mM in PBS.  From these stock solutions, 
solutions were prepared to enable peptide capture with the peptides at four different 
amounts in 1 µL aliquots: 50 nmol, 10 nmol, 5 nmol and 0.50 nmol in PBS.  These amounts 
are all in excess of the estimated nanomole levels of carboxylic acid groups available for 
reaction: the surface area of a single well on a gold-coated MALDI chip is approximately 3.2 
mm
2
.
169
  If the total density of a SAM on a clean gold surface is taken as approximately 585 
pmol cm
-2
,
154
 the amount of carboxylic acid functionality can be approximated (given that the 
ratio between carboxyl and alcohol terminated thiols is 1:4); this gives an estimate of a 
carboxylic acid level of 3.7 pmol on the surface of each well.   
Aliquots (1 µL) of solution containing peptide were spotted on the activated 4-BrPhe-tagged 
SAM and left overnight at ambient temperature.  The gold-coated MALDI chip was washed 
with acetonitrile and dried under a stream of nitrogen before analysis by MALDI-MS.  
Aliquots (0.3 µL) of THAP matrix solution were spotted on wells prior to mass spectrometric 
analysis. 
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Figure 2.13: Generic reaction of a peptide with the activated 4-BrPhe tagged SAM 
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Table 2.5 shows the expected m/z values for Leu-Gly-Gly and Gly-Gly-Val captured on the 
activated 4-BrPhe-tagged SAM, the amount spotted on the wells, and whether peaks were 
observed in the mass spectrum for peptide captured on the activated 4-BrPhe-tagged SAM.   
Table 2.5: Peptides captured on SAM construct and expected peaks (the product is defined as 
observed if the full isotopic distribution was observed in the mass spectra) 
Peptide Molecular 
mass of 
peptide / 
g mol
-1
 
Expected values of 
[M+Na]
+
 and [M+2Na-H]
+
 
for peptide on 4-BrPhe 
tagged SAM / m/z 
Amount of 
peptide 
spotted on 
well / nmol 
Product 
observed 
Leu-Gly-Gly 
(LGG) 
245 1503/1505 
1525/1527 
50 Yes 
10 Yes 
5 No 
0.5 No 
Gly-Gly-Val 
(GGV) 
231 1489/1491 
1511/1513 
50 Yes 
10 Yes 
5 Yes 
0.5 No 
 
A representative mass spectrum showing the results of spotting 50 nmol of Leu-Gly-Gly on 
the activated 4-BrPhe-tagged SAM spot is shown in Figure 2.14 (peak assignments are 
shown in Table 2.6). 
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Figure 2.14: MALDI mass spectrum of 50 nmol Leu-Gly-Gly spotted on the PFP-activated 4-
BrPhe-tagged SAM (* indicates a PFP-derived impurity (unidentified because product ion 
analysis failed))  
Peaks were observed at m/z 1503/1505 and 1525/1527, which correspond to Leu-Gly-Gly 
captured by the 4-BrPhe tag attached to the carboxylic acid group terminating one chain of a 
mixed disulfide (the other chain contains an alcohol terminus) (Table 2.6).  There were also 
peaks observed for a mixed disulfide having one alcohol terminus and one carboxylic acid 
terminus with Leu-Gly-Gly captured on it (in the absence of the 4-BrPhe tag) (m/z 1278,1300 
and 1316) and for unreacted SAM (m/z 1051 and 1073).  Peaks were not observed for the 
activated SAM.  The peak at m/z 1078 is only observed when PFP is used as the activating 
reagent, but has not been successfully identified.     
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Table 2.6: Peak assignments for mass spectrum of Leu-Gly-Gly captured on activated 4-BrPhe 
tagged SAM 
Nominal m/z value Assignment 
1051 [M+Na]
+
 - 1 alcohol terminus, 1 carboxyl terminus 
1073 [M+2Na-H]
+
 - 1 alcohol terminus, 1 carboxyl terminus 
1278 [M+Na]
+
 - 1 alcohol terminus, 1 CO-LGG terminus  
1300 [M+2Na-H]
+
 - 1 alcohol terminus, 1 CO-LGG terminus 
1316 [M+Na+K-H] - 1 alcohol terminus, 1 CO-LGG terminus 
1503/1505 [M+Na]
+
 - 1 alcohol terminus, 1 CO-4-BrPhe-LGG terminus 
1525/1527 [M+2Na-H]
+
 - 1 alcohol terminus, 1 CO-4-BrPhe-LGG terminus 
 
When the peptide Gly-Gly-Val was captured on the 4-BrPhe-tagged SAM, peaks were 
observed for a mixed disulfide having one alcohol terminus and one carboxylic acid terminus 
with Gly-Gly-Val captured on it, with (m/z 1264 ([M+Na]
+
) and 1286 (M+2Na-H]
+
)) and 
without (m/z 1489/1491 ([M+Na]
+
) and 1511/1513 ([M+2Na-H]
+
)) the 4-BrPhe tag, and also 
for unreacted SAM (m/z 1051 ([M+Na]
+
) and 1073 ([M+2Na-H]
+
)).   
For both Leu-Gly-Gly and Gly-Gly-Val, peaks were observed which corresponded to the 
peptide captured on the activated SAM with and without the 4-BrPhe tag.  This would 
suggest that during the activation of the 4-BrPhe-tagged SAM, untagged SAM was being 
activated, which subsequently reacted with the peptide (peaks were observed for unreacted 
SAM in spectra obtained after 4-BrPhe coupling to activated SAM).  This resulted in peaks 
being observed which are associated with peptide captured on activated untagged SAM.  In 
order to provide a comparison of the two peptide-containing products observed (peptide 
captured on the SAM with and without the 4-BrPhe tag), and therefore get a possible 
indication of the relative amounts of peptide captured on the tagged and untagged SAM, the 
peak intensity for each of the peaks in the isotopic cluster of each cationised species (e.g. 
[M+Na]
+
) was extracted from the data.  The total peak intensity of each of the peaks in the 
isotopic envelope was used due to the fact that peaks due to species including 4-BrPhe are 
split over the two Br isotope-containing species (Figure 2.8).  Peak intensity has previously 
been used as a means of comparing differing SAM-containing species from mass 
spectrometric data by Castangia and Flitsch.
170
   
The idea of using peak intensity for comparing the relative amounts of different ions is well 
accepted with proteomic relative quantification strategies often using peak intensity to 
generate quantification ratios (examples include SILAC
93,103
 and TMT
108
).   
For each spectrum, the extracted peak intensities were entered into Equation 2.1.  A mean 
was then taken for the peak intensity ratio of product:starting material peaks, and plotted 
Chapter 2: Thiol-derived SAM 
105 
 
against the amounts of each of the peptides spotted on the SAM, with and without the 4-
BrPhe tag (Figure 2.15).  This produced a comparison of relative intensities of the peaks 
from the two products formed.    
𝑀𝑒𝑎𝑛 𝑝𝑒𝑎𝑘 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑟𝑎𝑡𝑖𝑜 𝑜𝑓𝑝𝑟𝑜𝑑𝑢𝑐𝑡/𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔 𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙
=
(𝑝𝑒𝑎𝑘 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 + 𝑁𝑎+) + (𝑝𝑒𝑎𝑘 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 + 𝐾+) + (𝑝𝑒𝑎𝑘 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 + (2𝑁𝑎 − 𝐻)+)
(𝑝𝑒𝑎𝑘 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑆𝐴𝑀 + 𝑁𝑎+) + (𝑝𝑒𝑎𝑘 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑆𝐴𝑀 + 𝐾+) + (𝑝𝑒𝑎𝑘 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑆𝐴𝑀 + (2𝑁𝑎 − 𝐻)+)
 
Equation 2.1: Equation used to generate relative intensity ratio of product:starting materials 
 
Figure 2.15: Plot showing ratio between peak intensity of the product and the starting 
material MALDI signals for peptides Gly-Gly-Val and Leu-Gly-Gly on both the SAM and the 4-
BrPhe-tagged SAM (error bars show one standard deviation either side of the mean value) 
(number of replicates = 4). 
As can be seen in Figure 2.15, the relative peak intensity ratios for the signals for the 
peptide captured on the activated SAM that had not incorporated the 4-BrPhe tag are much 
larger than those for the peptide captured on activated 4-BrPhe-tagged SAM.  Of the two 
peptides, Gly-Gly-Val shows the higher peak intensity ratio of product:starting material.   
For the two peptides, the lowest amount of peptide spotted on a well for which peptide 
captured on the activated 4-BrPhe-tagged SAM was observed to be different.  Capture of 
Leu-Gly-Gly was observed at the 10 nmol level on the activated 4-Br-Phe-tagged SAM.  
However, capture of the peptide Gly-Gly-Val was observed at the 5 nmol level on the 
activated 4-BrPhe-tagged SAM.  Both of these are well above the estimated amount of 
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carboxylic acid groups available on the surface of a well (3.7 pmol), suggesting that the 
amount of SAM should not have been limiting. 
In order to determine whether any differences in mean values for peptide captured on 
activated SAM and peptide captured on activated 4-BrPhe-tagged SAM were statistically 
significant, the Mann-Whitney U-test was used.  The Mann-Whitney U-test is a non-
parametric test used to test the median of two populations without the need for the data to 
be normally distributed.
177,178
  A two-tailed U-test is applied when the analyst assumes that 
differences between the data sets can operate in both directions (i.e. either data set may be 
larger than the other).   
In order to perform the U-test, the data from the two groups are ranked from smallest to 
largest, with the smallest being given the rank ‘1’, the next lowest given the rank ‘2’, through 
to the highest number.  The ranks within each group are then summed.  The larger of the 
two rank totals is given the name of TX.  The total number of data entries in each of the 
groups is calculated (N1 and N2), with NX being denoted as the number associated with the 
group with the larger rank total (TX).  These values are then used to calculate the U-value for 
the data set (Equation 2.2).
179
    
𝑈 = 𝑁1 × 𝑁2 + 𝑁𝑋
(𝑁𝑋 + 1)
2
− 𝑇𝑋 
Equation 2.2: Mann-Whitney U-test calculation 
The minimum number of data/scores which are generally accepted for use with the Mann-
Whitney U-test is five within each data set.
179
  Therefore, for small data sets with groups of 
less than five, an indication of the statistical significance can be gleaned, although the 
values should be taken as more of a guide due to the small sample set.   
The Mann-Whitney U-test was used to determine whether any of the differences between 
the mean value for peptide captured on activated SAM and peptide captured on activated 4-
BrPhe-tagged SAM were statistically significant for the different peptide amounts.   
For Gly-Gly-Val: 50 pmol (Mann-Whitney, U = 0, n1 = n2 = 4, P < 0.05, two-tailed); 10 pmol 
(Mann-Whitney, U = 0, n1 = n2 = 4, P < 0.05, two-tailed); 5 pmol (Mann-Whitney, U = 0, n1 = 
n2 = 4, P < 0.05, two-tailed); and 0.5 pmol (Mann-Whitney, U = 0, n1 = n2 = 4, P < 0.05, two-
tailed). 
For Leu-Gly-Gly: 50 pmol (Mann-Whitney, U = 0, n1 = n2 = 4, P < 0.05, two-tailed); 10 pmol 
(Mann-Whitney, U = 0, n1 = n2 = 4, P < 0.05, two-tailed); 5 pmol (Mann-Whitney, U = 3, n1 = 
n2 = 4, P < 0.05, two-tailed); and 0.5 pmol (Mann-Whitney, U = 0, n1 = n2 = 4, P < 0.05, two-
tailed).   
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A Mann-Whitney U-value of ‘0’ is the critical value for data sets containing four values (two-
tailed, P < 0.05).  For seven of the eight data sets the U-value obtained meets the critical 
value for a two-tailed Mann-Whitney U-test where P < 0.05.  Therefore, the differences 
between the mean values obtained for peptide captured on activated SAM and peptide 
captured on activated 4-BrPhe-tagged SAM could be deemed as statistically significant.  
However, in practice, a U-value of less than ‘0’ is not possible.  For Leu-Gly-Gly at 5 pmol, U 
= 3 indicates that there is no statistical significance between the mean values obtained for 
peptide captured on activated SAM and peptide captured on activated 4-BrPhe-tagged SAM.  
However, it is worth repeating that these values should be seen as a guide, and the results 
should be treated with caution due to the small data sets.   
 
2.5. Peptides captured on untagged SAM 
When peptides had been left to react with the activated 4-BrPhe-tagged SAM, peaks 
associated with unreacted SAM and peptide captured on the activated SAM were observed 
in the spectra obtained.  Due to the inefficient coupling occurring between the activated 4-
BrPhe-tagged SAM and the peptide, the efficiency of peptide capture on an activated SAM 
without the addition of the 4-BrPhe tag was investigated.  The smallest amount of peptide 
which could be spotted on the SAM, and peaks observed in the resulting mass spectrum for 
peptide captured on the SAM, was also investigated.  The peptides were captured at levels 
of 50 pmol and 5 pmol.  These levels were chosen because they are closer to the realistic 
amounts which would be available in a typical proteomics experiment.  It would also show if 
peptide capture was successful at lower levels than on the activated 4-BrPhe-tagged SAM.   
 
2.5.1. Activation of SAM carboxylic acid groups 
Having determined the SAM had formed on the surface of the gold-coated MALDI chip, the 
carboxylic acid groups were activated toward nucleophilic attack by an amine using either 
PFP (180 mM) and EDC (180 mM), or NHS (25 mM) and EDC (100 mM), with both sets of 
reagents being prepared in dry DMF (NHS/EDC activation shown in Figure 2.9).  Aliquots (1 
µL) of these solutions (for PFP/EDC: 180 nmol of each spotted on a well, for NHS/EDC: 25 
nmol of NHS and 100 nmol of EDC spotted on a well) were left on the wells for an hour 
before washing the gold-coated MALDI chip with acetonitrile and drying under a stream of 
nitrogen.   
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2.5.2. Peptide capture on activated SAM carboxylic acid groups  
Capture of peptides on activated SAM was performed using the peptides Leu-Gly-Gly, Gly-
Gly-Val, Gly-Pro-Gly-Gly and Thr-Tyr-Ser (generic reaction showing peptide capture shown 
in Figure 2.16).  Stock solutions of the peptides detailed in Table 2.7 were prepared at 50 
mM in PBS.  Subsequent dilutions of the solutions were made to give solutions which would 
result in 50 pmol (0.05 mM) and 5 pmol (5 µM) amounts of peptide being spotted on each 
well in a 1 µL aliquot.  The peptide solutions were spotted on wells and left overnight at 
ambient temperature.  The gold-coated MALDI chip was washed with acetonitrile and dried 
under a stream of nitrogen prior to MALDI-MS analysis.  Aliquots (0.3 µL) of THAP matrix 
solution were spotted on wells prior to mass spectrometric analysis. 
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Figure 2.16: Generic reaction of a peptide with activated SAM 
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Table 2.7: Peptides and amounts used for capture, activating reagent used, expected m/z 
values of product captured on the activated SAM and whether the product was observed (the 
product is defined as observed if the full isotopic distribution of either of the species [M+Na]+ 
and [M+2Na-H]+ was observed in the mass spectra) 
Peptide Molecular 
mass of 
peptide / 
g mol
-1
 
Activated 
SAM 
Amount of 
peptide 
spotted on 
well / pmol 
Expected 
values of 
[M+Na]
+
 and 
[M+2Na-H]
+
 / 
m/z 
Product 
observed 
Leu-Gly-
Gly 
(LGG) 
245 NHS 50 1278 
1300 
Yes 
NHS 5 Yes 
PFP 50 Yes 
PFP 5 Yes 
Gly-Gly-
Val 
(GGV) 
231 NHS 50 1264 
1286 
Yes 
NHS 5 No 
PFP 50 Yes 
PFP 5 Yes 
Gly-Pro-
Gly-Gly 
(GPGG) 
286 NHS 50 1319 
1341 
Yes 
NHS 5 Yes 
PFP 50 Yes 
PFP 5 Yes 
Thr-Tyr-
Ser 
(TYS) 
369 NHS 50 1402 
1424 
Yes 
NHS 5 No 
PFP 50 Yes 
PFP 5 No 
 
Table 2.7 shows that for Leu-Gly-Gly, Gly-Gly-Val and Gly-Pro-Gly-Gly, peaks associated 
with the relevant peptide captured on the SAM were observed by MALDI-MS when wells 
were spotted with 5 pmol of peptide.  For Thr-Tyr-Ser, no peaks were observed for peptide 
captured on the SAM at an amount of 5 pmol for either NHS/EDC or PFP/EDC activation.   
In order to provide a comparison between the different peptides captured on the activated 
SAM, the amount of peptide spotted on the activated SAM and the activating reagent used 
(NHS or PFP), the peak intensity for each of the peaks in the isotopic cluster of each 
cationised species (e.g. [M+Na]
+
) was extracted from the data.  For each spectrum, these 
were entered into Equation 2.1.  A mean was then taken for the peak intensity of each of the 
peptides spotted on the SAM (at each amount) and with both of the activating reagents 
(NHS and PFP).  This produced a comparison of the relative intensities of the peaks from 
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the different peptides captured on the activated SAM and the different activating reagents 
used.  Figure 2.17 and Figure 2.18 show the results for NHS and PFP activation 
respectively.   
 
Figure 2.17: Plot showing the mean ratio of peak intensity for product:starting material 
MALDI signals for each of the peptides with NHS as the activating reagent (Error bars show 
one standard deviation either side of the mean) (number of replicates = 4) 
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Figure 2.18: Plot showing the mean ratio of peak intensity for product:starting material 
MALDI signals for each of the peptides with PFP as the activating reagent (Error bars show 
one standard deviation either side of the mean) (number of replicates = 4) 
With NHS used as the activating reagent, the peptides Leu-Gly-Gly and Gly-Pro-Gly-Gly 
were successfully captured on the activated SAM when 5 pmol of peptide was spotted on 
each well containing activated SAM.  Capture of the peptides Gly-Gly-Val and Thr-Tyr-Ser 
was not observed when 5 pmol of peptide was spotted on each well containing activated 
SAM.   
With PFP used as the activating reagent, the peptides Leu-Gly-Gly, Gly-Gly-Val and Gly-
Pro-Gly-Gly were all successfully captured on the activated SAM when 5 pmol of peptide 
was spotted on each well containing activated SAM.  Capture of the peptide Thr-Tyr-Ser was 
not observed when 5 pmol of peptide was spotted on each well containing activated SAM.   
For both NHS and PFP activation, the mean ratio of peak intensity for product:starting 
material for capture of the peptide Thr-Tyr-Ser is much lower than for the other peptides 
when 50 pmol of peptide was spotted on each well containing activated SAM.  This could be 
indicative of a problem with one of the amino acids in the peptide.  Based on the results 
seen for 4-BrPhe coupling to the activated SAM (Section 2.4), it could be assumed that the 
Tyr amino acid, with its aromatic side chain, is the reason for the low ratio of peak intensity 
for product:starting material.   
Figure 2.17 and Figure 2.18 both show that the peptide with the highest ratio of peak 
intensity of product:starting material is Gly-Pro-Gly-Gly.  For the peptides Gly-Pro-Gly-Gly 
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and Gly-Gly-Val (at 50 pmol), the mean ratio is higher where NHS, rather than PFP, is the 
activation reagent (Figure 2.17).  There have been numerous investigations into the 
susceptibility of activated esters to hydrolysis, where it has been surmised that NHS 
activated esters are more susceptible to hydrolysis than PFP activated esters.
180–182
  
However, due to the higher product:starting material ratio obtained for NHS as the activation 
reagent, NHS was used rather than PFP as the activation reagent for subsequent reactions.   
Due to the non-normal distribution of the data sets, the Mann-Whitney U-test was applied to 
the data, to compare the mean ratio of peak intensity for peptide captured at 50 pmol and 5 
pmol on activated SAM for both NHS and PFP as the activation reagent.  As was the case 
with the data in Section 2.4.4, only four replicates were performed, and therefore the U-
values obtained from the small data sets should be treated as a guide.   
For NHS: Leu-Gly-Gly (Mann-Whitney, U = 0, n1 = n2 = 4, P < 0.05, two-tailed); Gly-Gly-Val 
(Mann-Whitney, U = 0, n1 = n2 = 4, P < 0.05, two-tailed); Gly-Pro-Pro-Gly (Mann-Whitney, U 
= 4, n1 = n2 = 4, P < 0.05, two-tailed); and Thr-Tyr-Ser (Mann-Whitney, U = 4, n1 = n2 = 4, P 
< 0.05, two-tailed). 
For PFP: Leu-Gly-Gly (Mann-Whitney, U = 4, n1 = n2 = 4, P < 0.05, two-tailed); Gly-Gly-Val 
(Mann-Whitney, U = 0, n1 = n2 = 4, P < 0.05, two-tailed); Gly-Pro-Pro-Gly (Mann-Whitney, U 
= 2, n1 = n2 = 4, P < 0.05, two-tailed); and Thr-Tyr-Ser (Mann-Whitney, U = 9, n1 = n2 = 4, P 
< 0.05, two-tailed). 
There is a difference between the U-values obtained when NHS was used as the activation 
reagent compared to PFP as the activation reagent.  More non-zero results were obtained 
for data obtained using PFP than NHS as the activation reagent.  A Mann-Whitney U-value 
of ‘0’ is the critical value for data sets containing four values (P < 0.05, two-tailed).  
Therefore, Leu-Gly-Gly and Gly-Gly-Val captured on activated SAM using NHS as the 
activation reagent, and Gly-Gly-Val captured on activated SAM using PFP as the activation 
reagent meet the critical value for a two-tailed Mann-Whitney U-test where P < 0.05.  This 
implies that, in these three instances, the difference between the mean peak intensity values 
calculated when 50 pmol and 5 pmol of peptide are spotted on activated SAM could be 
deemed as statistically significant.  For Gly-Pro-Pro-Gly and Thr-Tyr-Ser captured on 
activated SAM using NHS as the activated reagent, and Leu-Gly-Gly, Gly-Pro-Pro-Gly and 
Thr-Tyr-Ser captured on activated SAM using PFP as the activation reagent, the difference 
between the mean peak intensity values calculated for the two peptide amounts is greater 
than ‘0’, and should not be deemed statistically significant.   
Levels of peptide capture were successful for a lower amount of peptide being spotted on 
wells containing activated SAM than for wells containing activated 4-BrPhe-tagged SAM 
(Section 2.4).  This could be due to low levels of incorporation of the 4-BrPhe prior to peptide 
capture on the activated 4-BrPhe-tagged SAM, inefficient activation of the SAM (and 
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subsequent activated 4-BrPhe-tagged SAM) or simply an accumulation of inefficient 
chemistry at the different stages of the reaction.   
 
2.5.3. Use of alternative activating reagents and conditions to 
investigate peptide capture on untagged SAM 
Peaks have been observed for species associated with unreacted SAM when peptide 
capture has been attempted on the 4-BrPhe-tagged SAM and the untagged SAM using both 
NHS/EDC and PFP/EDC activation.  Therefore, alternative activating reagents and 
conditions were explored in the hope of improving activation extent, and subsequent 
reactivity of the activated SAM species.  Reviews of coupling reactions have shown a variety 
of coupling reagents have been used for peptide coupling.
183,184
   
NHSS (Figure 2.19) has been used in conjunction with EDC for carboxyl activation due to 
the fact that both are water soluble.
133,185
  The conditions used (Sections 2.4.1, 2.4.3 and 
2.5.1) for activation using NHS/EDC or PFP/EDC in DMF are more suited to the 
solubilisation of the NHS and PFP than the EDC.  This mismatch of solubilities could have 
been a reason for activation inefficiency (and therefore spectra recorded after reaction of 
activated SAM with peptides showing peaks for unreacted SAM).  Therefore, the possibility 
that NHSS is more suited to this work was investigated as a potential way to increase 
reaction efficiency between the carboxylic acid group of the SAM and the activating moiety.   
 
Figure 2.19: (a) N-hydroxysuccinimide and (b) N-hydroxysodiumsulfosuccinimide 
Having prepared a SAM on a gold-coated MALDI chip, a comparison of the efficiency of 
activation using NHSS/EDC (25 mM/100 mM) chemistry or NHS/EDC (25 mM/100 mM) 
chemistry was performed.  For both sets of activation reagents, solutions were prepared 
using two solvent conditions: DMF and acetonitrile/water (50:50 v/v).  This was to provide a 
comparison with previous experiments with DMF, and secondly to use a solvent system 
more compatible with EDC and NHSS (i.e. acetonitrile/water).  Aliquots (1 µL) of the 
solutions (for NHS/EDC: 25 nmol of NHS and 100 nmol of EDC on a well, for NHSS/EDC: 
25 nmol of NHSS and 100 nmol of EDC spotted on a well) were spotted onto individual 
 a b 
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wells, and left for an hour at ambient temperature.  The gold-coated MALDI chip was then 
washed with acetonitrile and dried under a stream of nitrogen.   
The peptides Leu-Gly-Gly and Phe-Gly-Gly were prepared in PBS. Aliquots (1 µL) (5 nmol of 
peptide) were spotted on wells containing SAM and left overnight at ambient temperature.  
The gold-coated MALDI chip was then washed with acetonitrile and dried under a stream of 
nitrogen prior to MALDI-MS analysis.  Aliquots (0.3 µL) of THAP matrix solution were spotted 
on the wells prior to mass spectrometric analysis. 
When analysed, peaks were observed for each of the peptides captured on the SAM.  For 
Leu-Gly-Gly, a peak at m/z 1278 indicated the presence of a disulfide having one alcohol 
terminus and one carboxylic acid terminus with the peptide coupled to it.  For Phe-Gly-Gly, 
the presence of a peak at m/z 1312 indicated a disulfide having one alcohol terminus and 
one carboxylic acid terminus with the peptide coupled to it.  Peaks were observed at m/z 
1051 and 1073, which indicated the presence of a disulfide having one alcohol terminus and 
one carboxylic acid terminus (unreacted SAM).   
For spectra which were obtained using acetonitrile/water as the activation solvent, 
unassignable peaks were observed.  In spectra which were recorded for wells where 
NHS/EDC activation chemistry was used prior to peptide coupling, peaks were observed at 
m/z 1203 and m/z 1225.  In spectra which were recorded for wells where NHSS/EDC 
activation chemistry was used prior to peptide coupling, peaks were observed at m/z 1237 
and m/z 1259.  Upon MS/MS analysis the same product ions were observed at m/z 932 and 
958 for the two different unassigned precursors.  However, no reasonable assignment has 
been made.  The peaks were not observed when DMF was used as the solvent system.  
Therefore, it can be assumed that the formation of these ions was due to the use of the 
acetonitrile/water solvent system.   
One of the reasons for trying NHSS was to increase the solubility of EDC by using a solvent 
more suited to solubilising EDC (acetonitrile/water)
183
 than the DMF used for NHS/EDC and 
PFP/EDC activation.  However, there were unassignable peaks observed in the mass 
spectra recorded after peptide capture when the acetonitrile/water solvent system was used.  
This means that in spite of the theoretical advantage of solubility in acetonitrile and water, in 
practice this solvent system was less practical to use than DMF; the data suggest that a 
side-reaction of some kind is taking place when acetonitrile/water is used.  Therefore, the 
original methodology of NHS/EDC in DMF was used in further work.   
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2.6. Investigation of inefficient activation of carboxylic acid 
group activation for peptide capture 
In spectra obtained after activation of the carboxylic acid groups followed by subsequent 
tagging with 4-BrPhe or peptide capture, peaks were observed in the spectra which 
corresponded to unreacted SAM (m/z 1051 and 1073).  The coupling of the 4-BrPhe and of 
a peptide to the activated SAM is carried out in an aqueous medium, using PBS to prepare 
the 4-BrPhe tag/peptide solution and to control the pH.  There are several potential 
scenarios which could be causing the presence of the peaks associated with unreacted 
SAM.  The activated ester could have been hydrolysed before the tag or peptide could react 
with it which, due to the conditions used for the reaction, would mean trying to react a 
carboxylic acid and primary amine together at room temperature.  The peptide could have 
been captured on the SAM, but then be hydrolysed again during the reaction (the least likely 
option due to the fact that this would involve hydrolysis of an amide).  Finally, the 4-BrPhe 
tag may have not been coupled to the activated ester SAM efficiently in the first place.   
An investigation was undertaken to determine whether, in these aqueous steps, hydrolysis 
of the activated carboxylic acid group could occur, which would convert the activated SAM 
back to the carboxylic acid group, so that it would then not be available to react with either 
the 4-BrPhe tag (Figure 2.20) or the peptide.  This would reduce the efficiency of the 
chemistry by reducing the amount of SAM-based activated ester available for reaction.   
 
Figure 2.20: Proposed hydrolysis of NHS-activated carboxyl SAM 
In order to investigate the potential hydrolysis of the activated ester, an investigation was 
undertaken using H2
18
O-containing PBS.  Parallel control analyses were undertaken using 
H2
16
O-containing PBS for each H2
18
O-containing PBS experiment.  This meant that two gold-
coated MALDI chips were used in parallel: a ‘light/
16
O chip’ and a ‘heavy/
18
O chip’.  For each 
investigation, new gold-coated MALDI chips were used with freshly prepared SAMs.   
For each capture stage, two equal aliquots of PBS were dried down.  An equivalent volume 
of water, either H2
16
O or H2
18
O was then added, to re-dissolve the solid salt.  This created 
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two solutions, prepared in exactly the same way but one prepared in 
18
O-labelled water and 
one prepared in unlabelled water.  
After SAMs were formed on each of the two gold-coated MALDI chips, the chips were 
washed with acetonitrile and dried under a stream of nitrogen.  The carboxylic acid groups, 
onto which tag would be captured, were activated using either NHS or PFP in anhydrous 
DMF, with EDC as the coupling reagent.  Although PFP had previously been found to be 
less suitable for the activation of the SAM (due to the lower peak intensity ratio obtained for 
peptide captured on the untagged SAM), it was included in this investigation, to determine 
whether there was a preference for the theorised hydrolysis of one activated ester over the 
other.  The activation solution was left on the wells for an hour, before being washed off and 
dried under a stream of nitrogen.  The activated esters were then further reacted with either 
4-BrPhe or a simple tripeptide.   
Following mass spectrometric analysis, the peak intensity values for each of the peaks 
associated with the unreacted SAM were extracted from the spectra.  The ratio of peak 
intensity for [M+2]:M peaks was calculated for each of the isotopic peaks for each of the 
cationised unreacted SAM species (m/z 1051, 1073 and 1089) observed in the mass spectra 
for each well.  The mean of the ratios for all of the cationised species was then taken for 
each well.  Finally, the mean for all the wells was taken.  A comparison was then made 
between the ratios obtained in unlabelled buffer and 
18
O-labelled buffer.   
Incorporation and detection of 
18
O into the carboxylic acid group of the SAM was 
investigated by Roberto Castangia during the course of his PhD.
170
  The carboxylic acid 
group was activated using NHS, before H2
18
O was spotted on wells containing the activated 
SAM, and left overnight.  Upon MALDI-MS analysis, incorporation of the 
18
O into the 
carboxylic acid groups was clearly visible in the resulting mass spectra.  Since this positive 
control experiment had already been carried out and 
18
O incorporation successfully 
demonstrated in this system, this experiment was not repeated as part of this work.  
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2.6.1. Natural exchange 
It was possible that when a solution of PBS was spotted on the SAM, exchange of the 
oxygen between the buffer and the carboxylic acid group could occur naturally over time 
(Figure 2.21).   
 
Figure 2.21: Natural exchange of the oxygen in the buffer (red) with the oxygen in the 
carboxylic acid (blue) 
Wells with the SAM formed on them were spotted with aliquots (1 µL) of either the light or 
heavy PBS and left overnight at ambient temperature.  The wells were then washed with 
acetonitrile and dried under a stream of nitrogen.  Aliquots (0.3 µL) of THAP matrix solution 
were spotted on wells prior to mass spectrometric analysis.  The wells were analysed by 
MALDI-MS, in order to determine the extent of background exchange between H2
18
O in the 
buffer and 
16
O in the carboxylic acid group on the ‘heavy chip’.  If exchange between the 
oxygen in the buffer and carboxylic acid group took place then the isotopic distribution would 
be altered by an increase in the intensity of the [M+2] peak, which would be detectable mass 
spectrometrically.  The extracted data are shown in Figure 2.22.   
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Figure 2.22: Plot showing the mean peak intensity ratio for [M+2]:M for peaks associated 
with the SAM after 18O exchange overnight (Error bars show one standard deviation either 
side of the mean) (number of replicates = 8) 
As can be seen in Figure 2.22, there is a small difference between the values obtained for 
the mean peak intensity ratio for [M+2]:M when unlabelled and H2
18
O-containing PBS were 
spotted on wells with SAM formed on them and left overnight.  The mean ratio value 
obtained for wells spotted with H2
18
O-containing PBS is slightly lower than the ratio value 
obtained for unlabelled PBS.  The error bars for the two sets of data overlap.  Since the data 
are not normally distributed, it is not possible to determine the statistical significance of the 
difference between the mean ratio values using a T-test.  Therefore a Mann-Whitney U-test 
was performed, to assess whether there was any statistical significance to the differences 
observed between the two values (Mann-Whitney, U = 16.5, n1 = n2 = 8, P < 0.05, two-
tailed).  Based on the U-value obtained, the result is not statistically significant.   
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2.6.2. Investigating potential hydrolysis during 4-
bromophenylalanine coupling to activated SAM 
Having determined that there was no statistically significant natural exchange of the 
18
O in 
the PBS with the 
16
O of the carboxylic acid group, the next step was to determine whether 
hydrolysis of the activated ester was occurring during the 4-BrPhe tag coupling step.  The 
carboxylic acid groups were activated using either NHS/EDC or PFP/EDC in DMF for one 
hour prior to 4-BrPhe coupling.   
Activation was achieved using either PFP (180 mM) and EDC (180 mM), or NHS (25 mM) 
and EDC (100 mM), with both sets of reagents being prepared in anhydrous DMF.  Aliquots 
(1 µL) of these solutions (for PFP/EDC: 180 nmol of each spotted on a well, for NHS/EDC: 
25 nmol of NHS and 100 nmol of EDC spotted on a well) were left on the wells for an hour 
before washing the gold-coated MALDI chip with acetonitrile and drying it under a stream of 
nitrogen.   
A 50 mM solution of 4-BrPhe in PBS (light or heavy) was prepared, and aliquots (1 µL, 50 
nmol of 4-BrPhe) were spotted onto each well.  The gold-coated MALDI chips were left 
overnight at ambient temperature.  The gold-coated MALDI chips were then washed with 
acetonitrile and dried under a stream of nitrogen.  Aliquots (0.3 µL) of THAP matrix solution 
were spotted on wells prior to mass spectrometric analysis. 
If hydrolysis of the activated SAM occurred during 4-BrPhe coupling, then the isotopic 
distribution would be altered by an increase in the intensity of the [M+2] peak, which would 
be detectable mass spectrometrically.  The extracted data are shown in Figure 2.23.   
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Figure 2.23: Plot showing the mean peak intensity ratio for [M+2]:M for peaks associated 
with the SAM after coupling of the 4-BrPhe to the activated SAM when using two different 
activating reagents (Error bars show one standard deviation either side of the mean) (number 
of replicates = 8) 
As can be seen in Figure 2.23, the mean peak intensity ratio for [M+2]:M after coupling of 
the 4-BrPhe to the activated SAM is almost the same for wells spotted with 4-BrPhe in 
unlabelled PBS and H2
18
O-containing PBS when NHS was used for activation.   
There is a slight difference in the mean peak intensity ratio for [M+2]:M after coupling of the 
4-BrPhe to the activated SAM between wells spotted with 4-BrPhe in unlabelled PBS and 
H2
18
O-containing PBS when PFP was used for activation.  The mean peak intensity ratio for 
[M+2]:M is lower for spectra recorded for wells spotted with 4-BrPhe in H2
18
O-containing 
PBS.   The error bars for the two sets of data overlap, and the values are very comparable.  
Having examined the data, it is clear that the data are not normally distributed, and therefore 
a Mann-Whitney two-tailed U-test was performed on the data, to assess whether there was 
any statistical significance to the differences observed between the mean ratio values 
obtained for the 
16
O and 
18
O experiments using NHS and PFP.  For NHS (Mann-Whitney, U 
= 24, n1 = n2 = 8, P < 0.05, two-tailed) and PFP (Mann-Whitney, U = 32, n1 = n2 = 8, P < 
0.05, two-tailed) the results are not statistically significant.   
Hydrolysis of the activated carboxylic acid groups during 4-BrPhe coupling was thus not 
detectable mass spectrometrically.  Therefore, hydrolysis of the activated SAM during the 4-
BrPhe capture is not the reason for peaks being observed for unreacted SAM in spectra 
obtained after 4-BrPhe had been spotted on wells containing activated SAM.  This suggests 
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that the reason for peaks being observed for unreacted SAM is due to inefficient coupling of 
the 4-BrPhe to the activated SAM.   
Peaks were not observed for an activated SAM when either NHS or PFP were used as the 
activating reagents.  This, coupled with the fact that hydrolysis of the activated SAM during 
4-BrPhe coupling was not detectable suggests that the activation of the SAM is inefficient.   
 
2.6.3. Investigating potential hydrolysis during peptide capture on 
activated SAM 
Having determined that hydrolysis of the activated esters was not occurring when coupling 
the 4-BrPhe to the activated SAM, capture of the simple tripeptides Gly-Gly-Gly and Phe-
Gly-Gly was attempted on the activated SAM.  This was to determine whether the same 
result that was observed when coupling the 4-BrPhe to the activated SAM (i.e. no detectable 
hydrolysis) was obtained when capturing peptides on the activated SAM.  As a secondary 
element to the experiment, peptides were chosen which varied in their N-terminal amino 
acid, with one terminating in Phe.  This allowed a comparison between a peptide with an N-
terminal Phe and a similar tripeptide without an N-terminal Phe.  It was possible that when 
attempting to capture 4-BrPhe on the activated carboxylic acid groups, the capture was 
inefficient, as low intensity peaks were observed for 4-BrPhe coupling to the SAM (see 
Sections 2.4.2 and 2.6.2).  One theory was that this inefficient capture could have been due 
to steric hindrance due to the bulky aromatic side chain of the Phe amino acid.  The 
presence of the bulky side chain in Phe could have been reducing the ability of the N-
terminal of the 4-BrPhe to approach the activated SAM.  The comparison of the peptides 
Gly-Gly-Gly and Phe-Gly-Gly allowed an investigation into whether the Phe at the amino 
terminus hinders a reaction with the SAM activated ester.   
After SAM formation, the carboxylic acid groups were activated using either PFP/EDC, or 
NHS/EDC chemistry, with both sets of reagents being prepared in anhydrous DMF.  Aliquots 
(1 µL) of these solutions (for PFP/EDC: 180 nmol of each spotted on a well, for NHS/EDC: 
25 nmol of NHS and 100 nmol of EDC spotted on a well) were left on the wells for an hour 
before washing the gold-coated MALDI chip with acetonitrile and drying it under a stream of 
nitrogen.   
Stock solutions of the two peptides Gly-Gly-Gly and Phe-Gly-Gly were each prepared at 50 
mM in PBS (light or heavy).  Subsequent dilutions were prepared, in order to spot 50 pmol of 
peptide onto each well, and the gold-coated MALDI chips were left overnight at ambient 
temperature.  The gold-coated MALDI chips were washed with acetonitrile and dried under a 
stream of nitrogen.  Aliquots (0.3 µL) of THAP matrix solution were spotted on wells prior to 
mass spectrometric analysis.   
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If hydrolysis of the activated SAM occurred during peptide capture, then the isotopic 
distribution would be altered by an increase in the intensity of the [M+2] peak, which would 
be detectable mass spectrometrically.  The extracted data are shown in Figure 2.24 and 
Figure 2.25.   
 
Figure 2.24: Plot showing the mean peak intensity ratio [M+2]:M for peaks associated with 
the SAM after capture of the peptide Gly-Gly-Gly on the activated SAM when using two 
different activating reagents (Error bars show one standard deviation either side of the mean) 
(number of replicates = 8) 
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Figure 2.25: Plot showing the mean peak intensity ratio for [M+2]:M for peaks associated 
with the SAM after capture of the peptide Phe-Gly-Gly on the activated SAM when using two 
different activating reagents (Error bars show one standard deviation either side of the mean) 
(number of replicates = 8) 
As can be seen in Figure 2.24, there is little difference between the mean ratio of peak 
intensities for [M+2]:M after capture of Gly-Gly-Gly on the activated SAM for wells spotted 
with Gly-Gly-Gly in unlabelled PBS and H2
18
O-containing PBS when PFP was used for 
activation.  There is more of a difference in the mean ratio of peak intensities for [M+2]:M 
after capture of Gly-Gly-Gly on the activated SAM for wells spotted with Gly-Gly-Gly in 
unlabelled PBS and H2
18
O-containing PBS when NHS was used for activation.  For NHS, 
the mean ratio of peak intensities for [M+2]:M is higher after capture of Gly-Gly-Gly on the 
activated SAM for wells spotted with Gly-Gly-Gly in H2
18
O-containing PBS than in unlabelled 
buffer.   
As can be seen in Figure 2.25, there is little difference between the mean ratio of peak 
intensities for [M+2]:M after capture of Phe-Gly-Gly on the activated SAM for wells spotted 
with Phe-Gly-Gly in unlabelled PBS and H2
18
O-containing PBS when NHS and PFP were 
used for activation.  As was observed in Figure 2.24 with NHS, the mean ratio of peak 
intensities for [M+2]:M is higher after capture of Phe-Gly-Gly on the activated SAM for wells 
spotted with Phe-Gly-Gly in H2
18
O-containing PBS than in unlabelled buffer.   
The error bars for the sets of data overlap, and the values are comparable.  Having 
examined the data, it is clear they are not normally distributed, and therefore a Mann-
Whitney two-tailed U-test was performed on the data, to assess whether there was any 
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statistical significance to the differences observed between the 
16
O and 
18
O values obtained 
for NHS and PFP for the two peptides.   
For Gly-Gly-Gly: For NHS (Mann-Whitney, U = 14, n1 = n2 = 8, P < 0.05, two-tailed) and PFP 
(Mann-Whitney, U = 31, n1 = n2 = 8, P < 0.05, two-tailed), the results are not statistically 
significant.   
For Phe-Gly-Gly: For NHS (Mann-Whitney, U = 16.5, n1 = n2 = 8, P < 0.05, two-tailed) and 
PFP (Mann-Whitney, U = 16.5, n1 = n2 = 8, P < 0.05, two-tailed) the results are not 
statistically significant.   
Hydrolysis of the activated carboxylic acid groups during Gly-Gly-Gly and Phe-Gly-Gly 
capture was thus not detectable mass spectrometrically.  Therefore, as was seen with 4-
BrPhe coupling (Section 2.6.2), hydrolysis of the activated SAM during Gly-Gly-Gly and Phe-
Gly-Gly capture is not the reason for peaks being observed for unreacted SAM in spectra 
obtained after Gly-Gly-Gly and Phe-Gly-Gly had been spotted on wells containing activated 
SAM.  This suggests that the reason for peaks being observed for unreacted SAM is due to 
inefficient capture of the peptides on the activated SAM.   
 
2.7. Conclusions and future work 
A variety of peptides have been captured on the thiol-derived SAM, with and without the 
presence of the chemical tag 4-BrPhe.  Levels of peptide capture were lower for peptides 
captured on the activated SAM than for peptides captured on the activated 4-BrPhe-tagged 
SAM.  This could be due to low levels of incorporation of the 4-BrPhe prior to peptide 
capture, inefficient activation of the SAM (and subsequent activated 4-BrPhe-tagged SAM) 
or simply an accumulation of inefficient chemistry at the different stages of the reaction.   
Peaks for unreacted SAM were observed in mass spectra obtained after 4-BPhe had been 
coupled to the activated SAM and also when peptide had been captured on the activated 
SAM.  An investigation into the origin of these peaks was undertaken.  This involved the use 
of H2
18
O-containing PBS, to determine whether hydrolysis of the activated carboxylic acid 
groups was occurring.  However, it was found that the reason for the presence of peaks 
associated with unreacted SAM was not due to hydrolysis of the activated carboxylic acid 
groups.  Therefore, the assumption was that the chemistry is not efficient.  This may be due 
to the activation of the carboxylic acid groups not being efficient, or the capture of the 4-
BrPhe or peptide being inefficient.   
Peptides with aromatic N-terminal amino acids could be used to test the hypothesis that π-
stacking is occurring.  A variety of peptides with differing numbers of amino acids, with an 
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aromatic N-terminal amino acid, and their equivalent with a non-aromatic N-terminal amino 
acid should be used for peptide capture.  This would allow a comparison between the 
capture efficiency of two peptides equivalent except for their N-terminal amino acids.  If the 
capture efficiency was lower in all instances for peptides containing the aromatic N-terminal 
amino acid, then the theory that π-stacking was occurring could be supported.  If the issue is 
one of steric hindrance, it would be sensible to use peptides containing a non-aromatic, but 
bulky, N-terminal side chain.  This would allow a true conclusion to be made as to whether 
steric hindrance was the over-riding reason for inefficient peptide capture, or whether the 
presence of the aromatic side chain is the reason for inefficient peptide capture.   
It is highly likely that the carboxylic acid head groups are not exposed as depicted in Figure 
2.4, and are more likely to be buried within the main structure of the SAM.  This would 
restrict their accessibility to the 4-BrPhe/peptide.  The surface of the SAM could be analysed 
by a technique such as near-edge X-ray absorption fine structure (NEXAFS).
186
  Nelson et 
al. published a paper in which they used NEXAFS to determine the long-range chain 
alignment within alkylthiolate monolayers.
186
  NEXAFS provides structural information on the 
electronic structure and orientation of molecules or molecular fragments, by probing the 
absorption of electromagnetic radiation by excitation of core electrons into unoccupied 
bound or continuum states.
187
  NEXAFS could be used to determine the structure of the 
SAM on the surface of the gold-coated MALDI chips, to determine whether the carboxylic 
acid groups are buried within the main structure of the SAM, which would limit the ability of 
the carboxylic acid groups to react with 4-BrPhe or a peptide.  However, it is likely that it is 
not a single effect which is causing the presence of peaks associated with unreacted SAM 
after peptide capture, but a combination of a range of different effects.   
Alternative activation and coupling chemistry may improve the activation of the SAM prior to 
capture of a chemical tag or peptide coupling.  The alternative activation reagent NHSS was 
tested, to see whether a better solubility match between activation reagent and solvent 
would improve capture efficiency, as EDC (which is used in conjunction with the NHS and 
PFP) is more soluble in solvents such as acetonitrile, as opposed to DMF (which is used to 
solubilise the NHS and PFP).  However, there were unassignable peaks observed in the 
mass spectra recorded after peptide capture when an acetonitrile/water solvent system was 
used.  This negated the theoretical advantage of using a solvent which was more compatible 
with the EDC.  There are other alternative activation and coupling chemistries which could 
be tested.  One such example would be the conversion of the carboxylic acid groups to acid 
chloride groups.  An acid chloride would be more susceptible to reaction with the primary 
amine of the 4-BrPhe/peptide than the carboxylic acid.  The conversion of the carboxylic 
acid groups to acid chlorides was tested (using oxalyl chloride to convert the carboxylic acid 
groups to acid chloride groups), but mass spectra were obtained with a high S/N, and no 
peaks were observed for peptide captured on the acid chloride-derived SAM.   
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Another alternative which was briefly explored was the conversion of the carboxylic acid 
group to a ketene.  This was based on the work by Chan et al. in 2012, where they modified 
the N-terminal of peptides and proteins using an alkyne-functionalised ketene.
188
  However, 
when the SAM was derivatised to form the ketene, the resultant mass spectra were very 
noisy, and no peaks were observed for peptide captured on the ketene-derived SAM.   
The spectra obtained after conversion of the carboxylic acid groups on the gold-coated 
MALDI chip were very noisy.  This could have been due to unexpected chemistry occurring 
when the gold-coated MALDI chip with the SAM formed on the wells was placed in the 
reagents and solvents.  The possibility of converting the carboxylic acid groups of the thiols 
to a more reactive group (such as the acid chloride or ketene) in solution, prior to SAM 
formation on the gold-coated MALDI chip could be explored.  If the conversion of the 
carboxylic acid groups was to be performed prior to SAM formation, the possibility that some 
of the acid chloride or ketene could be converted back to the carboxylic acid during SAM 
formation would also need to be explored.   
Another avenue would be to investigate alternative components to form a SAM (such as the 
pre-activated SAM discussed in Chapter 3).  Another example would be to use the disulfide 
component used by Peelen et al. in 2006 for the capture of mammalian cells by cell surface 
receptor binding to a ligand immobilised on gold thin films.
189
  The group used an aldehyde-
terminated disulfide ((OHC-(CH2)9-S-)2), to form a SAM on a gold-coated glass substrate.  
They then immobilised proteins on the aldehyde-terminated gold surfaces.  This involved 
reacting a primary amine with the aldehyde, and then subsequent reduction of the imine 
using sodium cyanoborohydride.  Aldehyde-terminated disulfides with PEG groups within the 
chains are also available (e.g.(-S-(CH2)11-(OCH2CH2)nOCH2CHO)2).  Aldehyde-terminated 
disulfides could potentially be used for the capture of peptides on a SAM for subsequent 
MALDI-MS analysis.  A suitable spacer molecule would be needed, for example, (-S-(CH2)11-
(OCH2CH2)n-OH)2 for combination with the aldehyde-terminated disulfide containing PEG 
groups.   
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Throughout Chapter 3, the following terminology will be used to describe the SAM at the 
different stages of the peptide capture methodology.   
Terminology Structure 
Disulfide-derived SAM 
 
Disulfide-derived SAM containing 
NHS by-product 
 
Peptide captured on the disulfide-
derived SAM 
 
4-BrPhe captured on the 
disulfide-derived SAM 
 
Phe captured on the disulfide-
derived SAM 
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3.1. Introduction  
Peptide capture on the thiol-derived SAM (Chapter 2) had limited success, as peaks 
associated with unreacted SAM were observed in spectra obtained after peptide capture.  
Therefore, alternative SAM components were investigated, in an attempt to improve SAM 
activation and peptide capture, and minimise the number of synthetic steps in construction 
on the SAM-peptide structure.   
An alternative SAM component was a pre-activated disulfide (Figure 3.1).  If it was the 
activation step (and not the peptide capture step) that was the problem when attempting to 
capture peptides on the thiol-derived SAM, the pre-activated disulfide approach removes the 
need to activate the SAM prior to capture of the tag or peptide (which also removes one on-
chip synthesis step).   
 
Figure 3.1: NHS ester disulfide 
There have been several studies which have compared the reactivity of thiols and disulfides 
with a solid substrate.
160,161,190
  These studies concluded that thiols form a SAM on the 
substrate at a faster rate than disulfides.  Bain et al. found that in a solution containing 
mixtures of a thiol and a disulfide, adsorption of the thiol was strongly preferred, by a factor 
of approximately 75:1.
160
  Therefore, an mPEG disulfide spacer molecule (Figure 3.2) was 
used in combination with the NHS ester disulfide for construction of the SAM (to avoid 
preferential adsorption of spacer molecules when used with a disulfide NHS ester).   
 
Figure 3.2: mPEG disulfide 
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3.1.1. Aims and overview 
The aim of the work in this chapter was to investigate the suitability of a disulfide-derived 
SAM for peptide capture, prior to mass spectrometric analysis.  A pre-activated SAM was 
formed on the gold surface and a variety of peptides captured at two levels (5 nmol and 0.05 
nmol of peptide per well).   
In Chapter 2, when the chemical tag 4-BrPhe was coupled to the thiol-derived SAM, peaks 
were observed in the mass spectra which corresponded to unreacted SAM.  Coupling of the 
same 4-BrPhe chemical tag to the disulfide-derived SAM was thus attempted at the 5 nmol 
and 0.05 nmol level in order to determine whether more efficient coupling of the tag could be 
achieved using the disulfide-derived SAM.   
An investigation into whether there was a problem with Phe being located at the N-terminus 
of the species (i.e. 4-BrPhe or peptide) to be captured on the disulfide-derived SAM was 
also undertaken.   
 
3.2. Formation of a disulfide-derived SAM 
A gold-coated MALDI chip was cleaned with piranha solution prior to SAM formation.  The 
two components used for forming the SAM were both disulfides containing PEG spacers and 
either a methyl group ((SCH2CH2(OCH2CH2)6OCH3)2) or NHS ester 
((S(CH2CH2O)8CH2CH2COONC4O2H4)2) as their terminal group.  The SAM components 
were each dissolved in DMSO at a concentration of 0.1 mg/mL, and a 1:4 molar ratio of NHS 
ester:mPEG terminated groups was created from these stock solutions.  Aliquots (0.4 µL) of 
this mixture were then spotted onto wells of the gold-coated MALDI chip and the SAM was 
left to assemble overnight at ambient temperature (Figure 3.3).  The gold-coated MALDI chip 
was washed with acetonitrile and dried under a stream of nitrogen.   
Chapter 3: Disulfide-derived SAM 
135 
 
 
Figure 3.3: Formation of the disulfide-derived SAM. 
Aliquots (0.3 µL) of THAP solution were spotted on wells, and the formation of the SAM was 
assessed by MALDI-MS.  A typical MALDI mass spectrum is shown in Figure 3.4 (peak 
assignments shown in Table 3.1).   
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Figure 3.4: MALDI mass spectrum of the disulfide-derived SAM formed on a gold-coated 
MALDI chip  
As can be seen in Figure 3.4, a SAM was formed on the gold-coated MALDI chip from the 
mixture of the two disulfides.  Peaks can be seen which are associated with a disulfide 
having two mPEG termini, a disulfide having two NHS ester termini and a mixed disulfide 
having one mPEG terminus and one NHS ester terminus (Table 3.1).  There is also a peak 
at m/z 1041 ([M+Na]
+
) which was discovered to be due to the presence of a by-product in 
the commercial NHS ester disulfide.   
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Table 3.1: Peak assignments for mass spectrum of disulfide-derived SAM formation on a gold-
coated MALDI chip 
Nominal m/z value Assignment 
733 [M+Na]
+
 - 2 mPEG termini 
749 [M+K]
+
 - 2 mPEG termini 
771 [M+Na+K-H]
+
 - 2 mPEG termini 
932 [M+Na]
+
 - 1 NHS ester terminus, 1 mPEG terminus 
948 [M+K]
+
 - 1 NHS ester terminus, 1 mPEG terminus 
1041 [M+Na]
+
 - 1 NHS ester by-product terminus, 1 mPEG terminus 
1131 [M+Na]
+
 - 2 NHS ester termini 
1147 [M+K]
+
 - 2 NHS ester termini 
 
Polypure (the supplier) was contacted over the presence of the peak observed at m/z 1041.  
The information provided by Polypure highlighted the presence of a by-product in the 
commercial NHS ester (Figure 3.5).   
 
Figure 3.5: NHS ester by-product (containing a stable N-acyl urea) 
In order to confirm whether the by-product in the commercial NHS ester was contributing to 
the presence of the peak at m/z 1041, product ion analysis was performed.  The ion 
generating the peak at m/z 1041 was found to be due to a mixed disulfide having one mPEG 
terminus and the stable N-acyl urea half of one by-product NHS ester terminus.   
Based on information provided by Polypure, it is likely that the by-product is formed during 
the conversion of the carboxylic acid starting material to the NHS ester (Figure 3.6).  The 
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carboxylic acid groups are activated using N,N’-dicyclohexylcarbodiimide (DCC).  This 
produces an O-acyl isourea intermediate.  The NHS ester then reacts with the activated 
carboxylic acid to form the NHS ester and dicyclohexylurea (Figure 3.6 – Activation route).  
The contaminant is formed by rearrangement of the O-acyl isourea intermediate to form the 
more stable N-acyl urea product (Figure 3.6 – Rearrangement route).   
 
Figure 3.6: Carboxylic acid reacting with DCC to form O-acyl isourea intermediate and 
subsequent rearrangement or substitution (R = rest of the disulfide, Cy = cyclohexyl) 
The N-acyl urea by-product is stable, and will not go on to react with NHS to form NHS ester 
groups at the termini of the disulfide (unlike the O-acyl isourea).  The presence of the by-
product reduces the amount of NHS groups available for reaction with a peptide, and the N-
acyl urea will also not go on to react with a peptide.  Therefore, the amount of reactive 
groups available on the surface of the SAM is less than expected.  This could be accounted 
for when preparing the SAM, by including a higher amount of the NHS ester in the disulfide 
mixture prior to spotting the SAM components on the gold-coated MALDI chip.   
 
3.3. Peptide capture on SAM 
This work was done in collaboration with an MChem student (Rachel Bates).  In previous 
work (Chapter 2), the peptide capture step on the activated SAM was carried out over 18 h.  
This was based on the method developed by the Flitsch group in Manchester.
170
  However, 
there was no direct evidence that an overnight coupling reaction was necessary.  In fact, the 
reaction between an NHS ester and a primary amine is expected to occur rapidly.  The 
reaction of an NHS ester with an amine is typically performed between pH 7 and 9, and is 
completed between 30 minutes and 2 hours at ambient temperature.
191
  This suggests that 
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the reaction between the peptide and the SAM may not require overnight incubation.  A 
peptide capture reaction of one hour on the disulfide-derived SAM was tested (generic 
reaction showing peptide capture shown in Figure 3.7).  One hour was originally chosen as a 
compromise due to the fact that it lies between 30 minutes and 2 hours, to determine 
whether peptide capture was observed at all after one hour.   
Stock solutions of the peptides shown in Table 3.2 were prepared at 50 mM in PBS.  From 
these stock solutions, solutions were prepared to enable peptide capture on the disulfide-
derived SAM with the peptides at two different amounts in 1 µL aliquots: 5 nmol and 50 
pmol.  Aliquots (1 µL) of the peptide solution were spotted on wells and left for one hour at 
ambient temperature.  The gold-coated MALDI chip was washed with acetonitrile and dried 
under a stream of nitrogen.   
 
Figure 3.7: Generic reaction of a peptide with the disulfide-derived pre-activated SAM 
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Aliquots (0.3 µL) of THAP solution were spotted on wells, and the success of the capture of 
the peptides detailed in Table 3.2 was assessed by MALDI-MS.  Table 3.2 shows the 
expected m/z values for the peptides captured on the SAM.   
Table 3.2: Peptides spotted on the SAM and expected m/z values of product captured on the 
SAM 
Peptide Molecular mass 
of peptide /  
g mol
-1
 
Expected values of SAM-
peptide signal ([M+Na]
+
 
and [M+2Na-H]
+
) / m/z 
Leu-Gly-Gly (LGG) 245 1062 / 1084 
Gly-Gly-Val (GGV) 231 1048 / 1070 
Ala-Ala-Ala (AAA) 231 1048 / 1070 
Gly-Gly-Gly (GGG) 189 1006 / 1028 
Phe-Gly-Gly (FGG) 279 1096 / 1118 
Leucine enkephalin (Leu-Enk) 555 1372 / 1394 
 
Figure 3.8 shows a MALDI mass spectrum obtained following reaction for one hour of 
leucine enkephalin at 5 nmol with the disulfide-derived SAM (peak assignments shown in 
Table 3.3).   
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Figure 3.8: MALDI mass spectrum obtained following reaction for one hour of leucine 
enkephalin at 5 nmol with the disulfide-derived SAM  
Peaks were observed for species containing leucine enkephalin captured on the SAM (m/z 
1372, 1394 and 1416).  No peaks were observed corresponding to species bearing 
unreacted NHS groups (m/z 932, 948, 1131 and 1147).   
Table 3.3: Peak assignments for MALDI mass spectrum of leucine enkephalin captured on the 
disulfide-derived SAM 
Nominal m/z value Assignment 
733 [M+Na]
+
 - 2 mPEG termini 
749 [M+K]
+
 - 2 mPEG termini 
1372 [M+Na]
+
 - 1 mPEG terminus, 1 CO-Leu-Enk terminus 
1394 [M+2Na-H]
+
 - 1 mPEG terminus, 1 CO-Leu-Enk terminus 
1416 [M+Na+K-H]
+
 - 1 mPEG terminus, 1 CO-Leu-Enk terminus 
 
The reduced incubation time of one hour for capture of a peptide on the NHS ester of the 
SAM was shown to be successful for all peptides tested.  This means that one of the 
overnight reaction steps can be removed from our protocol, which is convenient in reducing 
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the overall sample handling time.  This considerable time-saving for the workflow could 
potentially mean that the entire process (from SAM formation to peptide capture and 
analysis) could take place in two days.  The formation of the SAM would remain an overnight 
step based on literature evidence that in order to ensure SAM formation, the disulfide 
solution should be left in contact with the gold-coated MALDI chip for at least 12 hours.
160,190
  
Although one overnight step would still be needed to form the SAM, the protein digest 
protocol used in this work (Chapter 7) is also an overnight reaction.  Therefore, the SAM 
could be left to form overnight simultaneously with the protein being digested.   
Having established that peptide capture was observed after one hour, a time course study 
was performed, with five minute intervals used between 5 and 60 minutes, in order to 
determine whether one hour was still an excessive amount of time for peptide capture.  The 
time course showed that a time of between 40 and 60 minutes was optimum for the peptide 
capture reaction (depending on the peptide).  This was measured by analysis of the mass 
spectra obtained after peptide capture for the specified times, and comparing the relative 
intensities of peaks due to SAM species bearing unreacted NHS groups and peaks due to 
peptide captured on the SAM.  After 40-60 minutes, there was a decrease observed in the 
relative amounts of SAM species bearing unreacted NHS groups and peptide captured on 
the SAM, possibly due to a deterioration of the SAM on the surface of the gold-coated 
MALDI chip over time.  For most peptides, the mass spectra obtained following peptide 
capture showed a combination of peaks.  In some instances, peaks were seen for peptide 
captured on the SAM and also for species bearing unreacted NHS groups.  In other 
instances, peaks were observed for peptide captured on the SAM, but no peaks were 
observed for species bearing unreacted NHS groups.  In both instances, no peaks were 
observed for hydrolysis of the NHS esters to carboxylic acid groups.  This variability could 
just be a reflection of the innate variability of MALDI.
192
  It can be difficult to obtain 
reproducible results using MALDI, mainly due to the fact that ion signals produced are not 
reproducible from sample to sample or from spot to spot, and shot to shot analysis of the 
same spot can produce varying results.
192–194
  Part of the reason for this may be due to 
inhomogeneity of the sample, due to the way that the matrix crystallises on the surface of 
the gold-coated MALDI chip.   
Power analysis can be used to determine the sample size required to detect an effect of a 
given size with a given degree of confidence.
195
  The power of an experiment is the 
probability that it can detect a treatment effect, if it is present.  Statistical power analysis 
exploits the mathematical relationship between power, sample size, significance criterion 
and the population effect size.
195
  There are examples of power analysis being applied to 
mass spectrometric proteomics analysis.  These include the use of power analysis to 
determine the smallest fold-change reliably detected for a complex peptide mixture.
196
  In 
2011, Levin published a paper detailing the role of statistical power analysis in quantitative 
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proteomics.
197
  The author sought to establish the importance of power analysis to calculate 
the number of biological replicates required for a study.  In 2007, Meng et al. published a 
paper detailing LC-MS analysis of complex peptide mixtures, where six standard peptides 
were spiked into a processed plasma background.
196
  The authors used a power analysis to 
show that with a sample size of 12, a 1.5-fold difference was expected to be detected about 
90% of the time.  However, in the instance of the work in this thesis, a qualitative 
comparison has been made, and therefore, a power analysis is not appropriate.   
There have been various publications in recent years which have looked into the variability 
observed during MALDI-MS analysis.  In 2013, Hu et al. published a paper discussing the 
coffee-ring effect.
176
  Here, the authors discussed the heterogeneous distribution of 
molecules within dry deposits of suspensions and solutions, which can compromise 
analytical performance and reproducibility.   
One of the compromises of the SAM technology is being unable to mix the analyte (the 
SAM) and the matrix prior to spotting the two on the gold-coated MALDI chip.  Therefore, a 
homogeneous solution cannot be formed prior to spotting.  It is possible that the matrix may 
be crystallising heterogeneously over the surface of the SAM, which could affect the quality 
of the spectra obtained.   
It has been shown over the years that sweet spots occur within a spot on a MALDI plate
198
 
(or chip), and that coffee-rings can also occur.
176
  Both of these phenomena can 
compromise the quality of the mass spectra obtained, and lead to inter- and intra-spectral 
variability.  These MALDI mass spectral effects could have affected the spectra obtained, 
resulting in differences obtained for the same peptide spotted on different wells of the SAM.   
Alternatively, the variability may derive from the protocol itself.  This could be a problem with 
the SAM formation.  A 1:4 mixture of the mPEG:NHS disulfides was spotted on the wells, 
and so it is tempting to assume that the distribution of species across the wells is random, as 
depicted in Figure 3.3.  There is no guarantee that SAMs formed on different wells of the 
same chip would be identical.  Within a mixed SAM, separation of the components can 
occur.
199
  Therefore, there could be regions which have a high density of NHS-bearing 
species, with very little of the spacer component, and vice versa.  If areas exist where NHS 
groups are packed closely together with few spacer molecules, peptide capture could be 
compromised as it may not be possible for peptide molecules to access and react with all of 
the NHS groups due to steric hindrance (hence peaks would be observed for peptide 
captured on the SAM and also for species bearing unreacted NHS groups).  Spectra in 
which no peaks were observed for species bearing unreacted NHS groups may arise if all 
the NHS groups were sufficiently separated by the spacer molecules to make them all 
accessible for peptide capture (hence peaks would only be observed for species bearing 
peptide captured on the SAM).   
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The presence of peaks due to different scenarios (peaks associated with peptide captured 
on the SAM, peaks associated with no peptide capture and no peaks associated with SAM 
or peptide captured on the SAM) for the same peptide, is likely to be a combination of the 
two possible sources of variability: innate MALDI variability and protocol variability.  Surface 
analysis of the SAM on the gold-coated MALDI chip would provide information on the 
surface composition of the SAM.  STM has been used previously to demonstrate phase 
segregation in mixed-component SAMs.
199
  Stranick et al. showed clear differences between 
the STM images obtained from SAMs comprising a single component, and SAMs comprising 
two components.
199
  The image produced from the mixed SAM (comprising a methyl 
terminated SAM and an ester terminated SAM) showed definitive areas for the two 
components, showing that the two components had segregated in areas to form single-
component domains.  It is possible that a similar phenomenon is occurring for the disulfide-
derived SAM used in this work.   
The mass spectra obtained for each peptide were examined for the presence of peaks due 
to species associated with peptide captured on the SAM and species bearing unreacted 
NHS groups.  The percentage of spectra (twelve spectra from twelve wells) where peaks 
were observed for species associated with peptide captured on the SAM and species 
bearing unreacted NHS groups was determined (Table 3.4).   
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Table 3.4: Table showing peptides spotted at 5 and 0.05 nmol levels on the disulfide-derived 
SAM, and percentage of spectra with species for peptide capture and unreacted SAM 
(number of replicates = 12) 
Peptide Amount 
spotted 
on wells / 
nmol 
Peaks seen 
for peptide 
captured on 
SAM? 
Percentage
v
 
of spectra 
with signal 
for captured 
peptide  
Peaks seen 
for unreacted 
SAM? 
Percentage
v
 of 
spectra with 
signal for  
unreacted SAM 
AAA 
5 Yes 20% Yes 90% 
0.05 Yes 100% Yes 10% 
LGG 
5 Yes 58% Yes 50% 
0.05 Yes 100% Yes 64% 
GGV 
5 Yes 75% Yes 25% 
0.05 Yes 100% Yes 45% 
GGG 
5 Yes 100% No 0% 
0.05 Yes 75% Yes 92% 
FGG 
5 Yes 92% Yes 8% 
0.05 Yes 17% Yes 100% 
Leu-Enk 
5 Yes 100% Yes 8% 
0.05 Yes 50% Yes 100% 
 
As can be seen in Table 3.4, the different peptides showed differing values for both the 
percentage of spectra with signals for peptide captured on the SAM, and for the percentage 
of spectra with signals for species bearing unreacted NHS groups.   
For each peptide, multiple experiments were performed, using a number of gold-coated 
MALDI chips.  Due to the fact that multiple chips were used for the peptide capture 
experiments, multiple batches of the disulfide-derived SAM components were prepared in 
solution and spotted on the gold-coated MALDI chips.  Therefore, if there were problems 
with one solution of the disulfide-derived components, this should have been noticeable 
when compared with the results of other experiments that used the same peptide.   
                                                          
v
 One mass spectrum recorded from each well.  Data extracted from spectra for relevant 
peaks (e.g. species bearing unreacted NHS groups).  Percentage values reported as a 
percentage of the total number of spectra recorded for each peptide at 5 nmol and 0.05 nmol 
amounts spotted on the SAM.   
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When the peptide Phe-Gly-Gly was spotted on the SAM, peptide capture appeared to be 
more successful when 5 nmol of peptide was reacted with the SAM than when 0.05 nmol of 
peptide was reacted with the SAM.  The percentage of spectra which had peaks for peptide 
captured on the SAM was higher from the wells spotted with 5 nmol of peptide (92%) than 
wells spotted with 0.05 nmol of peptide (17%).  The peptide Gly-Gly-Gly, which differs from 
Phe-Gly-Gly only by the presence of Gly at the N-terminus in place of Phe, showed a much 
higher percentage of spectra with peaks associated with peptide capture on the disulfide-
derived SAM at 0.05 nmol (75%) compared to Phe-Gly-Gly.  This suggests that the 
presence of the phenylalanine residue may be reducing the success of peptide capture on 
the disulfide-derived SAM.  The percentage of spectra with signals for unreacted SAM was 
also higher for Phe-Gly-Gly reacting with the disulfide-derived SAM when compared to Gly-
Gly-Gly reacting with the disulfide-derived SAM at both the 5 nmol and 0.05 nmol levels.  
The lower percentage of spectra with peaks associated with Phe-Gly-Gly capture on the 
disulfide-derived SAM is in agreement with the results obtained when reacting 4-BrPhe and 
Phe-Gly-Gly with the thiol-derived SAM (Chapter 2), where peaks associated with unreacted 
SAM were observed in the mass spectra obtained after 4-BrPhe had been reacted with the 
SAM.  The result obtained for Phe-Gly-Gly reacting with the disulfide-derived SAM suggests 
that the presence of Phe at the N-terminus may lead to inefficient capture of the peptide or 
amino acid residue.   
When Phe-Gly-Gly was used for capture, the results showed better peptide capture at the 
higher level of 5 nmol of peptide when compared to reacting 0.05 nmol of peptide with the 
disulfide-derived SAM.  The phenyl group makes the Phe residue hydrophobic.  However, 
the peptide was dissolved in PBS, which is hydrophilic.  Therefore, there is a mismatch in 
the properties of the solvent and the solute.  There have been many studies which have 
investigated peptide aggregation in solvents.
200–202
  It has been shown that peptides can 
form ordered aggregates in aqueous solution.
200
  Non-polar amino acid side chains are 
removed from water and packed together in the interior of the aggregate.  This could be the 
case for Phe-Gly-Gly.  The hydrophobic phenyls in the side chains of the Phe could be 
causing the peptides to aggregate, and pack the N-termini of the peptides inside the 
aggregate.  This would mean that the N-termini would not be available to react with the 
SAM, which could have resulted in the lower capture efficiency observed with Phe-Gly-Gly.   
Although the peptide Phe-Gly-Gly is small, Jayakumar et al. showed that ordered 
aggregates in aqueous solution could be formed by a tetrapeptide (Val-Leu-Pro-Phe).
200
  
Therefore, the possibility that a tripeptide could form aggregates in aqueous solution is 
viable.  The authors believed that the formation of aggregates is due to two processes: the 
positive entropy from water release due to intermolecular association of ionic moieties 
(between 5 °C and 40 °C) and intramolecular ionic interaction (above 40 °C).  These 
processes are driven by the desire to remove non-polar amino acid side chains from water, 
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and pack them together in the interior of an aggregate.  Jayakumar et al. monitored the 
formation of aggregates through fluorescence spectroscopy, where the critical micelle 
concentration for the peptide was determined.  This technique could be applied to Phe-Gly-
Gly due to the presence of the aromatic phenylalanine, which is naturally fluorescent.  It 
would be possible to prepare solutions of the peptide Phe-Gly-Gly at varying concentrations, 
and subject these to fluorescence spectroscopic analysis, in order to determine whether 
aggregates were forming in solution (which would subsequently inhibit reaction with the 
SAM).   
Alternatively, hydrophobic solvents could be used, to determine whether hydrophobic 
interactions occurred with the peptide in PBS.  A hydrophobic solvent should 
interrupt/prevent aggregates forming, as there would be no need to protect the hydrophobic 
amino acid side chains from water.   
The phenomenon of π-stacking in proteins is well established.
203,204
  π-stacking occurs when 
non-covalent interactions occur between aromatic rings, causing the aromatic rings to stack 
together.  It is also possible that π-stacking of the aromatic side chains of the Phe amino 
acid could be occurring in solution.   As with the theory that the hydrophobic Phe amino 
acids could be causing the formation of aggregates, the possibility of π-stacking of the 
aromatic side chain of the Phe amino acids would also result in aggregates being formed in 
solution.  If aggregates were formed in solution, this would mean that the peptide N-terminus 
would not be available to react with the SAM, which would have resulted in the lower capture 
efficiency observed with Phe-Gly-Gly.  This theory could be tested by using peptides with 
other aromatic terminal amino acids (e.g. those containing tyrosine or tryptophan).  The 
same amounts of peptide should be spotted on wells (e.g. 5 nmol and 50 pmol), in order to 
provide a comparison with the behaviour of Phe-Gly-Gly.  The extent of peptide capture on 
the disulfide-derived SAM could be calculated from the spectral data (in a similar manner to 
that used in Chapter 2) for the different peptides, in order to establish whether phenylalanine 
was causing the problem, or if it is a problem with all aromatic amino acid residues.   
A study by Samal and Geckeler in 2001 showed unexpected solute aggregation in water on 
dilution.
205
  They looked at aggregation in aqueous solutions of fullerene-cyclodextrin 
conjugates, β-cyclodextrin, sodium chloride, sodium guanosine monophosphate and a DNA 
oligonucleotide.  Their conclusion was that larger aggregates can exist in dilute aqueous 
solutions than in more concentrated solutions.  For some peptides, peaks were observed for 
unreacted SAM after peptide capture.  This theoretically, should not be the case, as 0.05 
nmol is still above the amount of reactive groups on the surface of the SAM.  Therefore, 
there is excess peptide, which should mean no unreacted SAM.  For the peptide Gly-Gly-
Gly, when 5 nmol of peptide was spotted on wells, 25% of spectra contained signals for 
unreacted SAM.  When 50 pmol of Gly-Gly-Gly was spotted on wells, 45% of spectra 
contained signals for unreacted SAM.  The fact that peaks are observed for unreacted SAM 
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in a higher percentage of spectra at the 50 pmol level than the 5 nmol level could imply a 
higher level of aggregation at the 50 pmol amount of peptide, which would mean that the 
peptides are less likely to react with the SAM.   
The fact that peptide aggregates may be forming in the PBS suggests that PBS is not the 
most suitable solvent for the peptide capture step.  PBS was used as a result of data 
obtained in previous work by the Flitsch group,
170
 where there has been a history of use of 
PBS with the SAM components discussed in Chapter 2.  With the possibility that this was not 
the most suitable solvent in mind, peptide capture on the SAM using 5% N,N-
diisopropylethylamine (DIPEA) in DMF was attempted.  However, no peaks were seen for 
peptide captured on the SAM and no further work was undertaken using DIPEA in DMF.  A 
variety of other solvents were also investigated, including triethylammonium bicarbonate 
(TEAB), DMF, phosphate buffer, acetonitrile and water.  However, none of these solvents 
proved to be more suitable than PBS for the reaction of a peptide with the disulfide-derived 
SAM.  Therefore, its use was continued during this work.   
Having established that peptide capture was possible at 50 pmol, peptide capture was 
attempted at 5 pmol for the peptides mentioned in Table 3.2.  For each peptide, four wells 
were spotted with the relevant peptide solution.  However, peptide capture was not observed 
for any of the peptides used.  Therefore, the limit of detection for the disulfide-derived SAM 
is between 50 pmol and 5 pmol.  This is quite a large amount of peptide, and is currently well 
above the amount which might be expected in a typical proteomics experiment.   
 
3.3.1. MS/MS analysis of peptides captured on the disulfide-derived 
SAM  
Product ion spectra were recorded in order to determine the structures of the species giving 
rise to the signals in the MALDI mass spectra obtained following peptide capture.   
Product ion spectra obtained from the ions corresponding to [M+2Na-H]
+
 for the peptides 
Gly-Gly-Val and leucine enkephalin captured on the SAM (m/z 1070 and 1394 respectively) 
are shown in Figure 3.9 and Figure 3.10 respectively.   
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Figure 3.9: MALDI-product ion spectrum of [M+2Na-H]+ for capture of the peptide Gly-Gly-Val 
on the SAM (precursor at m/z 1070) 
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Figure 3.10: MALDI-product ion spectrum of [M+2Na-H]+ for capture of the peptide leucine 
enkephalin on the SAM (precursor at m/z 1394) 
In both Figure 3.9 and Figure 3.10, there is a peak at m/z 763.  This suggests that the 
product ion originates from the SAM, and is not peptide specific.  There is also a change 
from even to odd m/z from the parent ion to the product ion observed at m/z 763, indicating 
the number of nitrogen atoms has changed from odd to even.  It was calculated that the ion 
at m/z 763 is due to the [M+Na]
+
 species of the SAM fragment shown in Figure 3.11, with 
CID-induced cleavage occurring within the PEG chain of the disulfide-peptide species, and 
not at the amide bond as might have been expected.  In Figure 3.10, the peak at m/z 654 
corresponds to the [M+2Na-H]
+
 species of the SAM-peptide structure shown in Figure 3.11, 
presumably produced via β-elimination of the peptide-containing fragment of the SAM-
peptide complex.   
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Figure 3.11: Proposed fragments for product generated on CID of leucine enkephalin captured 
on disulfide-derived SAM  
In Figure 3.9, the peak at m/z 903 is unassigned.   
The fact that ions at the same m/z value (m/z 763 ([M+Na]
+
)) were observed in the CID 
spectra of both peptides captured on the SAM (the fragment shown in Figure 3.11) could be 
a convenient diagnostic ion for peptide capture products.  For a more complicated peptide 
mixture in which the peptides may not have been identified (for example a protein digest 
captured on the SAM), CID MS/MS analysis could very conveniently be used to demonstrate 
successful peptide capture, using the ion at m/z 763 as a diagnostic fragment for the 
disulfide-derived SAM product (Figure 3.11).   
 
3.4. 4-Bromophenylalanine and phenylalanine coupling to 
SAM 
In previous results (Sections 2.4 and 2.6, and Section 3.3), problems have been noted when 
attempting to capture 4-BrPhe and Phe-Gly-Gly on both the thiol-derived SAM (Section 2.4 
and 2.6) and the disulfide-derived SAM (Section 3.3).  In Chapter 2, peaks associated with 
unreacted SAM were observed in spectra for peptide captured on the SAM.  This is most 
likely to be due to a cumulative inefficiency in the different chemical steps in the protocol.  
With the disulfide-derived SAM, the SAM is already pre-activated and so further investigation 
of coupling Phe-containing species to the SAM was undertaken using the disulfide-derived 
SAM, and 4-BrPhe and Phe.   
In the case of coupling 4-BrPhe to the SAM, it was not clear whether the presence of the 
Phe, or the combination of the Phe with the bromine in the chemical tag was contributing to 
the poor coupling of the tag to both the thiol-derived SAM and the disulfide-derived SAM.  It 
is possible that the size of the bromine atom could be contributing to any steric hindrance 
when the 4-BrPhe was reacted with the disulfide-derived SAM.  Therefore, coupling of 4-
BrPhe and Phe was attempted at 5 nmol and 0.05 nmol levels on the disulfide-derived SAM.   
β-elimination 
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4-BrPhe and Phe were prepared in PBS for capture on the disulfide-derived SAM at 5 nmol 
and 0.05 nmol levels.  Aliquots (1 µL) were spotted on wells and left for one hour at ambient 
temperature. The gold-coated MALDI chip was washed with acetonitrile and dried under a 
stream of nitrogen.  Aliquots (0.3 µL) of THAP solution were spotted on wells prior to MALDI-
MS analysis.   
Figure 3.12 shows the MALDI mass spectrum obtained following reaction for one hour of 4-
BrPhe at 5 nmol and 0.05 nmol with the disulfide-derived SAM (peak assignments shown in 
Table 3.5).   
 
Figure 3.12: MALDI mass spectra obtained following reaction for one hour of 4-BrPhe at 5 
nmol and 0.05 nmol with the disulfide-derived SAM.  Top = 5 nmol of 4-BrPhe spotted on the 
disulfide-derived SAM, bottom = 0.05 nmol of 4-BrPhe spotted on the disulfide-derived SAM 
As can be seen in Figure 3.12, 4-BrPhe coupling was achieved when 5 nmol or 0.05 nmol of 
4-BrPhe were used.  At the 0.05 nmol level, peaks can be seen in the mass spectra which 
correspond to species bearing unreacted NHS groups (Table 3.5), which are not observed in 
the spectrum obtained for the higher 4-BrPhe amount (5 nmol).   
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Table 3.5: Peaks associated with disulfide-derived SAM and 4-BrPhe coupled to the disulfide-
derived SAM 
Nominal m/z value Assignment 
733 [M+Na]
+
 - 2 mPEG termini 
932 [M+Na]
+
 - 1 mPEG terminus, 1 NHS terminus 
1082/1084 [M+2Na-H]
+
 - 1 mPEG terminus, 1 CO-4-BrPhe terminus  
1098/1100 [M+Na+K-H]
+
 - 1 mPEG terminus, 1 CO-4-BrPhe terminus 
 
For all mass spectra obtained following reaction for one hour of 4-BrPhe at 5 nmol and 0.05 
nmol with the disulfide-derived SAM, peaks associated with coupling of the 4-BrPhe to the 
SAM consistently showed a higher S/N value at the 5 nmol level than the 0.05 nmol level.  
The data suggest that coupling of the 4-BrPhe to the disulfide-derived SAM was more 
efficient when 5 nmol of 4-BrPhe was reacted with the disulfide-derived SAM than 0.05 nmol 
of 4-BrPhe reacted with the disulfide-derived SAM.  There is a 100-fold increase in the 
amount of 4-BrPhe spotted on the wells at 5 nmol compared to 0.05 nmol, which is likely to 
be the reason for the coupling being more efficient, as there is a larger excess of 4-BrPhe.  
This could drive the coupling of the 4-BrPhe and the SAM.   
 
Figure 3.13 shows MALDI mass spectra obtained following reaction for one hour of Phe at 5 
nmol and 0.05 nmol with the disulfide-derived SAM (peak assignments shown in Table 3.6).   
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Figure 3.13: MALDI mass spectra obtained following reaction for one hour of Phe at 5 nmol 
and 0.05 nmol with the disulfide-derived SAM.  Top = 5 nmol of Phe spotted on disulfide-
derived SAM, bottom = 0.05 nmol of Phe spotted on disulfide-derived SAM 
As can be seen in Figure 3.13, coupling of Phe was successful when both 5 nmol and 0.05 
nmol were spotted on the SAM.  As with 4-BrPhe, at the 0.05 nmol amount, peaks can be 
seen in the mass spectra which correspond to species bearing unreacted NHS groups.   
Table 3.6: Peaks associated with disulfide-derived SAM and Phe captured on the SAM 
Nominal m/z value Assignment 
733 [M+Na]
+
 - 2 mPEG termini 
932 [M+Na]
+
 - 1 mPEG terminus, 1 NHS terminus 
1004 [M+2Na-H]
+
 - 1 mPEG terminus, 1 CO-Phe terminus 
 
As with the coupling of 4-BrPhe to the disulfide-derived SAM, the mass spectra obtained 
following reaction for one hour of Phe at 5 nmol with the disulfide-derived SAM consistently 
showed a higher S/N compared with that from the spectra obtained following reaction for 
one hour of Phe at 0.05 nmol with the disulfide-derived SAM.  The data suggest that 
coupling of the Phe to the disulfide-derived SAM was more efficient when 5 nmol of Phe was 
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reacted with the disulfide-derived SAM than 0.05 nmol of Phe reacted with the disulfide-
derived SAM.  There is a 100-fold increase in the amount of Phe spotted on the wells at 5 
nmol compared to 0.05 nmol.  This could be the reason for the coupling to be more efficient, 
as there is an excess of Phe, which could drive the coupling of the Phe and the SAM.   
 
The mass spectra obtained for 4-BrPhe and Phe coupling to the SAM were examined for the 
presence of peaks due to species associated with 4-BrPhe/Phe on the SAM and species 
bearing unreacted NHS groups.  The percentage of spectra where peaks were observed for 
species associated with 4-BrPhe/Phe captured on the SAM and species bearing unreacted 
NHS groups was calculated (Table 3.7).   
Table 3.7: Table for 4-BrPhe and Phe spotted at 5 and 0.05 nmol levels on the disulfide-
derived SAM, and percentage of spectra with species for 4-BrPhe/Phe capture and unreacted 
SAM (number of replicates = 8). 
 
Amount 
spotted on 
wells / nmol 
Peaks seen 
for capture 
on SAM? 
Percentage
vi
 
of spectra 
with signal 
for capture 
Peaks seen 
for unreacted 
SAM? 
Percentage
vi
 of 
spectra with 
signal for 
unreacted SAM 
4-BrPhe 
5 Yes 100% Yes 0% 
0.05 Yes 66% Yes 6% 
Phe 
5 Yes 100% Yes 0% 
0.05 Yes 50% Yes 25% 
 
As can be seen in Table 3.7, the percentage of spectra for which peaks associated with 
coupling of the 4-BrPhe/Phe to the SAM is higher at 5 nmol than at 0.05 nmol.   
As was suggested and discussed in Section 3.3, it is possible that partitioning of the 4-BrPhe 
and Phe is occurring in solution due to the mismatch in the properties of the solvent and the 
solute.
200–202
  The hydrophobic phenyls in the side chains of the Phe could be causing 
aggregation, and pack the N-termini of the 4-BrPhe or Phe inside the aggregate.  This would 
result in lower coupling efficiency observed for 4-BrPhe or Phe reacting with the disulfide-
                                                          
vi
 One mass spectrum recorded from each well.  Data extracted from spectra for relevant 
peaks (e.g. species bearing unreacted NHS groups).  Percentage values calculated as a 
percentage of the total number of spectra recorded for each peptide at each amount spotted 
on the SAM.   
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derived SAM than an amino acid with no phenyl side chain, as the N-termini of the 4-BrPhe 
and Phe would be hidden within the aggregate.   
Alternatively, it is also possible that π-stacking of the aromatic side chains of the Phe amino 
acid could be occurring in solution.  As with the theory that the hydrophobic Phe amino acids 
could be causing the formation of aggregates, the possibility of π-stacking of the aromatic 
side chain of the Phe amino acids would also result in aggregates being formed in solution.  
If aggregates were formed in solution, this would mean that the N-termini of the 4-BrPhe and 
Phe would not be available to react with the SAM, which would have resulted in the low 
coupling efficiency observed with 4-BrPhe and Phe.   
Consistent with the results seen in Section 3.3, coupling of 4-BrPhe and Phe with the 
disulfide-derived SAM was more successful at the 5 nmol level than at the 0.05 nmol level.  
This could again be due to larger aggregates being present in the more dilute solution 
(where 0.05 nmol of 4-BrPhe or Phe was reacted with the disulfide-derived SAM), which 
would prevent reaction of the 4-BrPhe or Phe with the disulfide-derived SAM.
205
  There is 
excess 4-BrPhe or Phe, when compared to the theoretical amount of reactive-termini on the 
SAM, which should theoretically mean no peaks being observed for unreacted SAM.   
When the results seen for 4-BrPhe and Phe reacting with the disulfide-derived SAM are 
combined with the results seen in Section 3.3 for the peptide Phe-Gly-Gly reacting with the 
disulfide-derived SAM, the data may suggest that the presence of the phenylalanine residue 
at the N-terminus of a peptide reduces capture efficiency between the peptide and the SAM.  
This is likely to be due to some form of aggregation of the peptide, 4-BrPhe or Phe when in 
solution in the PBS and spotted on wells containing the SAM.  Aggregation could be due to 
the hydrophobic nature of the Phe amino acid or π-stacking of the aromatic side chains of 
the Phe amino acid.  Both of these would cause the aggregation of the Phe-containing 
species in the PBS, which would reduce the efficiency of the capture on the disulfide-derived 
SAM.   
There is also the possibility that the presence of the Phe amino acid increases the amount of 
peptide/amino acid needed for capture on the disulfide-derived SAM, due to the fact that a 
larger proportion of spectra contained peaks due to unreacted SAM at the 0.05 nmol level 
than the 5 nmol level.  This could be due to the fact that larger aggregates could occur in the 
more dilute solution (0.05 nmol of peptide, 4-BrPhe or Phe reacted with the disulfide-derived 
SAM) than in the more concentrated solution (5 nmol of peptide, 4-BrPhe or Phe reacted 
with the disulfide-derived SAM).   
It is possible that peptides which contain amino acids with aromatic side chains (Phe, Tyr, 
His and Trp) at the N-terminus may exhibit the same properties as Phe-Gly-Gly, 4-BrPhe 
and Phe when reacted with the disulfide-derived SAM.  This could be tested by reacting a 
variety of peptides containing an amino acid with an aromatic side chain with the disulfide-
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derived SAM.  Ideally, an equivalent peptide containing the same sequence, but an amino 
acid without an aromatic side chain (such as Gly) in place of the Phe, Tyr, His or Trp should 
be used.  This would build on the work undertaken using Phe-Gly-Gly and Gly-Gly-Gly 
(Chapter 2 and Section 3.3) by allowing a comparison between the two types of amino acids 
(those containing an aromatic side chain, and those without an aromatic side chain).  It 
would also be interesting to see whether the position of the aromatic side chain had any 
effect on the efficiency of the peptide capture on the disulfide-derived SAM (i.e. whether the 
capture efficiency is improved if the aromatic side chain is moved further away from the N-
terminus).   
 
3.5. Conclusions and future work 
A variety of peptides has been captured on the disulfide-derived SAM at 5 nmol and 0.05 
nmol levels.  The peptide capture step has been reduced from an overnight reaction to one 
hour.  This is a considerable time saving for the workflow, and could potentially mean that 
the entire process (from SAM formation to peptide capture and analysis) could take place in 
two days with one overnight step for simultaneous SAM formation and protein digestion.   
The data suggest that when reacting Phe-Gly-Gly, 4-BrPhe or Phe with the disulfide-derived 
SAM, the capture is inefficient.  When 5 nmol and 0.05 nmol levels of the Phe-containing 
species were reacted with the disulfide-derived SAM, the capture of the Phe-containing 
species was more efficient at the 5 nmol level than the 0.05 nmol level.  This is likely to be 
due to some form of aggregation occurring in the peptide solution.  There is a mismatch in 
the properties of the solvent (PBS) and the solute, which could result in the hydrophobic Phe 
amino acid causing aggregation in the aqueous solution, and packing the N-termini of the 
Phe-containing species inside the aggregate.  This would mean that the N-termini were not 
available for reaction with the SAM.  Alternatively, π-stacking of the aromatic side chain of 
the Phe amino acid could also be causing the formation of aggregates within the PBS.   
A possible explanation for the fact that for some peptides peaks were still observed for 
unreacted SAM after peptide capture at the 0.05 nmol level (even though this is above the 
estimated amount of reactive groups on the surface of the SAM) could be the fact that larger 
aggregates were formed in the more dilute peptide solution.  Therefore, there would be less 
peptide available to react with the SAM when 0.05 nmol of peptide was used, as larger 
aggregates could be present than when 5 nmol of peptide was reacted with the SAM.   
 
Further work into possible alternative solvents for the peptide solution (and therefore 
subsequent reaction of the peptide and SAM) should be undertaken.   
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Alternative chemical tags should also be investigated.  Due to the fact that there is a 
problem with phenylalanine, 4-BrPhe is not a suitable chemical tag to use.  A possible 
alternative would be to adapt a currently-used proteomics chemical labelling strategy (see 
Chapter 5 and Chapter 6).   
The disulfide-derived SAM consists of the sulfur head group, the PEG groups and the 
terminal groups.  This is in contrast to the SAM components used in Chapter 2, which 
contain an alkyl chain between the sulfur head group and the PEG groups.  The PEG groups 
do not have the structural rigidity of alkyl chains.  This is because these chains can be 
solubilised by water, with hydrogen bonds formed between the PEG groups and the 
water.
206
  The solubilisation of the PEG groups will disrupt the monolayer.  Therefore, the 
cartoon image of the SAM with the PEG chains protruding from the solid surface, and 
ultimately the NHS groups projecting beyond the end of the SAM, may well be an inaccurate 
interpretation.  Due to the incorporation of water between the PEG chains, it is possible that 
the PEG chains may be tangled, and the NHS groups may be buried within the SAM.  
Therefore, a peptide would not be able to react with the NHS group.  The disulfide-derived 
SAM components may lack structural integrity when the SAM is formed on the gold-coated 
MALDI chip.  In order to regain some of the rigidity that may be required for the SAM, an 
alternative SAM should be investigated.  The SAM components should include an alkyl 
region to give some rigidity to the SAM, as well as a PEG region, to stop non-specific 
adsorption on the gold surface.  Either thiol-derived or disulfide-derived components could 
be used to form a SAM for subsequent peptide capture.   
Alternative SAM components which could be explored include those published by Murray et 
al. in 2014.
207
  The group (in collaboration with Steven Johnson’s group at the University of 
York) synthesised a variety of alkanethiol-oligoethyleneglycols to produce a variety of 
functionalised SAMs.  One SAM which was formed consisted of two thiols: one terminating 
in an alcohol group (the spacer molecule) and the other terminating in a primary amine.  
These two components both contain alkyl chains followed by a PEG region, which would 
meet the proposed criteria for potential SAM components.  The group then reacted the 
amine termini of the SAM with bis(sulfosuccinimidyl) suberate (BS3) (Figure 3.14) to form an 
activated SAM to capture the antibody anti-hCG through amide bond formation.  This could 
potentially be adapted for use with the peptide capture work.   
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Figure 3.14: Structure of bis(sulfosuccinimidyl) suberate  
The BS3 molecule could be used as the chemical tag (a potential alternative chemical tag to 
4-BrPhe).  A ‘heavy’ version of the BS3 would need to be synthesised, to include either 
deuterium or 
13
C atoms (or a combination of the two), most likely within the alkyl region in 
the middle of the BS3 molecule.  After the SAM had been formed on the gold-coated MALDI 
chip, a 50:50 mixture of the light and heavy BS3 molecules would be reacted with the SAM.  
The peptide(s) would then be reacted with the BS3-labelled SAM and the resulting SAM-
peptide structure analysed by MALDI-MS. 
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4.1. Introduction  
Plasma is often referred to as the fourth state of matter.  It is an ionised gas which, on the 
macroscale, contains equal numbers of positive and negative charges.  However, on the 
microscale, strong electric fields can exist between the particles, due to an imbalance of 
charges in a particular region.  The charges arise from molecules of gas being split into ions 
and electrons.  Although the electrons and ions are no longer bound together, they cannot 
be described as free, as there is still an interaction between the two.   
There are some very different types of plasma (e.g. stars, lightning and nuclear fusion 
reactors), and plasmas can be used for many different applications (e.g. etching, X-ray 
lasers and semiconductor technology).
208–210
   
Plasma is generated either through heating, or by application of an electric field to a gas.  
When applying an electric field (e.g. to a laboratory-based plasma), the gas is turned into 
plasma by flowing it through the space between a pair of electrodes.  The high electric 
charge tears electrons from the particles of gas, creating charges within the gas.  This is a 
cascading process, creating more free electrons by collisions between the free electrons and 
ions already generated within the body of gas.  The degree of ionisation of the plasma
vii
 is 
expressed as a ratio between the number density of ions and the number density of 
neutrals, and ranges from fully ionised to partially ionised (Equation 4.1).   
𝐼 =
𝑛𝑒
𝑛𝑒 + 𝑛𝑜
 
Equation 4.1: Equation showing the degree of ionisation of a plasma (ne = electron density, no 
= number density of neutral atoms) 
Within plasma, Debye shielding occurs.  This essentially means that electrons tend to gather 
near a positive charge within the plasma, creating an electrostatic shield around the charge 
and vice versa.  The shielding length, known as the Debye length, is an important 
characteristic of plasma, as it must be much smaller than the physical size of the plasma.  
The Debye length is essentially a measure of how far electrostatic effects of a charge carrier 
persist.   
A quasi-neutral state exists throughout plasma, except near the boundaries (i.e. the edges of 
the plasma).  An example of a confined plasma is a laboratory-based plasma, where a 
plasma sheath exists on all cold walls (e.g. the electrode casing) with which the plasma 
makes contact.  A plasma sheath is a layer of charge imbalance near the cold surface.  It 
consists of a layer of negative charge, which repels electrons.  Electrons have a higher 
thermal velocity than ions and so stand a greater chance of colliding with the wall, and 
                                                          
vii
 The number of species per cm
3
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therefore the loss of electrons from the plasma is greater than the loss of ions.  A net 
positive charge thus develops over time, and raises the potential of the bulk of the plasma 
above the potential of the walls (i.e. makes the potential of the walls negative with respect to 
the bulk of the plasma).  This potential drop provides a barrier for electrons and attracts ions.  
Therefore, adjacent to the negative boundary layer is a layer of positive space charge, which 
has a rapidly increasing potential across it (as the distance from the wall increases), until a 
quasi-neutral state is reached (Figure 4.1).
211
 
 
Figure 4.1: Potential structure in a plasma sheath (φ = potential, x = distance from the cold 
surface) 211 
In plasma, the different particles that can arise fall into two categories: charged (such as ions 
and electrons) and neutral (such as radicals and metastables).  Metastables refer to 
molecules in a metastable state.  These are excited states which have a finite lifetime and 
relax after a period of time into a more stable state (i.e. the ground state).  A metastable 
state can be described as an energy trap, and is often visualised as a well in the energy 
profile for a molecule.  Therefore, metastable molecules can be thought of as molecules 
which spend an extended period of time in a long lived configuration, which is not the ground 
state.   
Particles within plasma are free to move about, and so can collide and interact with each 
other.  In a simplified model, electrons can be thought of as the objects that move within the 
plasma, and the neutral species can be thought of as staying stationary.  The electrons then 
make their way past these stationary neutral species (Figure 4.2).  When an electron collides 
with a neutral species in a plasma it bounces off, as the neutral species is assumed to be a 
hard sphere, and the electron behaves like a point mass.
211
  Using a collision cross section 
(σ), it is possible to quantify the probability of a collision between a neutral species and an 
electron, or how far into the space filled by neutral species an electron can travel before 
having a collision.  In the simplified model, the cross section of the species that the electron 
ϕ 
negative surface charge 
positive space charge 
x 
quasi-neutral 
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sees depends on the energy of the electron encountering the gas (the total kinetic energy in 
the encounter).
211
   
 
Figure 4.2: Simplified model for an electron travelling through stationary neutral species in a 
3D model (left) and 2D model (right) (e- = electron) 
The number of target atoms in the cuboid xyz is ngxyz (where ng = number of gas units per 
unit volume).  Each neutral species presents a cross section (σ) of: 
𝜎 = 𝜋𝑟𝑔
2 
Equation 4.2: Equation for cross section of an atom (rg = radius of an atom of the gas used in 
the plasma) 
When the path of the electron is viewed through the xy plane, the total area blocked by 
neutral species is ngxyzσ.  If the cuboid extends as far as one mean free path (λ), virtually 
the entire face xy is obscured:   
(𝑛𝑔𝑥𝑦𝜆)𝜎 = 𝑥𝑦 
𝜆 =
1
𝑛𝑔𝜎
 
Equation 4.3: Equation (upper) showing that virtually the entire face xy is obscured when the 
cuboid extends as far as one mean free path (and simplified (lower)) 
These equations show that the electron is very likely to have a collision.  The frequency of 
encounters can be estimated for the electrons: 
𝜐 = ῡ𝑛𝑔𝜎 
Equation 4.4: Equation for the frequency of encounters for electrons (ʋ = frequency of 
encounters, ῡ = mean speed) 
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However, this is a simplified model, and only takes into consideration simple elastic 
encounters between neutral species and electrons.  Cross sections are not independent of 
energy.
211
  High-energy electrons travel so fast that their interactions with the outer spheres 
of neutral species are reduced.   
Elastic and inelastic collisions are possible within plasma.  In an elastic collision, the total 
kinetic energy is conserved, but the momentum is redistributed between particles and there 
is a change of direction for the particles involved in the collision.
211
  Electrons cannot lose 
much energy to the ions or neutrals, but the change in momentum between the two can be 
large.  In an inelastic collision, excited states can occur due to energy transfer within the 
particles involved in the collision, and the total number of particles resulting from the collision 
does not have to be maintained.
211
  A fraction of the initial kinetic energy is transferred to 
internal energy to form excited states, which can go on to fragment.  Electrons can lose 
almost all of their kinetic energy when they collide with ions or neutrals.   
Plasma temperature is usually referenced in Kelvin.  At low temperatures, the ions and 
electrons within the plasma are likely to recombine to form atoms.  If enough recombination 
occurs, then the plasma returns to a gaseous state.  Temperatures are defined within the 
plasma for electrons (Te), ions (Ti) and neutrals (Tneutrals).  It is possible for a laboratory-
based plasma to either be thermal or non-thermal.  For thermal plasma, the bulk of the 
plasma is at thermal equilibrium, meaning that the three specified temperatures are the 
same.  For non-thermal plasma, the electron temperature is much higher than the ion and 
neutral temperatures.  Due to the relative differences in mass between the ions and the 
neutrals versus the electrons, energy transfer is not efficient between the high temperature 
electrons and the larger, cooler ions and neutrals, and so overall the plasma is considered to 
be at room temperature.  This gives rise to the term ‘atmospheric pressure plasma’.  The two 
plasma instruments used in the work described in this chapter were both operated at 
atmospheric pressure, and are termed an ‘atmospheric-pressure plasma jet’ (APPJ).  These 
plasma sources offer advantages over low-pressure plasmas, such as the fact that 
expensive vacuum systems are not required.
212
  However, it can be difficult to maintain a 
glow discharge in an atmospheric-pressure plasma due to the absence of a vacuum.
212
  
Higher voltages are required, and arcing can occur between the electrodes.   
An example of a high temperature plasma is the plasma in an inductively coupled plasma 
mass spectrometer (ICP-MS) which uses a high temperature, inductively coupled plasma 
source with a mass spectrometer.   
Laboratory-generated plasmas can be thought of as steady, non-thermal equilibrium 
states.
211
  Continuous electrical discharges are often used to create and maintain a dynamic 
steady state, such as forcing an electric current through a gas in order to ionise it and create 
plasma.  The electric current must be continually supplied to ensure the plasma is 
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maintained.  A balance exists between production and loss of ions.  For laboratory-
generated plasmas, where production and loss processes are generally separated 
physically, energy which is invested in the production of ions is effectively transported to the 
place of loss (sink).   
When plasma comes into contact with a solid surface, the surface acts as a sink, which 
‘drains away’ the plasma.  There is a recombination of electrons and ions at the surface due 
to the fact that the electrons and ions are suddenly at lower temperature.  The environment 
surrounding the plasma (such as the physical boundaries of a laboratory-generated plasma, 
or the blanket of neutral gaseous molecules surrounding the plasma effluent) can also act as 
a sink.   
In plasma generated using an admixture (e.g. helium and a small amount of another gas), 
the species generated can be altered from those produced using a single gas.  The key 
chemistry occurring within the plasma is largely dependent on the ratio of the other gas 
(often oxygen or nitrogen) added to the helium.  Oxygen and nitrogen allow different species 
to be produced within the plasma, which may not be observed with a pure helium gas 
plasma.  With the addition of oxygen, reactive oxygen species (ROS) are produced (e.g. 
hydroxyl radicals and ozone), whilst the addition of nitrogen leads to reactive nitrogen 
species (RNS) being produced (e.g. nitric oxide and nitrogen dioxide).  The effect of these 
different species on the properties of the plasma effluent is not yet understood.
213
   
Plasmas have previously been used for cleaning of metal surfaces, but have mainly been 
generated using argon.
214,215
  In 2005, Raiber et al. published a paper in which they used 
plasmas generated from hydrogen or oxygen to remove an alkanethiolate SAM from a gold 
surface.
209
  They compared the efficiency of the two plasmas using XPS, STM, ellipsometry 
(to determine the thickness of the film) and contact angle measurements.  The authors found 
that although use of the oxygen plasma resulted in a level of oxidation on the gold surface, 
the changes in surface topology detected by STM were not significant.  Therefore, they were 
satisfied that either of the plasmas could be used for the removal of alkanethiolate SAMs 
from a gold surface.   
In 2012, Favrat et al. published a paper detailing the removal of stearic acid from a gold 
surface using atmospheric-pressure plasma.
216
  Although this is not removal of SAMs from a 
gold surface using plasma, it is still removal of an organic layer from a metal surface.  The 
group used a Kelvin probe to monitor residual stearic acid on the surface.  The atmospheric-
plasma was generated using compressed air (giving a high composition of nitrogen and 
oxygen in the plasma effluent).  The group found that after four exposures to the plasma 
effluent, residual contamination (remaining stearic acid) was between 5.7 and 8.1% 
compared to initial contamination.   
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For the work described in this chapter, two different plasma instruments were used: a kHz 
dielectric barrier discharge (DBD) plasma instrument and a radiofrequency (RF) plasma 
instrument.  A DBD plasma is a non-equilibrium plasma, which exhibits similar charged-
species density to a weakly ionised gas.
212
  The RF plasma instrument is operated with 
insulated or external electrodes and can be operated at a wide range of pressures, whilst the 
DBD plasma instrument operates at or near atmospheric pressure.  Both the DBD and RF 
plasma instruments used in this work are classed as APPJs.  A schematic of the area where 
the plasma is generated is shown in Figure 4.3 for each of the two plasma instruments.   
 
Figure 4.3: RF plasma electrode set up (left) and kHz plasma electrode set up (right).  The 
electrode gap on the RF plasma electrode is 30 × 1 × 1 mm.  On the kHz plasma electrode, the 
lower electrode is powered, whilst the upper electrode is grounded.   
With the RF plasma instrument, the electric field is perpendicular to the flow of gas, which 
results in charged species being confined within the electrode region.  This means that they 
are not present in the plasma effluent, and therefore not interacting with the surface of the 
gold-coated MALDI chip.  The kHz plasma instrument has an electric field which is parallel to 
the flow of the gas, resulting in no confinement of the charged species within the electrode 
region.   
This work was undertaken in collaboration with Martin Blake and Deborah O’Connell of the 
York Plasma Institute and Victor Chechik of the Department of Chemistry.   
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4.1.1. Aims 
The method currently used for cleaning the gold-coated MALDI chips is to use a piranha 
solution.  However, this is a corrosive cleaning technique, and removes the outermost layer 
of gold from the gold-coated MALDI chip.  After a number of cleans with piranha solution, the 
thin layer of gold which coats the gold-coated MALDI chips can become eroded enough for 
the metal underneath to be seen (Figure 4.4).  A helium-based plasma effluent was 
suggested as an alternative to the piranha solution to remove the SAM from the gold-coated 
MALDI chip, whilst potentially causing minimal damage to the gold surface.  Therefore, a 
helium-based plasma effluent was investigated as an alternative method for cleaning the 
gold-coated MALDI chips being used in the SAM-based workflow.   
 
Figure 4.4: Damaged gold chip (arrow indicates where the metal layer under the gold can be 
seen after repeated use of piranha solution)  
 
  
Damaged gold surface 
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4.2. Formation of a thiol-derived SAM 
A gold-coated MALDI chip was cleaned with piranha solution and spotted with aliquots of an 
alcohol thiol (HS(CH2)17(OCH2CH2)3OH), which was left to assemble overnight at room 
temperature.  The gold-coated MALDI chip was washed with acetonitrile and dried under a 
stream of nitrogen.  Aliquots of matrix were spotted on wells, and the success of the 
formation of the SAM was assessed by MALDI mass spectrometry (Figure 4.5) before wells 
were subjected to the plasma effluent.  Aliquots (0.3 µL) of THAP matrix solution were 
spotted on the wells prior to mass spectrometric analysis. 
 
Figure 4.5: MALDI mass spectrum of the alcohol thiol-derived SAM 
As can be seen in Figure 4.5, the alcohol thiol successfully formed a SAM.  A peak at m/z 
861 indicates the presence of an [M+Na]
+
 disulfide having two alcohol termini.  A peak at 
m/z 877 indicates the presence of an [M+K]
+
 disulfide having two alcohol termini.   
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4.3. Testing the kHz plasma instrument for cleaning SAM-
coated gold 
The suitability of the kHz plasma instrument for SAM removal was assessed.  It was 
observed that the plasma effluent extended beyond the end of the casing (Figure 4.6), and 
that the effluent didn’t cover the surface area of a well.  Consequently, the gold-coated 
MALDI chip needed to be moved whilst a well was being treated with the plasma effluent, in 
order to treat the whole surface of the well.   
 
Figure 4.6: The electrode region of the kHz plasma instrument  
 
4.3.1. Optimising conditions for the kHz plasma instrument 
Wells which had SAM and matrix on them were treated with plasma effluent.  The time that 
wells were subjected to the plasma effluent (30, 60, 90 and 120 seconds), and the distance 
of the plasma casing from the gold surface (2 mm, 10 mm, 17 mm, 25 mm and 40 mm), 
were varied to ascertain the potential cleaning ability of the plasma.  Multiple wells were 
treated for each treatment combination (Table 4.1).  The treated wells were then respotted 
with aliquots (0.3 µL) of matrix solution and reanalysed by MALDI-MS.  Spectra were 
obtained from the middle of each well and also from the outer edge of each well.  This was 
due to the fact that the gold-coated MALDI chip had to be moved whilst the well was being 
treated with the plasma effluent, to see whether the movement had been successful.   
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Table 4.1: Treatment combinations for kHz plasma instrument, and for each treatment the 
percentage of spectra in which peaks for the SAM were detected (number of wells per 
condition = 4) 
Treatment m/z 861 detected 
Middle of the well Outer edge of the well 
17 mm 
30 s 75% 100% 
60 s 25% 100% 
90 s 25% 100% 
120 s 25% 75% 
30 s 
2 mm 100% 100% 
10 mm 100% 100% 
17 mm 100% 100% 
25 mm 100% 100% 
40 mm 100% 100% 
 
As can be seen in Table 4.1, it was found that peaks associated with the SAM (m/z 861 
([M+Na]
+
)) were observed in spectra obtained after plasma treatment for all treatment 
combinations tested.  However, the S/N obtained after plasma treatment was approximately 
a fifth to a tenth of the S/N value from spectra obtained before plasma treatment.  Peaks 
associated with the SAM were observed in mass spectra obtained after plasma treatment at 
all distances.   
As a comparison, wells which had been cleaned with piranha solution were spotted with 
aliquots of matrix and analysed by MALDI-MS.  No peaks were observed for species 
associated with the SAM (m/z 861 and 877).   
Peaks associated with the SAM were observed in spectra obtained after plasma treatment of 
wells with SAM formed on them, but no peaks were observed in spectra obtained after 
piranha cleaning of wells with SAM formed on them.  The data suggest that the plasma 
treatments used in this experiment were not as effective at removing the SAM from the gold-
coated MALDI chips as the piranha solution.   
 
4.3.2. Incremental treatment time course study  
While it was evident that the relative intensities of SAM-derived mass spectrometric signals 
were decreased by kHz plasma treatment, it was not possible to determine from this 
experiment whether this was because cleavage within the SAM was occurring, or whether 
the SAM was being cleaved at the gold-sulfur bond.  Therefore, a time course study was 
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undertaken, with sequential wells being subjected to increasing periods of treatment with 
plasma effluent; periods from 10 seconds to 160 seconds were tested, with periods 
increased by 10 second increments.  A parallel experiment was carried out to determine 
whether removal of the SAM from the gold-coated MALDI chip was affected by matrix 
addition; a duplicate experiment was performed without adding matrix to the wells before 
treatment (in both cases wells were subjected to irradiation periods increasing in increments 
of 10 seconds).  The plasma effluent was created using helium with 0.5% oxygen.   
The S/N of the peak at m/z 861 ([M+Na]
+
, disulfide containing two alcohol termini) was 
extracted from each mass spectrum recorded for wells which had been spotted with matrix 
prior to plasma irradiation, and plotted (Figure 4.7). 
 
Figure 4.7: Plot showing the S/N of m/z 861 after SAM-bearing, matrix-spotted wells were 
treated with the plasma effluent of the kHz plasma instrument 
Figure 4.7 shows an overall decrease in the relative S/N of m/z 861 with increasing period of 
plasma treatment.  However, the downward trend is not smooth, with spikes seen at some 
time points (e.g. 90 seconds).  This is likely to be due to MALDI’s innate variability
192
 and the 
fact that only one well was analysed for each time point; there was no reanalysis of the wells 
(to allow an average value to be determined) and the experiment was not repeated.  This 
was due to time-constraints, and subsequent loss of access to the plasma instruments.  Had 
there been the opportunity to repeat the analysis, a minimum of four wells would have been 
analysed for each time point, allowing mean S/N values to be calculated for each time point.  
This would allow easier identification of anomalous results, which could then be excluded 
from the data.  Although the data point at 90 seconds does not fit the downward trend 
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observed for the time-course study, this result was included in the overall analysis due to the 
fact that only single wells were analysed.   
An example of the mass spectra obtained after plasma treatment of matrix-free SAM-
containing wells is shown in Figure 4.8.   
 
Figure 4.8: MALDI mass spectrum obtained from a well with SAM but no matrix treated with 
the effluent of the kHz plasma instrument for 10 seconds 
As can be seen in Figure 4.8, there was no detectable signal at m/z 861 or 877, which would 
have indicated an [M+Na]
+
 and [M+K]
+
 for a disulfide having two alcohol termini.  This 
indicates that the SAM had been reduced below the levels of detection from wells within the 
shortest treatment period of 10 seconds.  The fact that the presence of the SAM had been 
removed from a well in less than 10 seconds indicates that this could be a suitable 
alternative method to the piranha solution for removing SAMs from gold-coated MALDI 
chips, provided the matrix solution is rinsed from the wells before treatment with the plasma 
effluent.   
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4.4. Testing the radiofrequency (RF) plasma instrument for 
cleaning SAM-coated gold 
The plume from the RF instrument plasma (Figure 4.9) did not protrude from the end of the 
casing, in contrast to that of the kHz plasma instrument.  Consequently, the end of the 
electrodes was placed 2 mm from the surface of the gold-coated MALDI chips.  The distance 
between the two electrodes is 3 mm, which is the approximate diameter of a well on the 
gold-coated MALDI chip.  Therefore, the gold-coated MALDI chip was not moved around 
whilst each well was being treated with the plasma (contrary to treating wells with the kHz 
plasma instrument).   
 
Figure 4.9: The electrode region of the RF plasma instrument 
 
4.4.1. Optimising conditions for the RF plasma instrument 
The RF plasma instrument is usually run with addition of small amounts (e.g. 0.3%) of 
nitrogen or oxygen to the helium.  The addition of oxygen or nitrogen alters the properties of 
the plasma.  The possible benefits of addition of one or other of the gases to the helium 
were investigated, to determine whether addition of such a modifier gas produced a plasma 
that exhibited improved cleaning properties compared to only helium being used.  The times 
that the wells were treated with the RF plasma instrument were longer than those used for 
the kHz plasma instrument.  These times were suggested by the collaborators due to the 
differences in the orientation of the electric fields of the two plasma instruments.   
After SAM formation, aliquots (0.3 µL) of matrix solution were spotted on wells, and the wells 
were treated with the RF plasma instrument (Table 4.2).  Multiple wells were subjected to 
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the same treatment conditions.  The wells were then respotted with aliquots (0.3 µL) of 
matrix solution and analysed by MALDI-MS.   
Table 4.2: Treatment combinations for the RF plasma instrument, and for each treatment the 
percentage of spectra in which peaks for the SAM were detected (number of wells analysed 
for each condition = 2) 
Gas added Percentage added Time / mins m/z 861 detected 
Nitrogen 
0.1% 
3 100% 
5 100% 
0.25% 
3 100% 
5 100% 
0.5% 
3 100% 
5 100% 
0.75% 
3 100% 
5 100% 
Oxygen 
0.1% 
3 100% 
5 50% 
0.25% 
3 50% 
5 50% 
0.5% 
3 50% 
5 50% 
0.75% 
3 50% 
5 50% 
 
As can be seen in Table 4.2, the addition of oxygen to the helium had more of an impact 
than the addition of nitrogen, as the number of wells from which the mass spectra obtained 
after plasma treatment contained the peak associated with the SAM (m/z 861) was lower.  
Where the ion at m/z 861 was observed in the mass spectrum, the S/N value was lower than 
in spectra recorded prior to plasma treatment (an approximate tenth to twentieth decrease in 
the S/N value).  For both nitrogen and oxygen incorporation, spectra obtained for wells 
which were treated for five minutes showed lower S/N values for the peak associated with 
the SAM (m/z 861) than spectra obtained for wells which were treated for three minutes.   
 
4.4.2. Time course study 
A similar experiment to the time course study with the kHz plasma instrument was 
performed.  It was evident that the relative intensities of SAM-derived mass spectrometric 
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signals were decreasing with increasing time of plasma treatment, but it was not possible to 
determine whether this was because cleavage was occurring within the SAM, or whether the 
SAM was being cleaved at the gold-sulfur bond.  Therefore, a time course study was 
undertaken, with sequential wells being subjected to increasing periods of treatment with the 
RF plasma effluent; periods from 10 to 160 seconds were tested with periods increased by 
ten second increments.  A parallel experiment was carried out to determine whether removal 
of the SAM from the gold-coated MALDI chips was affected by matrix addition, by carrying 
out the same experiment without adding matrix to the wells before cleaning.  The plasma 
effluent was created using helium with either oxygen or nitrogen incorporation.  Two gas 
mixtures were tested: 0.25% nitrogen incorporation in helium and 0.5% oxygen incorporation 
in helium.  The wells were irradiated with the plasma effluent at a distance of 2 mm.   
The S/N of the peak at m/z 861 ([M+Na]
+
, disulfide containing two alcohol termini) was 
extracted from each mass spectrum recorded for wells which had been spotted with matrix 
prior to plasma treatment for both oxygen and nitrogen incorporation, and plotted (Figure 
4.10).   
 
Figure 4.10: Plot showing S/N of m/z 861 after SAM-bearing, matrix spotted wells were 
treated with the plasma effluent of the RF plasma instrument.  Results are shown for the 
addition of 0.25% nitrogen (blue) or 0.5% oxygen (red) 
Figure 4.10 shows an overall decrease in the relative S/N of m/z 861 with increasing period 
of plasma treatment.  However, as was seen with the kHz plasma instrument (Figure 4.7), 
spikes were seen at some time points (e.g. oxygen incorporation at 50 seconds).  This is 
likely to be for the same reasons as with the kHz plasma instrument.   
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There is a sudden decrease in the relative S/N of the peak at m/z 861 after 20 seconds 
treatment with the plasma formed with oxygen incorporation.  Based on the graph produced, 
in can be implied that incorporation of oxygen into the helium is the better option, rather than 
nitrogen incorporation.  This is in agreement with the data in Table 4.2, which suggest that 
oxygen incorporation provides better SAM removal than nitrogen incorporation.  However, 
as with the earlier analysis with the kHz plasma instrument, these conclusions are based on 
a single well for each time point, and so replicate analyses should be performed to allow 
mean values to be obtained.   
An example of the spectra obtained after plasma treatment of matrix-free SAM-containing 
wells is shown in Figure 4.11.   
 
Figure 4.11: MALDI mass spectrum obtained from a well with SAM but no matrix treated with 
the effluent with nitrogen incorporation of the RF plasma instrument for ten seconds 
When mass spectra were obtained from wells which only had SAM on them, there was no 
detectable signal at m/z 861 ([M+Na]
+
, disulfide having two alcohol termini).  This indicates 
that the presence of the SAM had been reduced below the levels of detection from wells 
within the shortest treatment period of 10 seconds.  The fact that the SAM could be removed 
from a well in less than 10 seconds indicates that this could be a suitable alternative method 
to the piranha solution for removing SAMs from the gold-coated MALDI chips, provided the 
matrix was washed off the surface of the gold-coated MALDI chip prior to plasma treatment.   
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4.5. Investigation into unassigned mass spectrometric peaks 
observed after plasma irradiation using either kHz or RF 
plasma instruments 
Peaks (such as those at m/z 607, 638, 668, 689), which were not associated with the SAM, 
were observed in mass spectra recorded after wells were subjected to plasma treatment 
using either one of the different instruments (Figure 4.12).   
 
Figure 4.12: MALDI mass spectra obtained after treatment with the kHz plasma instrument 
(top) and RF plasma instrument (bottom) (* indicates peaks which are associated with the 
SAM) 
The source of these peaks was investigated using the kHz plasma instrument (30 second 
irradiation), to determine whether they were related to cleavage of the SAM, the matrix or 
the gold surface.   
Wells on which no SAM was formed were spotted with matrix and irradiated with the plasma 
effluent prior to mass spectrometric analysis.  The unassigned peaks were observed in the 
resulting mass spectra.  This suggested that the peaks observed were derived from either 
the matrix or the gold as they had been observed in mass spectra in the absence of the 
SAM on the gold-coated MALDI chip, and so do not derive from cleavage of the SAM.   
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Wells with no SAM and no matrix were irradiated with the plasma effluent prior to mass 
spectrometric analysis.  The unknown peaks were observed in the resulting mass spectra, 
suggesting that the peaks were due to the gold, and not to an interaction between the 
plasma and the matrix.   
In order to determine if the species giving rise to the unknown peaks were present on the 
gold surface before plasma treatment, a new gold chip (which had never been cleaned) was 
analysed.  Wells on the gold-coated MALDI chip were spotted with aliquots (0.3 µL) of matrix 
solution and analysed by MALDI-MS.  The gold-coated MALDI chip was then treated with 
piranha solution before being spotted with matrix and reanalysed.  Figure 4.13 shows 
example mass spectra obtained before and after cleaning a new gold-coated MALDI chip 
with piranha solution.   
 
Figure 4.13: MALDI mass spectrum obtained for a new gold chip before (top) and after 
(bottom) cleaning with piranha solution 
As can be seen in Figure 4.13, peaks at m/z 638, 668 and 696, observed in all spectra 
recorded from the plasma experiments, are also present in spectra recorded before the gold-
coated MALDI chip had been subjected to any of the SAM-forming or cleaning treatments.  It 
can thus be concluded that cleaning the gold-coated MALDI chips with plasma effluent does 
not appear to alter the gold-coated MALDI chip, as far as is observable through MALDI mass 
spectrometry.   
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4.6. Respotting of thiol-derived SAM on wells cleaned with a 
plasma effluent 
Having determined that the SAM could be removed from the gold-coated MALDI chip by 
treatment with the kHz and RF plasma instruments, the ability to reform a SAM on wells 
which had been subjected to plasma effluent was investigated.   
Wells on a gold-coated MALDI chip were treated using the RF plasma instrument.  A 
solution of the alcohol thiol was then spotted on wells of the gold-coated MALDI chip and left 
to assemble overnight.  The success of the formation of the SAM was determined by MALDI 
mass spectrometry (Figure 4.14).   
 
Figure 4.14: MALDI mass spectrum showing alcohol thiol-derived SAM respotted on a well 
cleaned with plasma effluent (m/z 861 ([M+Na]+, disulfide having two alcohol termini)) 
 As can be seen in Figure 4.14, the formation of the SAM on wells which had previously 
been irradiated with plasma effluent was successful, as indicated by the presence of the 
peak at m/z 861 (c.f. Figure 2.4 which shows formation of a mixed SAM, with one 
component being the alcohol thiol on a well cleaned with piranha solution).  Therefore, a 
SAM can be successfully formed on the surface of a well which has been treated with 
plasma effluent.   
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4.7. Conclusions and future work 
An alcohol thiol-derived SAM was removed from gold-coated MALDI chips using kHz and 
RF plasma instruments.  Removal of the SAM was much easier without the presence of 
matrix on the surface of the wells.  Therefore, it is suggested that the matrix deposited on 
wells after MALDI-MS analysis be removed by washing (e.g. with acetonitrile), before 
cleaning the gold-coated MALDI chip using either of the plasma instruments.  This has the 
potential to be an effective alternative to the piranha treatment currently used.  Removal of 
the matrix deposit prior to plasma treatment would allow each well to be cleaned in less than 
10 seconds.  This represents a considerable decrease in the time taken to clean a gold-
coated MALDI chip over that required using piranha solution as a full chip could be cleaned 
in less than 11 minutes, as opposed to approximately 30 minutes when cleaning with the 
highly caustic piranha solution.  A SAM has also been reformed on wells which had been 
treated with plasma effluent.  Plasma treatment provides a promising new method for 
cleaning the gold-coated MALDI chips, which may lead to the chips being usable for a longer 
period of time, as the caustic piranha solution damages the gold surface (Figure 4.4).   
The theory that removing the matrix by washing the gold-coated MALDI chip and then 
treating the wells with either plasma instrument is an effective way of removing SAM from 
wells of the chip would need to be tested.  This would involve a simple comparison of 
plasma treatment of wells that had only had SAM formed on them and wells that had SAM 
formed on them and were then spotted with matrix solution and washed.  Provided that 
washing the gold-coated MALDI chip to remove the matrix, followed by plasma treatment of 
the wells proved an effective way to clean the wells, this would provide an alternative 
cleaning strategy to the caustic piranha treatment used currently.   
Replicates should be analysed for the time course studies with both of the plasma 
instruments to allow a greater confidence in the results obtained.  This would enable mean 
values of the S/N of m/z 861 to be derived for each time point, which could help reduce the 
effects of experimental variability.   
While MALDI mass spectrometry allows the formation or removal of a SAM to be studied, it 
does not analyse the surface of the wells directly, to see if they are being damaged by the 
plasma effluent.  Techniques such as XPS, AFM and STM could be used to give insight into 
the effects of the plasma on the gold surface.  XPS and STM were used by Raiber et al. to 
monitor the removal of organic monolayers from a gold surface.
209
   
XPS is a surface-sensitive quantitative technique, which measures elemental composition of 
a material, and gives an indication of the chemical state of the element.  In the case of the 
gold-coated MALDI chips, it would give an indication of whether the gold is in an oxidised 
state on the surface of the chip after treatment with the different plasma effluents or piranha 
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solution.
217
  The purpose of cleaning the gold-coated MALDI chips is to clean the surface, 
but also to ensure the gold is in an unoxidised state.   
AFM and STM are used to investigate the structure and profile of a surface.  AFM essentially 
involves the movement of a tip over a surface.
218
  This tip is attached to a cantilever.  The 
movement of the tip across the surface is monitored, and movement up or down is recorded.  
In this way, a model of the surface can be produced.  STM is a technique used to image a 
surface at the atomic level.
219
  A probe is held close to the sample surface.  Electrons tunnel 
between the surface and the probe, causing an electrical signal.  The probe scans across 
the surface of the sample, generating an image of the surface through the current produced.  
These techniques could be used to determine whether the surface of a well has been 
completely freed from SAM by comparison with an underivatised area of the gold-coated 
MALDI chip which had not been treated with plasma effluent, and also with piranha solution-
cleaned wells.  AFM and STM could also be used to determine whether damage to the 
surface had occurred by assessing whether tracks or other surface damage to the surface of 
the gold-coated MALDI chip had resulted from any of the cleaning treatments.   
XPS could be applied to the analysis of the surface of the gold-coated MALDI chip due to 
the fact that the technique can be used to look at the chemical and electronic states of the 
elements.  This would allow oxidation of the gold to be detected.  Oxidation of the gold 
surface after cleaning will reduce the ability of the SAM to form a perfect monolayer as 
atomic gold is needed.  AFM could be applied to determine whether damage had occurred 
to the surface of the gold-coated MALDI chip after the different cleaning treatments, but also 
to check that the plasma effluent is capable of removing all traces of the SAM from the 
surface of a well.   
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5.1. Introduction  
Having established (Chapters 2 and 3) that 4-BrPhe was not wholly suitable as the chemical 
tag for use with the SAM technology, alternative labelling strategies were sought.  Non-
commercial chemical labels (e.g. dimethyl labelling
122,123
) and commercial labels (e.g. 
iTRAQ
112
 or TMT
108
) were researched, with the aim to adapt an already-validated and well 
adopted labelling strategy for incorporation into the SAM/gold-coated MALDI chip 
technology.  iTRAQ and TMT are well-established commercial labels, which use expensive 
reagents, and were therefore discounted.  The DiLeu strategy uses quantification at the 
MS/MS level.  This may provide an additional complication when combining with the SAM.  
Dimethyl labelling and 
18
O incorporation through protein digestion were both considered.  
With 
18
O incorporation, there is the possibility of either one or two 
18
O (either 2 or 4 Da) 
being incorporated.  If only one 
18
O is incorporated, a mass difference of 2 Da would mean a 
large overlap of the isotopic envelopes, which could lead to quantification errors.  The 
chemical labelling strategy which appeared to be most promising for potential use with the 
SAM technology, and was thus chosen for further investigation, and possible adaptation, 
was dimethyl labelling.  This was chosen for a number of reasons: dimethyl labelling occurs 
on the amino terminus of peptides which makes it readily compatible with the SAM 
technology thus far developed; the technology is not commercialised, making it amenable to 
modification and cheaper to work on; the dimethyl label has good potential to be modified for 
incorporation into the SAM technology (see discussion in Chapter 6); and there was an 
interest to develop dimethyl labelling as a mainstream labelling strategy within the group.   
Dimethyl labelling uses reductive amination with formaldehyde to label the primary amino 
group at the N-terminus of peptides and in the side chain of lysine residues, replacing the 
two hydrogen atoms on the primary amine with methyl groups.  One advantage of dimethyl 
labelling is that it does not rely on costly commercial reagents like some other labelling 
strategies (e.g. iTRAQ and TMT), since it uses readily available rather than custom 
reagents.  In addition, it has the advantages of being reliable, cost-effective and procedurally 
undemanding.
122
  The dimethyl labelling approach allows relative quantification, in which 
ratios of the intensities of the peaks for light and heavy labelled peptide pairs are compared.   
The addition of two methyl groups to a primary amine results in an increase of 28 Da for the 
light label and an increase of 32 Da for the heavy label (Figure 5.1) when compared with 
unlabelled peptide.  This means that there is a mass difference of 4 Da between the light 
and heavy versions of a singly-derivatised peptide.   
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Figure 5.1: Dimethyl labelling strategy developed by Hsu et al. (X = H (light) or D (heavy))122 
In 2009, a paper by Boersema et al. described three strategies which could be used for 
dimethyl labelling: in-solution, online and on-column.
123
  In each of the strategies, labelling 
was reported to be complete within 60-90 minutes.  The in-solution dimethyl labelling 
strategy described
123
 was the basis for the work reported in this chapter.   
 
5.1.1. Aims and overview 
It was important to determine that quantitative results could be obtained using in-solution 
dimethyl labelling, before attempting to adapt the dimethyl label for incorporation into the 
SAM technology.  Therefore, the aim of the work described in this chapter was to investigate 
the viability of dimethyl labelling for quantitative analysis, using two ionisation methods for 
mass spectrometric analysis: MALDI and ESI.  ESI is the more usual choice of ionisation 
technique for chemical labelling and quantitative proteomics work.  However, MALDI is 
highly relevant for the SAM aspect of this thesis, and therefore the ability to combine 
dimethyl labelling and MALDI mass spectrometric analysis has an important bearing on the 
potential to combine dimethyl labelling with the SAM technology.  Having determined the 
viability of dimethyl labelling for quantitative analysis, the method was applied to muscle 
protein samples (these samples were readily available for analysis, and there was interest in 
making a comparison with an emPAI analysis being undertaken on these samples at the 
same time).   
The Boersema paper described the application of triplex dimethyl labelling to a BSA digest, 
but the authors themselves did not apply dimethyl labelling to ‘real’ samples.
123
  There have, 
however, been several examples of dimethyl labelling being used for quantitative proteomics 
of ‘real’ samples.  In 2009, Ji et al. published a paper using dimethyl labelling for absolute 
quantification of therapeutic monoclonal anitbodies.
220
  The group used a labelling strategy 
based on previous publications, which involved the guanidination of lysine side-chains, to 
prevent multiple labels being incorporated into lysine-containing peptides.
221
  The publication 
details an LC-MS method (and its subsequent validation) for absolute quantification of a 
therapeutic monoclonal antibody in biological fluids using dimethyl labelling.   
In 2011, Munoz et al. published a paper detailing the use of dimethyl labelling for the 
quantitative proteomic analysis of human-induced pluripotent stem cells and embryonic stem 
cells.
222
  The authors used one of the labelling strategies (presumed to be the in-solution 
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labelling strategy due to there being no mention of column details for online or on-column 
strategies) detailed by Boersema et al..
123
  Human embryonic stem cells, two different 
human-induced pluripotent stem cell lines and their precursor fibroblast cell lines were 
investigated.  The group found a high level of similarity between human-induced pluripotent 
stem cells and embryonic stem cells proteomes, with a small subset of proteins differentially 
expressed in the two human-induced pluripotent stem cell lines.   
Wilson-Grady et al. published a paper in 2013, which appeared during the course of the 
work described in this thesis, detailing the use of dimethyl labelling for the quantitative 
comparison of the phosphoproteomes of fasted and re-fed mouse livers.
223
  They used an 
on-line desalting and reductive dimethylation strategy.  The authors varied the pH at which 
the labelling occurred using 2-(N-morpholino)ethanesulfonic acid, and found that at 
increasing pH, there were fewer peptide and protein identifications following LC-MS 
analysis.  An optimum pH of between pH 5 and pH 6 was identified, and therefore pH 5.5 
was used for the quantitative phosphoproteomics work.  The group used a labelling solution 
of either 0.2% formaldehyde or D2-formaldehyde with 60 mM sodium cyanoborohydride in 
0.25 mM 2-(N-morpholino)ethanesulfonic acid.   
Of the three papers mentioned above, only one uses an un-adapted version of the dimethyl 
labelling strategies published by Boersema in 2009.
224
  There have been multiple variations 
on the dimethyl labelling of peptides.  Due to the fact that the overall aim of this work was to 
develop a labelling strategy which could be modified for use with the SAM technology, it was 
important that the labelling strategy chosen was an in-solution approach for best 
compatibility with the SAM workflow.  The online and on-column strategies proposed by 
Boersema et al. are clearly not ideal for integration with the SAM technology, as they would 
add extra complexity to the overall workflow.   
The in-solution dimethyl labelling method (as used by Boersema et al.)
224
 was thus first 
validated for quantification using standard solutions of light and heavy labelled simple 
protein digests mixed in a range of ratios.  This was because there are variants of the 
dimethyl labelling strategy, and therefore demonstration that the in-solution dimethyl 
labelling strategy was suitable for quantification (and subsequent adaptation for use with the 
SAM technology) was sought, as well as the need to test its application with ESI and MALDI.  
Two different software packages were also assessed for analysing the data to determine 
whether one or other was more suitable for dimethyl labelling quantification: Bruker 
ProteinScape (PS) and Mascot Distiller (MD).   
Having demonstrated that for a single protein digest, standard solutions could be analysed 
and quantified, more complex samples were analysed.  An E. coli lysate digest (labelled with 
light:heavy reagents at 1:1) was spiked with single protein digests labelled and mixed in 
ratios that differed from 1:1.  These protein digests were spiked in at 1% or 5% (w/w) of the 
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total E. coli lysate digest amount.  The resultant spiked solutions were analysed by LC-ESI-
MS.  The levels at which spiked proteins could be identified and reliably quantified needed to 
be ascertained, in order to determine how abundant a protein would need to be in a ‘real’ 
sample for a change in protein expression between two samples to be detectable.   
After determining the limits of detection for analysing complex samples, the validated 
approach was applied for the analysis of muscle protein samples.  Having established the in-
solution dimethyl labelling, analysis of the muscle samples provided a convenient way to 
analyse samples and compare the quantification results obtained with those obtained via 
emPAI analysis.  The detailed comparison of the data is beyond the scope this thesis.  The 
muscle protein samples were one unstretched muscle sample, and two stretched muscle 
samples, where the stretched muscle samples were stretched for three hours.  The aim of 
the experiment was to determine whether differences in the abundance of proteins between 
the unstretched and stretched muscle samples could be identified.   
Data from this chapter, except for the muscle protein data, are available in an electronic 
format: MSV000080344 (BSA digests – ESI), MSV000080345 (BSA digest – MALDI) and 
MSV000080346 (E. coli spiking data).  The raw muscle protein data are embargoed at 
present, and so not available for viewing at this time.    
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5.2. Validation of dimethyl labelling for quantification using 
standard solutions of light and heavy dimethyl-labelled 
protein digests 
For dimethyl labelling to be used for relative quantitation of unknowns, it must be validated 
(i.e. shown to generate the expected experimental results from standards containing defined 
levels of different components).  This is in order to demonstrate that the approach gives the 
expected results, before modifying it to develop a SAM-compatible version of the method.  In 
order to assess the viability of dimethyl labelling for relative quantitation work, a simple 
system was tested, using digests of a single protein (in this case BSA).  A standard protein 
tryptic digestion protocol was used, as recommended for use with iTRAQ (Section 7.5).
112,225
  
This digestion protocol was used because it is well adopted and generates peptides under 
conditions appropriate for subsequent N-terminal labelling.  The digestion solvent system is 
free of primary amines, which reduces the chance of competition when dimethyl labelling of 
peptides is underway.  There was also an interest in comparing dimethyl labelling with 
iTRAQ, and therefore using the same digestion protocol for both labelling strategies 
provided a level of comparability.  Digests were labelled with heavy or light formaldehyde 
and mixed in a range of different relative amounts, and subjected to mass spectrometric 
analysis.   
The peak areas of the [M+H]
+
 signals for the heavy and light peptide pairs in the resulting 
spectra were used to determine relative amounts.  In all instances, each standard solution 
was prepared in triplicate, and forward and reverse labelling was performed by comparing 
both light:heavy (L:H) (forward) and heavy:light (H:L) (reverse) ratios.  It is standard practice 
in relative quantification proteomics to prepare solutions allowing comparison of intensities 
when the light, and also the heavy label is the more abundant.  The function of forward and 
reverse labelling is to ensure there is no bias associated with which sample carries the 
heavy or the light label.  There are several reasons to prepare triplicate solutions, and 
perform forward and reverse experiments.  These include the ability to test the 
reproducibility of preparing the solutions (e.g. are there any pipetting errors?), to allow 
systematic errors due to labelling to be identified,
226
 and to identify errors arising from 
overlapping isotopic envelopes in comparing the light and heavy label intensities.   
 
5.2.1. Analysing standard ratios using aliquots of the same BSA 
digest 
It is important to establish the dynamic range of a labelling strategy, which is to say the 
dynamic range over which accurate and reliable relative quantification data can be 
generated.  Hsu et al. demonstrated a dynamic range over two orders of magnitude for 
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dimethyl labelling.
122
  Ideally, a proteomics labelling strategy should be able to provide 
accurate quantification data when there is a large or small difference in the expression of a 
protein.   
Tryptic digestion of BSA was performed (as detailed in Section 7.5.1), and two aliquots of 
the digest were labelled: one with the light formaldehyde and the other with the heavy 
formaldehyde.  Aliquots of the light and heavy labelled digests were dissolved to the same 
concentrations and combined in known ratios (v/v) and the resulting solutions analysed by 
MALDI-MS and LC-ESI-MS.  The MALDI-MS data were analysed using PS, and the LC-ESI-
MS data were analysed using PS and MD.   
 
5.2.1.1. MALDI-MS analysis 
MALDI-MS analysis was coordinated through WARP-LC software and the results were 
reported in PS (both are software by Bruker Daltonics) (Figure 5.2).  The ratios of the 
solutions prepared were 1:1, 2:1, 3:1, 5:1 and 10:1 (L:H and H:L).  A mass spectrum was 
acquired from each solution (each sample was prepared in triplicate and analysed).  From 
the resulting data, a list of all possible peptide pairs was generated, indicating m/z values for 
peptides with masses 4 Da or 8 Da apart (peaks for peptides with a difference of 4 Da 
contain one dimethyl group or 8 Da contain two dimethyl groups), and the ratio of peak 
areas for each peptide pair was calculated.  The ratios were calculated by WARP-LC from 
the mass spectrum by summing the areas of the peaks associated with the isotopic 
envelope for a peak for a heavy labelled peptide and dividing it by the area of the peaks 
associated with the isotopic envelope for the peak of the corresponding light labelled 
peptide.  The software then selected up to ten m/z values for product ion analysis (specified 
in the method as the peaks with the highest S/N).  Once the MS/MS acquisition had been 
completed, the data were sent to PS.  Subsequently, a protein search was performed, where 
the product ion spectra were submitted to the search engine Mascot, in order to identify the 
peptides, and ultimately the protein that had been labelled.  Once the search had been 
completed, statistics for the protein quantification were generated in PS.   
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Figure 5.2: Workflow showing the steps in the acquisition of quantification data from MALDI-
MS analysis using WARP-LC and PS 
In PS, what Bruker (personal communication from Susanne Fütteer, in Proteineer 
Support/Software Development) refer to as a ‘median’ value is reported for the relative 
quantification of each quantified protein.  However, in spite of its name, this is not a true 
median.  In fact, a lognormal distribution is used by WARP-LC and PS to calculate a defined 
median (Equation 5.1), mean (Equation 5.2) and coefficient of variance (CV) (Equation 5.3) 
for each quantified protein.
227
  The peptide ratios calculated from the area of the heavy 
labelled peptide’s isotopic envelope divided by the area of the light labelled peptide’s 
isotopic envelope are defined as data set X.  These values are then converted to their 
natural log values, creating data set Y.  From the mean (µ) and variance (σ
2
) of Y, the so-
called ‘median’, mean and CV of X are calculated.   
𝑴𝒆𝒅𝒊𝒂𝒏𝒙 = 𝒆
𝝁      
Equation 5.1: Formula used by Bruker PS for the determination of the protein quantification 
“median” 
𝑴𝒆𝒂𝒏𝒙 = µ𝒙 = 𝒆
(µ+𝟎.𝟓𝝈𝟐)  
Equation 5.2: Formula for the determination of the protein quantification “mean” 
 
MALDI-MS acquisition 
WARP-LC generated list of "peptide pairs" (i.e. the m/z values for 
light and heavy labelled peptides) and all possible ratios 
MS/MS acquisition for the ions producing the ten most intense peaks, 
for peptide identification 
Peptide/protein identification through Mascot search 
Generation of protein statistics (e.g. median, mean and CV%) in PS 
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𝑪𝑽𝒙 = √𝒆𝝈
𝟐
− 𝟏        
Equation 5.3: Formula for the determination of the coefficient of variation of data set X 
A geometric mean and standard deviation was calculated using the ratios generated in PS 
for each of the triplicate solutions.  Table 5.1 gives the ratios generated from the 
measurements carried out on the standard solutions (plotted in Figure 5.3).  FDR values of 
0.00% were obtained for all searches (Table 7.3).   
Table 5.1: Ratios generated using PS for MALDI-MS analysis of prepared standard solutions of 
BSA tryptic digest (geometric standard deviations (SDgeo) calculated for the three replicate 
solutions prepared for each ratio) (number of peptides and sequence coverage for the three 
replicate solutions indicated) (see 7.5.6 for FDR values) 
Ratio prepared (L:H) Protein ratio SDgeo Number of 
peptides 
Sequence 
coverage / % 
0.10:1 0.06:1 1.03 5, 5, 5 19, 20, 16 
0.20:1 0.11:1 1.10 4, 3, 4 7, 6, 10 
0.33:1 0.20:1 1.14 1, 3, 4 1, 11, 9 
0.50:1 0.32:1 1.04 5, 6, 7 12, 16, 18 
0.67:1 0.51:1 1.06 2, 2, 7 5, 5, 16 
1:1 1.02:1 1.03 1, 4, 1 2, 8, 6 
1:1 (H:L) 1.02:1 1.06 2, 6, 5 4, 16, 12 
1.5:1 1.62:1 1.03 2, 3, 5 4, 10, 13 
2:1 2.57:1 1.06 3, 4, 3 9, 9, 12 
3:1 5.00:1 1.04 3, 7, 5 6, 17, 11 
5:1 10.54:1 1.05 0, 7, 6 0, 19, 16 
10:1 12.02:1 1.33 4, 2, 7 14, 9, 19 
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Figure 5.3: Plot showing the geometric mean generated from three replicate solutions 
analysed by MALDI-MS against the prepared ratio (error bars show the geometric standard 
deviation) 
As can be seen from the results in Table 5.1 and Figure 5.3, the ratios obtained using PS 
deviated from the ratios of the standard solutions that had been prepared when the ratios 
are above 2:1, with the more abundant label being over-represented in each case.  The 
geometric standard deviations are relatively large for each of the PS ratios.  For 5:1 (L:H) 
solution 1, no useable data was obtained (the mass spectrum was very noisy, and no 
MS/MS data were acquired automatically, as the S/N ratios of the peptide signals were not 
high enough to trigger product ion spectra acquisition).  Upon reanalysis of the well, the 
same result was obtained.  This meant that either there was a problem with the formation of 
the dried spot on the well, or with the solution itself.  However, the decision was taken not to 
respot the well, as an inspection of the data showed that the PS ratios were deviating 
considerably from the prepared solutions above 2:1, and therefore further investigation 
would be required anyway.   
The largest geometric standard deviation generated is for the 10:1 (L:H) ratio.  The 
geometric standard deviation of 1.33 was generated from the PS ratios 8.33:1, 12.50:1 and 
16.67:1 of the three 10:1 L:H solutions.  There is a considerable difference between the 
ratios obtained from the three solutions.  The geometric standard deviation value obtained 
for the ratios for the 10:1 H:L solutions is smaller (generated from the PS ratios 16.22:1, 
15.16:1 and 16.17:1).  Based on the values obtained for the six solutions (the three forward 
(L:H) and three reverse (H:L)), the ratio 8.33:1 could be deemed an outlier, due to the fact 
that it differs so much from the other five ratios (SD (all six values) = 3.23, SD (five excluding 
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8.33) = 1.68).  This outlier could have been a result of the innate variability which is a 
characteristic of MALDI spectra,
192,193
 which could have a profound impact on the 
quantification data obtained.  For MALDI-MS analysis, a single mass spectrum was obtained 
per spot, with multiple MS/MS acquisitions for peptide identification.  For dimethyl labelling, 
the quantification takes place at the MS level, and the quality of the quantification is 
dependent on the quality of the mass spectrum obtained.  MALDI’s variability derives from 
the inherent inhomogeneity of the matrix/analyte spot with sweet spots a characteristic of 
MALDI analyses.
101,192,194
  Depending on where on the spot the laser hits, spectral quality 
and signal intensities can be very variable.  With traditional MALDI-MS, the analyte is not 
distributed evenly across the surface of the MALDI spot, which can lead to the variability in 
different mass spectra obtained from a single MALDI spot.
176
  This can impact the peptide 
(and ultimately protein) ratios generated from the data.  This would theoretically be reduced 
with the SAM technology, as the analytes would be immobilised on the well surface, 
presumably uniformly. 
The 2003 paper by Hsu et al. detailed the analysis of dimethyl labelled peptides by MALDI-
MS.
122
  The group published a plot detailing the linearity range of the dimethyl labelling 
method, with the ratio of components in solutions being analysed by MALDI-MS.  The plot 
shows a linear range for a single protein containing four lysine residues for ratios over the 
range 0.05:1 and 20:1.  This is in contrast to the data shown in Figure 5.3, where the 
relationship is clearly not linear.  Hsu et al. used a Micromass MALDI-ToF mass 
spectrometer.  Samples were analysed using CHCA in ethanol, acetonitrile and 0.1% 
trifluoroacetic acid as the matrix solution.  A 0.5 M solution of hydrochloric acid was mixed 
with both the matrix and the sample (1:2:1 v/v/v) prior to deposition of the solution onto the 
MALDI plate.  In the work presented in this thesis, CHCA in acetonitrile was used as the 
matrix solution.  The labelled BSA digest was spotted on the MALDI plate wells 1:1 with the 
matrix solution.  Hsu et al. state that as the ratio increases above 1:5 (L:H), the method is 
less precise relative to small variations.  The authors discuss the fact that they perform three 
measurements, although it is unclear whether this is three MALDI-MS acquisitions of the 
same well, or three samples analysed once (as in the case of the work in this thesis).  The 
different matrix solution used in the work in this thesis compared to that in the work by Hsu 
et al., and the inclusion of hydrochloric acid, along with the different mass spectrometers 
used could all contribute to the different results obtained in the two studies.   
As the results obtained by MALDI-MS deviated from the ratios of the standard solutions that 
had been prepared, particularly as the standard solution ratio moved further away from 1:1, 
LC-ESI-MS was investigated as a possible alternative to MALDI-MS.   
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5.2.1.2. LC-ESI-MS analysis 
The ratios generated by PS from the MALDI-MS data deviated from the expected ratios 
when greater than 2:1.  The variance between data produced for solutions with the same 
ratio was quite large in some cases, and the more abundant of the labelled digests was 
over-represented.  In order to determine whether this was a problem with analysing the 
samples by MALDI-MS, and to determine whether this could have been due to pipetting 
errors, the same solutions (subjected to a 1 in 100 dilution) were also analysed using LC-
ESI-MS.   
LC-ESI-MS analysis was controlled using HyStar (Bruker Daltonics), and the data analysed 
using PS and MD.  Two software packages were tested in the event that the problem with 
the ratios generated was due to the software package.  Other software packages 
(MaxQuant
228
, MSQuant
229
 and Skyline
230
) were researched, to determine what software is 
available and being used by the proteomics community and which might be suitable for the 
application described in this thesis.  Some software packages were discounted due to 
incompatibility between the data format and the software.  MD was trialled due to the fact 
that it is compatible with the data files acquired, but also contains a ‘built-in’ dimethyl 
quantification method.  It is commercially available software (as is PS) which can be used for 
protein searches and quantification and is an interface with quantification algorithms for use 
with the locally available Mascot search engine.  The data workflows for the two software 
packages are shown in Figure 5.4 (PS) and Figure 5.5 (MD). 
Chapter 5: Dimethyl labelling 
198 
 
 
Figure 5.4: Data workflow for data processed through PS, including the data format at each 
stage 
 
Figure 5.5: Data workflow through MD, including the data format at each stage 
Through MD, the MS processing options used were: Un-centroiding (Peak half width: 0.2, 
Data points per Da: 10); Re-gridding (Data points per Da: 100); Multi-format spectra 
Data importation into MD (bruker.d file) 
Peak list generation in MD (.rov and .mgf) 
Peak list submitted to Mascot server (.mgf).  
Dimethyl labelling selected as quantification 
method (.dat) 
Mascot search results (.dat) returned to MD (.rov) 
Quantification performed in MD from relative 
areas of XIC from identified peptides containing 
label (.rov) 
Data imported into WARP-LC (bruker.d)  
SILE pairs (ratios of XIC areas for peaks 
matching expected mass differences) extracted by 
WARP-LC (.baf) 
SILE pairs (.baf) imported into PS and overlaid 
with peptide identifications 
Protein level quantification performed by PS from 
peptide level SILE pairs 
Data imported into DataAnalysis (DA) (bruker.d)  
Peak list generation in DA (bruker.xml) 
Peak list imported into PS (.xml) 
PS converts .xml into .mgf for Mascot database 
search (.dat) 
Search result (.dat) imported onto peak list in PS 
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(Preferred type: Profile); Peaks (Minimum number: 1, Maximum charge: 4); and Aggregation 
(Scan group aggregation method: Sum).  The MS peak peaking processing options used 
were: Filtering (Correlation threshold: 0.7, Minimum S/N: 10, Minimum peak m/z: 50, 
Maximum peak m/z: 100,000); Peak profile (Minimum peak width: 0.005 Da, Expected peak 
width: 0.025 Da, Maximum peak width: 0.125); and General (Baseline correction applied, Fit 
Method: Isotope distribution, Maximum peak iterations per scan: 500). The same options 
were used for the MS/MS peak picking processing options.  The correlation threshold is a 
measure of the correlation between the predicted and observed precursor isotope 
distribution (the higher the correlation threshold, the greater the correlation between the 
predicted and observed precursor isotope distributions).   
Peak picking is not performed using PS, but is performed in DA.  The settings used by DA 
for peak picking were: Sum Peak settings were used in DA; Use the same width as in 
acquisition; S/N: 1; Relative intensity threshold: 0.001%; Absolute intensity threshold: 20.  
The only parameters which are in common between the two peak picking processes are the 
S/N parameters (MD = 10, DA (PS) = 1).  The threshold is set higher for data processed 
through MD than for data processed through PS.  This should mean that less noise is picked 
up in the peak lists generated through MD than PS, which should lead to ‘cleaner’ data.  
Neither software package returns peak areas with the quantification results, meaning that it 
is not easily possible to compare peak areas obtained for individual peptides using the 
different software packages.   
The data acquired for each solution were submitted to each of the two software packages for 
analysis.  A geometric mean was calculated using the ratios generated by the software for 
the triplicate analyses, and a geometric standard deviation was generated for each ratio.  
Table 5.2 shows the ratios generated for the standard solutions using PS or MD software 
(plotted in Figure 5.6).  For PS data, FDR values were in the range of 0.00-2.01%, and for 
MD data, FDR values were in the range of 0.00-2.13% (Table 7.4).   
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Table 5.2: Ratios generated for each BSA digest solution (geometric standard deviations 
(SDgeo) for the average of three replicate solutions per ratio) (number of peptides and 
sequence coverage for individual solution replicates for each ratio) (see 7.5.6 for FDR values) 
Ratio 
prepared 
(L:H) 
PS MD 
Protein 
ratio 
SDgeo Number 
of 
peptides 
Sequence 
coverage 
/ % 
Protein 
ratio 
SDgeo Number of 
peptides 
Sequence 
coverage 
/ % 
0.10:1 0.14:1 1.05 25, 30, 25 39, 52, 41 0.09:1 1.06 55, 54, 56 67, 63, 70 
0.20:1 0.28:1 1.11 23, 22, 31 46, 42, 66 0.21:1 1.03 23, 29, 27 34, 43, 41 
0.33:1 0.39:1 1.05 25, 32, 20 52, 64, 46 0.32:1 1.03 26, 27, 31 42, 37, 58 
0.50:1 0.54:1 1.01 37, 29, 27 68, 60, 57 0.48:1 1.00 42, 31, 28 68, 46, 34 
0.67:1 0.77:1 1.08 31, 31, 38 52, 59, 61 0.67:1 1.01 38, 29, 28 54, 47, 36 
1:1 1.00:1 1.01 43, 36, 21 48, 57, 21 0.99:1 1.02 48, 42, 24 67, 64, 41 
1:1 (H:L) 1.01:1 1.04 14, 22, 19 34, 37, 42 0.99:1 1.01 20, 26, 27 33, 36, 40 
1.5:1 1.48:1 1.05 34, 32, 21 62, 54, 37 1.47:1 1.01 36, 37, 41 51, 55, 57 
2:1 2.00:1 1.02 37, 25, 23 70, 48, 37 2.01:1 1.01 39, 31, 35 62, 56, 53 
3:1 3.15:1 1.27 20, 20, 29 45, 38, 65 3.01:1 1.03 28, 39, 29 49, 59, 42 
5:1 3.43:1 1.21 21, 26, 23 34, 43, 44 5.06:1 1.04 30, 29, 36 42, 42, 59 
10:1 7.16:1 1.06 28, 28, 26 39, 41, 39 10.91:1 1.07 54, 71, 74 70, 72, 73 
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Figure 5.6: Plot showing the geometric mean generated from three replicate solutions 
analysed by LC-ESI-MS against the prepared ratio (error bars show the geometric standard 
deviation) (PS = blue diamonds, MD = red squares) 
 
As can be seen in Table 5.2 and Figure 5.6, there is a difference between the ratios 
obtained using the two different software packages (PS and MD) applied to the same set of 
measurements.  It can be seen in Figure 5.6 that as the ratio deviates from 1:1, the 
software-generated ratio obtained using PS deviates further from the expected values than 
with MD.  As can be seen in Figure 5.6, with the MD software-generated ratios, the trend is 
much more linear.  It should be noted that there is a difference between the number of 
peptides used for quantification and the sequence coverage for the two software packages 
(Table 5.2).  For each of the software packages, different database searches were 
performed.  For MD, at the time of the data being analysed it was not possible to import 
calibrated data into the software (personal communication, John Cottrell, Mascot Science).  
This meant that for database searches conducted through Mascot for MD, wider tolerances 
were needed for mass errors than for PS.  PS is Bruker software and has the ability to use 
the lock-mass-corrected data generated from the Bruker maXis instrument.  Better calibrated 
data should give more peptide identifications, meaning a greater number of peptides 
available for quantification.  Therefore, it is unlikely that the search tolerances are the reason 
for the difference in the number of peptides used for quantification through the two software 
packages.   
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With the data analysed in PS, the greater the difference between the amount of the light and 
heavy labelled peptides, the more the ratio tends to be under-represented.  It can be argued 
that identifying a difference is sufficient and that the exact extent of this is not the issue.  As 
long as the difference in expression of a protein is identified, the numerical value obtained 
may not necessarily be important: the protein has been identified for further investigation 
and validation is necessary whatever the number determined from the mass spectrometric 
results (with the MALDI data presented in Section 5.2.1.1, it is important to note that the 
number of peptides used for quantification was low, especially bearing in mind that the 
experiment was performed using a simple protein digest, and raised the possibility of 
problems with peptide identification and quantification with a more complex mixture).  What 
is important is to ensure that a protein which is differentially expressed between the two 
samples is called as different and not missed due to an under-representation of the ratio.  
With under-representation of the ratio, there is a danger of generating a false negative result 
(i.e. not recording a difference when there is one).  With PS, the under-representation of the 
prepared ratio starts to become apparent at ratios greater than 2:1.  Under-representation of 
ratios is commonly observed for isobaric labelling strategies.
118,231,232
  However, there 
appears to be little in the literature about labelling strategies, like dimethyl labelling, where 
quantification occurs using the mass spectral data rather than the tandem data.  With under-
representation of the ratios, a difference should still be observed (and could then be further 
investigated), although the real difference in expression could be greater than the difference 
returned by the software.   
In the data generated by MD, the values obtained are much closer to the ratios of the 
standard solutions prepared.  There is also no apparent systematic preference, as there is 
with the PS results, for the most abundant label to be over- or under-represented, as can be 
seen from the fact that in some cases the MD ratio is slightly higher or slightly lower than the 
solution ratio prepared (e.g. 5:1 L:H = 5.07:1 and H:L = 4.76:1).  The ratios generated for 
10:1 (L:H and H:L) are within 10% of the level in the standard solution prepared, which is 
much closer than the ratios for the same data from the same samples, determined using PS.  
The difference must be due to a difference in the software packages.  The data generated 
by MD used, in general, a larger number of peptides to generate the protein ratios than did 
PS.  MD has a built in dimethylation method.  However, with PS a method for quantifying the 
dimethyl data had to be designed, so that the two methods certainly differ in some details.  
For example, in MD, the H/D elution time shift experienced with dimethyl labelling, although 
small, is automatically considered.  With PS however, a small difference in elution times 
between the light and heavy labelled peptides had to be included in the created method.  It 
is possible that a difference in the methods used by the two software packages could have 
resulted in the differing numbers of peptides used for quantification in MD and PS.  The two 
software packages are very different; including in the way the peak lists are generated for 
the protein database search (as discussed earlier).  Based on the fact that MD applies a 
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higher S/N threshold than PS, it could be assumed that a smaller number of peptides would 
be available for quantification through MD than through PS.  However, this is clearly not the 
case.  Therefore, the difference between the numbers of peptides available for quantification 
from the two software packages is likely not due to the peak picking parameters (certainly 
not due to the S/N parameters).  However, S/N is only one of the parameters needed for 
peak identification; others include peak width and isotopic distribution settings.  Within MD, 
there are several acceptance criteria which must be met before a peptide quantification 
result is accepted, which can be altered by the analyst.  These include the correlation 
threshold (discussed above), the fraction threshold and the standard error threshold.  The 
fraction threshold is the fraction of the peak area in the precursor region of the mass 
spectrum which is accounted for by the components (i.e. the light and heavy labelled 
peptides).  This parameter is set as part of the quantification method.  The standard error 
threshold is also set within the quantification method, and is the estimated standard error for 
the calculated ratio.  Each peptide ratio is calculated by making a least squares fit to the 
component intensities from the scans in the extracted ion chromatogram peak.
233
   
However, the ultimate difference between the two software packages, leading to the 
difference in the number of peptides available for quantification (and ultimately the superior 
quantification results obtained through MD over PS), has proved impossible to identify, and 
is also beyond the scope of this thesis.  It would also be worth waiting until the calibration 
issue with Bruker data files in MD has been remedied, so that the same search parameters 
could be used for the database searches (i.e. peptide tolerance, 10 ppm; MS/MS tolerance, 
0.1 Da), in order to determine whether this changes the quantification results in MD.  It is 
possible that the tolerances used for database searching through MD and PS may be the 
reason for the differences in the number of peptides used for quantification.  The vast 
majority of peptides identified through the two searches are the same.  However, it is 
possible that peptides whose peptide and MS/MS tolerances fell just outside of the search 
tolerance limits would have been lost through PS (whereas these may have been included in 
MD, therefore accounting for the larger number of peptide quantification ratios available for 
protein quantification used through MD rather than PS), and therefore there would be fewer 
peptide quantification ratios available for protein quantification.  In order to investigate this, 
several database searches were repeated with larger tolerances (peptide tolerance, 10 ppm; 
MS/MS tolerance, 0.1 Da), in order to determine whether the number of peptides identified 
increased.  However, there was no increase in the number of peptides identified.  This would 
suggest that it is not the search parameters which are creating the differences between the 
number of peptides identified through MD and PS (and subsequently available for peptide 
quantification), and may be due to the peak picking parameters.  It would be interesting to 
compare the quantification results obtained from calibrated data using MD and PS, with 
those obtained from the uncalibrated data using MD.   
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The ratios produced from the data obtained using LC-ESI-MS analysis are much closer to 
the ratios of the standard solutions prepared than those produced using MALDI-MS analysis.  
The data suggest that the analysis method (MALDI-MS or LC-ESI-MS) plays a part in the 
accuracy of relative quantification results generated.  The fact that multiple spectra were 
acquired over a chromatographic peak for LC-ESI-MS analysis, meaning that the 
quantification ratio can be averaged over multiple spectra, could have resulted in the 
generated ratios being more accurate for LC-ESI-MS than MALDI-MS.  With MALDI-MS 
data, only one ratio value is generated for the peptide in each measurement.  If the result for 
that peptide varies greatly from the expected ratio for the protein, it is possible that the 
software may not class the ratio for that peptide as an outlier as it has nothing else to 
compare it to.   
Due to the fact that the ratios generated from the acquired data using MD were much closer 
to those of the standard solutions than those generated from the acquired data using PS, 
MD was used in future LC-ESI-MS analysis.   
 
5.2.1.3. Pseudo LC-MALDI-MS analysis 
MD cannot process MALDI data when the file consists of a single mass spectrum, and a few 
tandem mass spectra (a typical MALDI-MS acquisition format).  The software is unable to 
read the file, as it is expecting an LC-type file.  LC-MALDI-MS analysis of samples could be 
performed and the data analysed computationally using MD and PS to allow a comparison 
of the results.  A ‘pseudo LC-MALDI-MS’ analysis was performed, in order to determine 
whether LC-MALDI-MS data could indeed be processed using MD.  This was done by using 
a single ZipTip to load a labelled (1:1 L:H) BSA digest, and then fractionating eluting 
peptides using increasing percentages of acetonitrile in aqueous mixtures.  The resulting 
fractions were then spotted on a pre-spotted LC-MALDI plate (this means that the sample 
wells are pre-spotted with matrix onto which aliquots of the fractions were spotted and 
allowed to air dry, and the calibrant and matrix are pre-spotted on the calibrant well).  When 
the data from these fractions were imported into MD, the data could be processed as if the 
few different ZipTip fractions were LC fractions, and a quantification result was produced 
(1:0.98).  When the same data were imported into PS, a quantification result was not 
obtained.   
 
5.2.2. Reproducibility of protein digestion and labelling 
In a quantitative proteomics experiment the samples to be compared are digested, and then 
differentially labelled, before being mixed in equal amounts for analysis.  For example, a 
‘healthy’ sample could be compared with a ‘disease’ sample in a forward and reverse 
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labelling experiment: the samples are distinct and so they are handled and digested 
separately before being labelled and mixed for analysis.  This would enable differences not 
only in the levels of identical peptides to be revealed, but also differences in the peptides 
present in the two samples to be identified (e.g. if there were differences in a peptide 
sequence, only the light or heavy labelled version would be present for detection mass 
spectrometrically).   
Since in the first validation experiment (Section 5.2.1) a single BSA digest was made and 
split for subsequent labelling and recombining, it was necessary to demonstrate that 
labelling and combining aliquots of different digests would not affect the measured ratios.  
For this purpose, two separate aliquots of BSA were digested.  One was labelled with light 
formaldehyde and the other with heavy formaldehyde.  The light and heavy labelled digests 
were then combined, in triplicate, in a 1:1 (v/v) ratio (L:H and H:L).  The labelled solutions 
were analysed by LC-ESI-MS and analysed using MD (Table 5.3).  FDR values ranged 
between 0.00-0.97% (Table 7.5). 
Table 5.3: Ratios obtained using MD for LC-ESI-MS analysis of different BSA digest solutions 
(see Section 7.5.6 for FDR values) 
Ratio Replicate Protein ratio SD (geo) 
L:H 
1 0.94:1 1.101 
2 0.95:1 1.096 
3 0.95:1 1.084 
H:L 
1 1.02:1 1.119 
2 1.05:1 1.105 
3 1.03:1 1.091 
 
As can be seen for the data in Table 5.3, the ratios obtained through MD consistently reflect 
the ratios of the prepared 1:1 standard solutions.  The geometric standard deviations are all 
approximately 1.1.  These values, combined with the consistency of the MD ratios for the six 
solutions give confidence in the relative quantification data produced and thus in the 
reproducibility of the sample handling procedures established.   
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5.3. Spiking labelled protein digests into labelled E. coli lysate 
digest 
Having established that dimethyl labelling could be performed on a simple BSA digest, and 
acceptable ratios generated over the range 1:0.1 to 1:10, a more complex sample was 
generated for testing.  In a relative quantitative proteomics experiment using dimethyl 
labelling, differences between peptides, and ultimately proteins, in two samples are identified 
and analysed.  Following labelling, the two samples are combined in a 1:1 total protein 
weight ratio.  On analysis, proteins whose relative levels have not changed (expected to be 
the majority) remain at 1:1, while proteins whose abundances have changed need to be 
validated using alternative experiments and methods.  Validation can be achieved through 
using an alternative labelling or label free strategy to determine whether the change in level 
was also observed using an additional mass spectrometric approach.  Alternatively, a non-
mass spectrometric analysis technique such as western blotting could be used, to test for 
changes in abundance of a protein between the two samples.  Alternative LC-MS strategies 
could also be investigated, using orthogonal techniques such as HILIC
234
, strong cation 
exchange
235
 or high pH reversed phase chromatography.  In the work presented in this 
thesis, a strategy was employed which did not set a fold change threshold cut-off.   
The obvious reason for a measured difference in levels of a particular protein could be due 
to under- or over-expression of that protein or differential breakdown of it in one of the two 
samples.  However, perhaps less intuitively, it could also be due to a difference in the amino 
acid sequence of the protein in the two samples.  For example, a ‘disease’ sample could 
have a mutation in the amino acid sequence of a protein.  The mutation could be a change 
in the amino acid sequence, a PTM or a single nucleotide polymorphism.
236
  When 
analysed, such a situation could result in two separate peptide peaks for which there was no 
corresponding peak in the other labelled sample: one peak would correspond to the version 
of the peptide only present in the ‘healthy’ sample, and the other corresponding to the 
version of the peptide only present in the ‘disease’ sample.  This would result in a measured 
difference in the abundance level of the protein between the two samples.  Therefore, both a 
difference in expression and/or breakdown of a protein as well as the possibility of 
differences in the amino acid sequence of the protein need to be considered as reasons for 
a measured difference.  In order to determine whether proteins whose expression differs 
from a 1:1 ratio could be detected not only in a single protein digest mixture but also in a 
complex background, a spiking experiment was performed.  The proteins BSA, rabbit 
muscle glycogen phosphorylase (Phos B), human transferrin (Trans) and horse heart 
myoglobin (Myo) were digested with trypsin and aliquots labelled with light and heavy 
formaldehyde.  Additionally, a tryptic digestion was performed on an aliquot of E. coli lysate 
(the background proteins), and aliquots labelled with light and heavy formaldehyde.   
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The light and heavy labelled E. coli lysate digests were combined to create a solution with a 
1:1 (v/v) L:H ratio, with a total digest concentration of 100 ng/µL.  Having labelled the 
additional separate protein digests, the protein digest solutions were combined in known 
ratios (v/v) (Table 5.4) which differed from the 1:1 ratio of the E. coli lysate digest.  The 
labelled protein digest mixtures were then spiked into aliquots of the 1:1 labelled E. coli 
lysate digest, at either 1% (i.e. 1 ng/µL) or 5% (5 ng/µL) of the total E. coli lysate digest 
amount.  As with all other experiments, labelling was carried out to allow both the forward 
and reverse experiments to be performed (L:H and H:L), and each spiked solution was 
prepared in triplicate.   
Table 5.4: Proteins used for spiking into E. coli lysate digest, and the ratios (L:H and H:L) they 
were prepared at 
Protein Ratio 
BSA 2:1 
Trans 3:1 
Phos B 4:1 
Myo 5:1 
 
Following LC-ESI-MS analysis, the data were processed using MD.  The number of proteins 
identified and quantified in each of the solutions was extracted from the data (Table 5.5).  
FDR values ranged from 0.15-0.91% (Table 7.6). 
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Table 5.5: Number of proteins identified and quantified for each of the L:H and H:L solutions 
prepared with proteins spiked in at 1% and 5% of the total E. coli lysate digest amount (see 
Section 7.5.6 for FDR values) 
Solution Replicate Number of proteins 
identified 
Number of proteins 
quantified 
L:H 1% 1 427 245 
2 436 234 
3 427 251 
L:H 5% 1 423 237 
2 423 228 
3 401 239 
H:L 1% 1 423 246 
2 436 235 
3 423 236 
H:L 5% 1 423 220 
2 412 161 
3 436 236 
 
As can be seen in Table 5.5, the number of proteins identified and the number of proteins 
quantified were similar for the 1% and 5% spiked solutions.  The number of proteins 
quantified across the three replicate solutions for each condition (i.e. L:H with proteins 
spiked in at 1% of the total E. coli lysate digest amount) are shown in Venn diagrams in 
Figure 5.7 to Figure 5.10.   
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Figure 5.7: Venn diagram showing the number of proteins quantified across all three 
replicates for L:H solutions with proteins spiked in at 1% of the total E. coli lysate digest 
amount (Venn diagram produced using Venny237). 
 
 
Figure 5.8: Venn diagram showing the number of proteins quantified across all three 
replicates for L:H solutions with proteins spiked in at 5% of the total E. coli lysate digest 
amount (Venn diagram produced using Venny237). 
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Figure 5.9: Venn diagram showing the number of proteins quantified across all three 
replicates for H:L solutions with proteins spiked in at 1% of the total E. coli lysate digest 
amount (Venn diagram produced using Venny237). 
 
Figure 5.10: Venn diagram showing the number of proteins quantified across all three 
replicates for H:L solutions with proteins spiked in at 5% of the total E. coli lysate digest 
amount (Venn diagram produced using Venny237). 
As can be seen in Figure 5.7 to Figure 5.10, the number of proteins quantified across all 
three replicate solutions is high for each condition.  The high number of commonly quantified 
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proteins increases confidence in the results as it shows replicate solutions have a high 
degree of inter-sample reproducibility when considering MS/MS sampling.   
 
In order to perform a statistical analysis of the spiked data, further interpretation of the data 
was performed.  There are important considerations when performing statistical analysis of 
data sets.  These include the multiple testing problem, which states that if a test is performed 
multiple times across a data set, the likelihood of random errors increases.
238
  Therefore, a 
number of results will falsely be declared positive results.  In order to combat this, 
researchers have suggested a number of corrections, with the Bonferroni correction
239
 and 
Hochberg and Benjamini correction
240
 being two commonly used tests in proteomics.   
The false discovery rate (FDR) is an important metric when quoting the results of database 
searches.  It is a measure of the proportion of errors committed by falsely rejecting the null 
hypothesis.
240
  The null hypothesis for a database search is that when assigning a 
significance measure to a match between a peptide sequence and a tandem mass 
spectrum, the peptide was not identified by the mass spectrometer.
241
   
The p-value is the smallest level of significance at which the null hypothesis would be 
rejected (i.e. the probability that the null hypothesis is not true).
242–244
  It is a statistical 
measure used to determine a level of significance for a result.  The q-value is similar to the 
p-value, except it is a measure of significance in terms of the FDR.
245
 
The Bonferroni correction sets the significance (q-value) at (significance level)/(number of 
tests) (Equation 5.4).
238,242
  For example, with 20 tests, and a significance level of 0.05, a 
null hypothesis would be rejected if the p-value was less than 0.0025.  There are those who 
consider the Bonferroni correction method to be controversial.
239,246
  Perneger published an 
article in 1998 detailing what the author highlighted as problems with the Bonferroni 
correction.  Firstly, that the general null hypothesis (that all null hypotheses are true 
simultaneously) is rarely of interest or use to researchers.  Secondly, that the interpretation 
of a finding depends on the number of other tests performed; and finally, the likelihood of 
incorrect retention of a false null hypothesis (a false negative result) is increased.
246
   
𝑞 =
𝑆
𝑁
 
Equation 5.4: Bonferroni correction (S = significance level, N = number of tests) 
Benjamini and Hochberg published a paper in 1995, detailing a way of controlling the 
FDR.
240
  The p-values are ordered from smallest to largest, and then given a rank from one 
to ‘n’.  The Benjamini and Hochberg correction is an estimation of the FDR, and is calculated 
by multiplying the p-value by the number of tests, and dividing this number by the p-value 
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rank (Equation 5.5).  The calculated FDR is an estimated FDR in the list of ‘significant’ 
results above a threshold (a maximum desired FDR), rather than of the global data set.   
𝑞 =  
𝑝 × 𝑁
𝑟𝑎𝑛𝑘
 
Equation 5.5: Benjamini and Hochberg correction (N = number of tests) 
For each solution data set, the peptide-level data were extracted.  For each protein where 
the minimum number of peptides used for protein quantification was three, the p-value was 
calculated using the corresponding peptide data.  Once p-values had been calculated for 
each of the protein results, a Hochberg and Benjamini multiple test FDR estimation was then 
applied to the p-values.  The corrected p-values (q-values) were then used, in combination 
with the protein quantification ratios, to generate volcano plots
247–249
 (Figure 5.11 to Figure 
5.14).  A minimum number of peptides of three was required for the spiked data, as initial 
interrogation of the data showed a large number of false positive quantification results 
obtained when q-values were included for proteins quantified using two peptide ratios.  In 
general, a minimum of two false positive quantification results were obtained when the 
minimum number of two peptide ratios were used to generate the protein quantification ratio.  
As this is the model data for which the answer is known, the decision was taken to exclude 
protein ratios generated using two peptide ratios.   
 
Figure 5.11: Volcano plot showing –log10(q-value) against log2(protein ratio) for proteins 
spiked in at 1% of the total E. coli lysate digest amount (L:H) (Blue = solution 1, red = solution 
2, green = solution 3) 
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Figure 5.12: Volcano plot showing –log10(q-value) against log2(protein ratio) for proteins 
spiked in at 1% of the total E. coli lysate digest amount (H:L) (Blue = solution 1, red = solution 
2, green = solution 3) 
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Figure 5.13: Volcano plot showing –log10(q-value) against log2(protein ratio) for proteins 
spiked in at 5% of the total E. coli lysate digest amount (L:H) (Blue = solution 1, red = solution 
2, green = solution 3) 
0
10
20
30
40
50
60
-20 -15 -10 -5 0 5 10 15 20 25 30
-L
o
g
1
0
(q
-v
a
lu
e)
 
Log2(Protein ratio) 
Chapter 5: Dimethyl labelling 
215 
 
 
Figure 5.14: Volcano plot showing –log10(q-value) against log2(protein ratio) for proteins 
spiked in at 5% of the total E. coli lysate digest amount (H:L) (Blue = solution 1, red = solution 
2, green = solution 3) 
The data in Figure 5.11 to Figure 5.14 show that for each set of solutions (e.g. proteins 
spiked in at 5% of the total E. coli lysate digest amount (H:L)), the plots are very similar, as 
the majority of points overlap between the three replicate solutions.  This emphasises the 
inter-sample reproducibility.   
Proteins with a q-value of less than 0.05 were deemed to show a statistically significant 
difference between samples.  These proteins are listed for solutions with proteins spiked in 
at 1% of total E. coli lysate digest amount (Table 5.6) and 5% of the total E. coli lysate digest 
amount (Table 5.7).   
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Table 5.6: Table showing the proteins with a q-value of less than 0.05 for proteins spiked into 
the E. coli lysate digest at 1% of the total lysate digest amount  
 
 
 
L:H or H:L Solution Protein q-value 
L:H 
 
1 
Trans 1.99 × 10
-7 
Myo 1.57 × 10
-4 
2 
EG10241 1.60 × 10
-117 
EG10805 7.72 × 10
-77 
EG20173 3.11 × 10
-53
 
EG12316 1.16 × 10
-51
 
EG10022 3.75 × 10
-49
 
EG10906 1.03 × 10
-40
 
EG10586 5.02 × 10
-39
 
EG10770 2.44 × 10
-34
 
Trans 1.43 × 10
-7
 
Myo 5.92 × 10
-6
 
EG12204 2.42 × 10
-3
 
EG10576 2.86 × 10
-2
 
EG10421 4.93 × 10
-2
 
3 
Myo 5.41 × 10
-5 
EG10586 6.39 × 10
-4 
H:L 
1 
Trans 2.64 × 10
-4 
BSA 7.15 × 10
-3 
2 
Trans 1.10 × 10
-4 
Myo 2.48 × 10
-4 
3 
Trans 9.47 × 10
-4 
Myo 2.09 × 10
-3
 
EG10953 7.23 × 10
-3
 
EG10699 1.03 × 10
-2
 
EG11581 1.28 × 10
-2
 
EG10158 1.54 × 10
-2
 
EG10794 2.15 × 10
-2
 
EG10256 2.19 × 10
-2
 
EG10497 2.65 × 10
-2
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Table 5.7: Table showing the proteins with a q-value of less than 0.05 for proteins spiked into 
the E. coli lysate digest at 1% of the total lysate digest amount  
L:H or H:L Solution Protein q-value 
L:H 
1 
BSA 2.52 × 10
-18 
Trans 1.68 × 10
-16
 
Myo 7.03 × 10
-12
 
Phos B 1.10 × 10
-4
 
2 
EG10895 3.42 × 10
-60 
BSA 3.47 × 10
-19 
Trans 5.04 × 10
-13 
Myo 9.24 × 10
-12 
EG10550 1.25 × 10
-3 
Phos B 1.74 × 10
-3 
EG10576 8.47 × 10
-3 
3 
BSA 1.93 × 10
-18 
Myo 1.31 × 10
-13 
Trans 5.65 × 10
-13 
Phos B 3.55 × 10
-5 
EG10420 3.50 × 10
-2 
H:L 
1 
Trans 5.86 × 10
-7 
Myo 1.40 × 10
-4 
BSA 5.29 × 10
-3 
2 
EG10789 2.68 × 10
-58 
EG11003 2.75 × 10
-58 
BSA 1.68 × 10
-12 
Myo 6.85 × 10
-10 
Trans 1.96 × 10
-9 
Phos B 4.30 × 10
-3 
EG10599 2.65 × 10
-2 
3 
BSA 1.80 × 10
-259 
Trans 2.80 × 10
-16 
Myo 2.09 × 10
-6 
EG10870 9.88 × 10
-3 
Phos B 1.80 × 10
-2 
EG10347 3.72 × 10
-2 
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As can be seen in Table 5.6 and Table 5.7, the number of false positive quantification results 
(i.e. E. coli lysate proteins which should have been present at 1:1, and deviate from this) is 
higher when the proteins were spiked at 1% of the total E. coli lysate digest amount.  A total 
of 19 false positive quantification results were obtained for solutions with the proteins spiked 
in at 1% of the total E. coli lysate digest amount.  This is compared with the nine false 
positive quantification results that were obtained for solutions with the proteins spiked in at 
5% of the total E. coli lysate digest amount.  No E. coli lysate protein was identified as a 
false positive quantification result in both the forward and reverse labelled solutions.  It 
would be expected that a true positive change in ratio would be evident in both the forward 
and reverse labelling data sets and in more than one replicate.  That is not the case for any 
of the false positive quantification results generated from the E. coli lysate proteins.   
 
For the solutions with proteins spiked in at 5% of total E. coli lysate digest amount, in the L:H 
labelling all four of the spiked proteins generated q-values of less than 0.05.  In the reverse 
labelled solutions (H:L), for one of the solutions only three of the four spiked proteins 
generated q-values of less than 0.05.  In this instance, the protein with the non-statistically 
significant q-value was Phos B (q-value = 0.27).  For solution 1, a total of three peptides was 
used for generation of the p-value, and subsequent q-value.  It is possible that the small 
number of peptides used for protein quantification, and subsequent q-value determination, is 
the reason for the non-statistically significant q-value.  This is a false negative quantification 
result, meaning that a change in protein levels has not been detected in this instance.   
The main difference between the solutions with proteins spiked in at 1% and 5% of the total 
E. coli lysate amount is the fact that a protein quantification ratio for Phos B was not 
obtained when Phos B was spiked in at 1% of the total E. coli lysate amount.  Quantification 
of Phos B was not possible from the LC-ESI-MS data obtained either because only one 
peptide could be quantified (in which case MD does not include this), or no peptides could 
be quantified.  Phos B was the not the smallest of the four proteins which were spiked into 
the E. coli lysate digest.  Therefore, the reason for the lack of peptide quantification ratios for 
Phos B when the protein was spiked in at 1% of the total E. coli lysate digest amount is not 
due to a lack of peptides being produced in the digest.  It is likely to be due to the fact that it 
has been observed within the group that Phos B does not ionise as well by ESI as BSA, 
Trans and Myo ionise (personal communication with Adam Dowle, Department of Biology).  
Phos B was identified during the Mascot search in all instances, but quantification was not 
possible.  In the PRIDE database
250
, Project PXD000001 contains data from a TMT spike 
experiment.  In that experiment, Phos B was spiked in to an equimolar Erwinia carotovora 
lysate with varying proportions in each channel of quantification.
251
  A total of 44 peptides 
were identified for Phos B in the spiked experiment.  This is compared with 24 peptides for 
BSA, 31 peptides for yeast enolase and two peptides for bovine cytochrome C.  These 
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results are in contrast to the data obtained during the dimethyl labelling experiment 
presented in this thesis.  However, whilst the dimethyl labelling experiments were analysed 
using a maXis q-TOF, the TMT spiking experiment was analysed using an LTQ Orbitrap 
velos.  The different mass spectrometers have different mass analysers and different source 
designs, will have been tuned differently (not least because of their different designs) and 
will likely have different responses for some of the same peptides analysed on the two 
instruments, which may lead to the differing results.  The ‘background proteins’ used in the 
dimethyl labelling experiment and TMT experiments are also different (E. coli lysate versus 
Erwinia carotovora lysate), which could have led to the differences observed for the number 
of Phos B peptides identified in the two sets of experiments.   
Another PRIDE database entry (Project PXD000288) details the results of a deep skeletal 
muscle proteome investigation in mice.
252
  Nearly complete sequence coverage was 
obtained for Phos B, which was found to be one of the 10 most abundant proteins, which in 
total make up 50% of the total protein mass in skeletal muscle.  The analysis was performed 
using a Q Exactive mass spectrometer.  The fact that Phos B was one of the most abundant 
proteins observed, and the fact that the analysis was performed on a Q Exactive could both 
be reasons for the high sequence coverage (i.e. a large amount of the protein is known to 
increase the chance of peptides from Phos B being selected for analysis, and the type of 
mass spectrometer could also affect the response of different peptides). 
However, there are instances where Phos B has been recorded as having the lowest 
sequence coverage in a spiking experiment.  In 2005, Silva et al. published results from an 
absolute quantification spiking experiment using six proteins spiked in to an E. coli protein 
digest.
253
  Of the six proteins spiked into the E. coli protein digest, Phos B generally had the 
lowest sequence coverage of the six spiked proteins.  This analysis was performed on a q-
ToF Ultima API.  The fact that a q-ToF was used, along with the spiking-nature of the 
experiment means that this experiment, and its results, are more in line with the nature of 
the dimethyl experiments performed in this work. 
The fact that Phos B was not quantified using the data obtained from the proteins spiked in 
at 1% of the total E. coli lysate digest amount, but was always quantified using the data 
obtained from the proteins spiked in at 5% of the total E. coli lysate digest amount is likely to 
be due to the fact that more of the protein was spiked in to the E. coli lysate digest for the 
5% spiked solutions, and therefore more would be present in the solution.   
In all cases for each of the proteins spiked in at 1% of the total E. coli lysate digest amount, 
the spiked protein which was quantified using the greatest number of peptides is BSA.  The 
same is observed in the plots showing the proteins spiked in at 5% of the total E. coli lysate 
digest amounts apart from L:H replicate 3.  This is not due to the fact that BSA is a larger 
protein than the other proteins used for spiking (in fact it is the second smallest).  It is 
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therefore likely that the peptides produced from a BSA digest are particularly well ionised in 
this LC-ESI-MS system.   
The data suggest that dimethyl labelling with LC-ESI-MS analysis and MD for quantification 
can be used for reliable quantification.  The spiked proteins were identified as statistically 
significantly different from the data from all of the solutions where the proteins were spiked in 
at 5% of the total E. coli lysate digest amount.  However, using the data obtained from the 
proteins spiked in at 1% of the total E. coli lysate digest amount, Phos B could not be 
quantified.  Therefore, it is possible that in an experiment with two unknown samples, if the 
abundance of the protein which is changing is low (e.g. around 1% of the total amount of 
protein in the sample) or it ionises poorly, then the change may not be detected.   
 
5.4. Applying dimethyl labelling to relative quantification of 
muscle protein samples 
Having established that spiked proteins could be identified as statistically significantly 
different in a complex background (principally at 5% of the total background amount), and 
validated in-solution dimethyl labelling for relative quantification, the method was applied to a 
quantitative proteomics experiment with ‘real’ samples.  A duplex experiment was performed 
using mouse-derived skeletal muscle cell samples (undifferentiated C2C12 myoblasts), 
prepared by Elliot Jokl (Department of Biology).  After stretching, the cells were washed and 
scraped in PBS.  Three protein extracts were prepared: one from unstretched muscle (U), 
and two from stretched muscle (stretched 1 (S1) and stretched 2 (S2)), where the 
unstretched muscle sample was to be compared with the two stretched muscle samples.  
Both stretched muscle samples were subjected to dynamic (continuous) stretching for three 
hours.  The aim of the experiment was to determine whether there was a difference between 
levels of any of the proteins in extracts of stretched and unstretched muscle cells.  At the 
time of the analysis, it was not known whether there are any differences in protein 
abundances between the unstretched and stretched samples.  The protein extracts were 
subjected to an in-gel tryptic digestion, performed by Rachel Bates, prior to dimethyl 
labelling, as the samples were also analysed using label-free quantification (analysis 
performed by Adam Dowle; those results are not included in this work).    
Aliquots of the unstretched muscle and stretched muscle proteins were labelled with both 
the light and heavy formaldehyde labels (in order to perform the forward and reverse 
experiments).  The unstretched muscle sample was compared with each of the stretched 
muscle samples.  Aliquots of these now-labelled digests were combined in a 1:1 (v/v) ratio 
(L:H and H:L) and analysed by LC-ESI-MS.   
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The number of proteins identified and quantified in each of the solutions was extracted from 
the data (Table 5.8).  FDR values ranged from 0.00-0.30% (Table 7.7). 
Table 5.8: Number of peptides identified and quantified across the muscle protein samples 
(see 7.5.6 for FDR values) 
Solution Replicate Number of proteins 
identified 
Number of proteins 
quantified 
U:S1 
 
L:H 455 142 
H:L 459 164 
U:S2 L:H 492 152 
H:L 582 210 
 
As can be seen in Table 5.8, the number of proteins identified and the number of proteins 
quantified were similar between the L:H and H:L unstretched:stretched 1 solutions.  For the 
L:H and H:L unstretched:stretched 2 solutions, 90 more proteins were identified, and 58 
more proteins were quantified from analysis of the H:L solution than the L:H solution.  It is 
possible that for unstretched:stretched 2, the differences between the number of proteins 
identified and quantified for the L:H and H:L experiments could be due to systematic errors 
due to labelling, errors in the reproducibility of preparing the solutions, or errors arising from 
overlapping isotopic envelopes.  The difference between the L:H and H:L experiments for 
unstretched:stretched 2 highlights the need for sample replicates and replicate analyses 
being carried out, to increase coverage and help to identify anomalous results.   
The number of proteins identified and quantified across the L:H and H:L 
(unstretched:stretched 1 and unstretched:stretched 2) solutions are shown in Venn diagrams 
in Figure 5.15 to Figure 5.18.   
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Figure 5.15: Venn diagram showing the number of proteins identified in the 
unstretched:stretched 1 L:H and H:L experiments (Venn diagram produced using Venny237) 
 
Figure 5.16: Venn diagram showing the number of proteins quantified in the 
unstretched:stretched 1 L:H and H:L experiments (Venn diagram produced using Venny237) 
 
Figure 5.17: Venn diagram showing the number of proteins identified in the 
unstretched:stretched 2 L:H and H:L experiments (Venn diagram produced using Venny237) 
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Figure 5.18: Venn diagram showing the number of proteins quantified in the 
unstretched:stretched 2 L:H and H:L experiments (Venn diagram produced using Venny237) 
As can be seen in Figure 5.15 to Figure 5.18, the overlap between the proteins from 
unstretched and stretched samples is approximately 50% for proteins identified and proteins 
quantified.   
 
With the E. coli lysate digest experiments, known amounts of protein were digested, so that 
it was easy to prepare a 1:1 (v/v) solution of the E. coli lysate digest and have confidence 
that it was indeed a 1:1 mixture.  With the muscle samples, an unknown amount 
(approximately 100-200 ng) of protein was digested for each of the three samples.  
Therefore, although a 1:1 (v/v) solution was prepared, there was no guarantee that equal 
amounts of light and heavy labelled proteins were combined.   
Due to the inability to ensure direct comparability of protein amounts being used for each 
digest (100-200 ng), a global normalisation was applied.  It was expected that the vast 
majority of proteins would be unchanged in level between the two samples, and should 
therefore be present in equal amounts (i.e. give a ratio of 1:1).  In MD, the ‘median’ 
normalisation option was used.  MD’s median option applies a correction factor to each 
peptide ratio such that the median of the ratios for all peptide matches that pass the quality 
test is 1:1.   
As was the case with the E. coli lysate digest spiking experiments, the data were 
interrogated at the peptide level.  For each protein where the protein ratio was generated 
using a minimum of three peptide ratios, a p-value was generated from the peptide ratio 
data.  The p-values were then converted to q-values using the Hochberg and Benjamini 
multiple test FDR estimation.  The resulting q-values were used along with the protein ratios 
to generate volcano plots (Figure 5.19 and Figure 5.20).   
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Figure 5.19: Volcano plot showing –log10(q-value) against log2(protein ratio) for 
unstretched:stretched 1 (Blue = L:H, red = H:L) 
 
Figure 5.20: Volcano plot showing –log10(q-value) against log2(protein ratio) for 
unstretched:stretched 2 (Blue = L:H, red = H:L) 
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Figure 5.19 shows a wider spread of data points along the x-axis for the H:L solution than 
the L:H solution for unstretched:stretched 1.  However, overall for both the 
unstretched:stretched 1 and unstretched:stretched 2 plots, the L:H and H:L plots look similar 
in the sense that the majority of points fall along the y-axis (as is expected).   
The same parameters as were used in the E. coli lysate spiking experiments (a minimum of 
three peptides used for quantification, and a significance level of q < 0.05) were applied to 
the muscle protein data.  The proteins identified as having a significant q-value are detailed 
in Table 5.9. 
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Table 5.9: Table showing proteins with a q-value < 0.05 for muscle protein samples 
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As can be seen in Table 5.9, more proteins were found to have a significant q-value for the 
unstretched:stretched 1 experiment than the unstretched:stretched 2 experiment.  In fact, no 
proteins were found to have a significant q-value for the L:H solution of 
unstretched:stretched 2.  Bearing in mind that more proteins were identified and quantified 
for the unstretched:stretched 2 experiment, this lack of significance serves as a reminder 
that small data sets (with no replicates or repeat sampling) can lead to inconclusive or 
misleading information, and of the need for replicate analyses.  The significant q-values 
obtained for unstretched:stretched 1 experiment are all close to the significance threshold 
used (0.05).  It is important to bear in mind that this was a quick investigation with no 
biological or technical replicates provided or possible due to the very limited sample amount 
and time.  The results should thus be considered as a preliminary investigation aimed at 
generating candidates for consideration in further studies, and for comparison with the 
emPAI analysis carried out separately by Adam Dowle.  Further work should be performed 
in the first instance to generate technical and biological replicates, to enhance the 
understanding of these samples and give greater confidence in these preliminary dimethyl 
labelling results obtained.   
No protein was identified as changing levels in both the forward and reverse experiments for 
stretched 1 or stretched 2, which suggests these results may be false positive quantification 
results or that the level of change is low.  Further investigation is needed to determine 
whether the changes reported in Table 5.9 are true positive results.  However, an initial 
interpretation of the data was performed.  There is some agreement between the dimethyl 
labelling experiment and the more detailed emPAI experiment (data not reported in this 
work):   
The proteins mitochondrial ATP synthase subunit alpha and mitochondrial aldehyde 
dehydrogenase were both found to be up-regulated in the stretched muscle protein sample 1 
compared with the unstretched muscle protein sample in both the dimethyl labelling 
experiment and the emPAI experiment.  In the dimethyl labelling experiment, the protein 60S 
ribosomal protein L13 was found to be up-regulated, whilst in the emPAI experiment, the 
protein 60S ribosomal protein L5 was found to be up-regulated.  For the 
unstretched:stretched 1 samples, the protein tubulin beta-4B chain was found to be down-
regulated in both the dimethyl labelling and the emPAI experiments.  For the 
unstretched:stretched 2 samples, heat shock protein HSP 90-beta was found to be up-
regulated in both the dimethyl labelling and the emPAI experiments.   
For the unstretched:stretched 1 samples, ribosomal proteins were found to show differential 
abundance.  40S ribosomal protein SA, 60S ribosomal protein L13 and 60S acidic ribosomal 
protein P0 were found to be up-regulated in stretched muscle protein sample 1 compared 
with the unstretched muscle sample.  It has been found that early responses to damaged 
muscle include the early induction of transcription genes.
248
  The up-regulation of some 
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ribosomal proteins in the stretched muscle protein sample compared with the unstretched 
muscle protein sample would be consistent with this observation.   
Transitional endoplasmic reticulum ATPase was found to be down-regulated in stretched 
muscle protein sample 1 compared with the unstretched muscle protein sample.  
Transitional endoplasmic reticulum ATPase is necessary for the fragmentation of Golgi 
stacks during mitosis and for their reassembly after mitosis.
254
  The protein myosin-9 was 
found to be down-regulated in the unstretched:stretched 1 sample.  Myosin-9 plays a role in 
cytoskeleton reorganisation, cytokinesis and cell shape.
255
  Decarboxylating 6-
phosphogluconate dehydrogenase was found to be down-regulated in stretched muscle 
protein sample 1 compared with the unstretched muscle protein sample.  The function of this 
decarboxylating enzyme is to catalyse the oxidative decarboxylation of 6-phosphogluconate 
to ribulose 5-phosphate and carbon dioxide, with concomitant reduction of NADP to 
NADPH.
256
   
Heat shock protein HSP 90-beta was up-regulated in the stretched muscle protein 2 sample 
when compared with the unstretched muscle protein sample, which is not surprising.  The 
muscle samples were stretched for three hours, and therefore were likely to have been 
showing shock responses.  HSP 90 is a molecular chaperone, many of which are known to 
interact with cytoskeletal elements such as microfilaments and intermediate filaments, and 
regulate the folding of cytoskeletal or cytoskeleton-related proteins.
257,258
  HSPs are known 
to be produced in stressed cells (they are still an important part of the non-stressed cell), 
which would explain their up-regulation in the stretched muscle protein 2 sample.
257,259
 
Chloride intracellular channel protein 1 was found to be down-regulated in stretched muscle 
protein sample 1 when compared with the unstretched muscle protein sample.  Chloride 
intracellular channel protein 1 is a protein which inserts into membranes to form chloride ion 
channels.
260
  In 2004, Baek et al. published findings which included a down-regulation of 
chloride intracellular channel protein 1 under oxidative stress in Helicobacter pylori-infected 
human gastric mucosa.
261
  It is possible that a similar effect is observed during stretching of 
the muscle proteins, which would account for the down-regulation of chloride intracellular 
channel protein 1 in stretched muscle protein sample 1 compared with the unstretched 
control sample.   
The annexin family of proteins are calcium and phospholipid binding proteins, and are 
involved in the regulation of calcium in cells.  Annexin A1 was found to be down-regulated in 
stretched muscle protein sample 1 when compared with the unstretched muscle protein 
sample.  This is perhaps contrary to the expected result as annexin A1 has been found to 
play an important role in cell repair.
262–264
  In 2015, Leikina et al. published a paper in which 
the authors proposed that a deficiency in annexin A1 did not have a detrimental effect on 
myofibre repair after lengthening contraction injury, although its absence did delay muscle 
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regeneration.
262
  This suggests that its presence is not necessarily key to muscle 
regeneration over the seven day period investigated by Leikina et al..  However, the result 
observed during the dimethyl labelling investigation presented in this thesis could also be a 
false positive quantification result. 
Desmin was found to be down-regulated in both the stretched muscle protein sample 1 and 
2 compared with the unstretched muscle protein sample.  Desmin is an intermediate filament 
protein which connects myofibrils to each other and to the plasma membrane in striated 
muscle.  Due to the fact that the muscle samples were stretched, it is highly likely that 
damage occurred to the proteins.  There have been several papers which have discussed 
the possibility that if a muscle is damaged, desmin can be broken down within the cell.
248,265–
267
   Therefore, it is possible that the down-regulation of desmin in the stretched muscle 
protein samples compared with the unstretched control could be due to damage occurring to 
the stretched muscle proteins, and subsequent desmin break-down.   
Two mitochondrial proteins were found to be up-regulated in stretched muscle protein 
sample 1 compared with the unstretched muscle protein sample.  Mitochondrial aldehyde 
dehydrogenase and mitochondrial ATP synthase subunit alpha were both found to be up-
regulated in unstretched:stretched 1.  Mitochondrial aldehyde dehydrogenase is involved in 
the conversion of aldehydes to carboxylates.
268
  The up-regulation of aldehyde 
dehydrogenase proteins has been noted during organism stress, particularly oxidative 
stress.
269
  Mitochondrial ATP synthase subunit alpha is a protein which produces ATP from 
ADP, which in turn is used as energy by cells.
270
  This could explain its up-regulation in 
stretched muscle protein sample 1 compared with the unstretched muscle protein sample, 
due to a possible increased energy demand during stretching.  Alternatively, muscle 
contraction is known to require energy,
271
 and therefore it is possible that as a result of 
stretching (where subsequent contraction would be expected), the up-regulation of 
mitochondrial ATP synthase subunit alpha may occur. 
Tubulin beta-4B chain was found to be down-regulated in the stretched muscle protein 
sample 1 compared with the unstretched control.  It is a major constituent of 
microtubules.
257,272
  Tubulin beta-chain has previously been found to be up-regulated when 
cells are subjected to oxidative stress.
273
  Tubulin has also been found to be down-regulated 
during heat stress.
274,275
  In 2010, Weis et al. published a paper detailing the relationship 
between heat shock protein 90 and tubulin.
275
  Based on that work, it is possible that the up-
regulation of heat shock protein 90 observed here is due to the down-regulation of tubulin 
beta-4B chain in the stretched muscle protein sample 1. 
Phosphoglycerate kinase 1 and phosphoserine aminotransferase were both found to be up-
regulated in the stretched muscle protein sample 1 compared with the unstretched muscle 
protein sample.  Phosphoglycerate kinase 1 is a glycolytic protein.
276
  There have been 
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several publications reporting up-regulation of phosphoglycerate kinase 1 for different 
organisms under stress conditions.
276,277
  Therefore, the up-regulation of phosphoglycerate 
kinase 1 in stretched muscle protein sample 1 is perhaps not surprising given the fact that 
stretching the samples for three hours is likely to have induced stress.  Phosphoserine 
aminotransferase catalyses the reversible conversion of 3-phosphohydroxypyruvate to 
phosphoserine.
278
  Phosphoserine aminotransferase has previously been found to be up-
regulated in response to heat stress.
279
  It is possible that the effect could be the same for 
stretching stress as it is for heat stress.   
Fructose-bisphosphate aldolase A was also found to be up-regulated in the stretched 
muscle protein sample 1 compared with the unstretched muscle protein sample.  This 
protein plays an important role in glycolysis and gluconeogenesis.
280
  Fructose-bisphosphate 
aldolase A has previously been found to be up-regulated in mice after low-intensity 
exercise.
281
  Therefore, the observation of fructose-bisphosphate aldolase A being up-
regulated in the stretched muscle protein sample 1 is thus consistent with this previously-
observed result.   
Several of the proteins with significant q-values have been observed as being up-regulated 
when an organism is placed under stress (e.g. heat shock proteins and phophoglycerate 
kinase 1).  Wang et al. published a paper in 2009 where they analysed data from many 
different experiments to determine whether there were any generally detected proteins in 
comparative proteomics.
282
  The authors concluded that the reason for commonly 
differentially abundant proteins could be due to cellular stress response.  Some of the 
proteins identified as being frequently detected as having differential abundance include 
heat shock proteins, chloride intracellular protein 1, phosphoglycerate kinase 1 and fructose-
bisphosphate aldolase A.  Therefore, these proteins having differential abundance in the 
stressed muscle experiment may be due to a cellular stress response.   
The fact that the most abundant proteins do not show a significant difference in abundance 
between the unstretched and stretched muscle samples is an interesting result.  It is 
possible that it is some of the less abundant proteins within the muscle that show a 
difference in abundance between the unstretched and stretched samples.   
Although the two stretched muscles samples were both subjected to dynamic stretching for 
three hours, the proteins with differential abundance are not the same in the two samples.  
This has also been noted through emPAI LC-ESI-MS analysis and western blotting analysis 
carried out by others on the same samples.  For example, during the emPAI analysis, the 
protein 60S ribosomal protein L18 was found to be up-regulated in stretched muscle protein 
1 sample compared with the unstretched muscle protein sample.  However, it was not 
determined to be up-regulated in stretched muscle protein 2 sample compared with the 
unstretched control.  It is not currently known why the two stretched muscle samples, which 
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came from the same flask of undifferentiated C2C12 myoblasts, and were subjected to the 
same stretching treatment, were found to have different proteins up-regulated and down-
regulated when compared with the unstretched muscle protein sample.  However, it is 
possible that this could be due to biological variation, or differing amounts of total protein in 
samples 1 and 2.  It is possible that for unstretched:stretched 2, the differences between the 
number of proteins identified and quantified for the L:H and H:L experiments could be due to 
systematic errors due to labelling, errors in the reproducibility of preparing the solutions, or 
errors arising from overlapping isotopic envelopes.   
 
5.5. Conclusions and future work 
As detailed above, dimethyl labelling is now regarded as a routine labelling strategy in 
mainstream proteomics.  However, due to time constraints affecting the work in this chapter, 
a full-scale investigation was not possible.  The work in this chapter acts as a starting point 
in the broader aim to develop dimethyl labelling as a mainstream labelling strategy within the 
group, as well as to adapt and develop it for use with the SAM technology.   
The in-solution dimethyl labelling strategy is cheap, quick and efficient.  Labelling of 
standard samples was performed and samples mixed in a variety of ratios (both L:H and 
H:L), and the solutions were then analysed by MALDI-MS and LC-ESI-MS.  The ratios 
generated from the LC-ESI-MS data are closer to those of the standard solutions than the 
MALDI-MS data, with a smaller spread in the data for LC-ESI-MS than MALDI-MS 
generated results, which suggests that LC-ESI-MS produced the more accurate and precise 
results.   
Two software packages were tested for data analysis of the LC-ESI-MS data: PS and MD.  
Having compared the two software packages, MD provided better results than PS.  In PS, 
the data generated for the standard solutions always resulted in an under-representation of 
the ratio.  However, this problem was not observed with MD.  With the E. coli lysate spiking 
experiments, more peptides were identified (and subsequently used for quantification) for 
proteins in the E. coli lysate spiking experiment data analysed with MD than with PS.  
Additionally, the spread in quantification results was much smaller for the data handled with 
MD than PS.  With PS, the range of ratios obtained for E. coli lysate proteins (which should 
have been 1:1) was much larger than with MD.   
There are differences between the two software packages used.  For MD, at the time of the 
data being analysed, it was not possible to import calibrated data into the software.  This 
meant that for database searches conducted through Mascot for MD, wider tolerances were 
needed for mass errors than for PS.  Once MD can incorporate the calibrated Bruker data 
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files, it would be interesting to compare the quantification results obtained from calibrated 
data using MD and PS with uncalibrated data using MD.  Although search tolerances wider 
than 10 ppm (peptide tolerance) and 0.1 Da (MS/MS tolerance) can be used in PS, 
uncalibrated data would need to be used in PS in order to gain a complete comparison.  PS 
automatically uses the calibrated data, so that a way to use uncalibrated data would need to 
be investigated.  The ultimate difference between the two software packages, leading to the 
difference in the number of peptides available for quantification (and ultimately the superior 
quantification results obtained through MD over PS), is unknown.  This would be worth 
investigating as part of a larger comparison of different software packages for quantification.   
 
An investigation using LC-MALDI-MS could be undertaken, in a similar manner to the LC-
ESI-MS analysis.  In this way, a set of standard labelled solutions of a single protein digest 
could be analysed.  A set of spiked solutions could then be prepared and analysed.  This 
would allow a direct comparison between LC-ESI-MS analysis and LC-MALDI-MS analysis.  
Ultimately, MALDI-MS would be the analysis technique used, if a dimethyl labelling 
derivative was used in combination with the SAM technology.  Therefore, the suitability of 
MD for processing LC-MALDI-MS analysis should be investigated.  It is possible that, with 
the analytes separated prior to MALDI-MS, the relative quantification may be improved.  This 
would help mitigate the issue that when all the peptides are spotted in one well, peptides 
which ionise least efficiently may be less well represented in the mass spectrum, which may 
adversely affect the quantification ratio for that peptide.  The LC-MALDI-MS technique may 
mean that these peptides are better represented in the resulting mass spectra if the spectra 
are not dominated by a few highly-ionisable peptides; this may improve the quantification 
results obtained.   
 
Future work should include further investigation of the muscle protein samples.  Replicate 
analyses of the samples should be performed (in order to maximise the protein coverage) 
(technical and biological replicates should be considered).  An alternative quantification 
method, such as iTRAQ quantification, could be used to corroborate the results.  
Alternatively, an orthogonal chromatographic method could be used (e.g. HILIC or strong 
cation exchange chromatography).  An alternative analysis would provide greater confidence 
in the data obtained.  Potential changes in protein expression, observed through differing 
protein abundance between samples, should then be validated using alternative methods 
such as western blotting.   
Potentially important information could be missed on the less abundant proteins (which may 
be up- or down-regulated), as it is possible that peptides associated with these proteins may 
not be detected due to their low abundance.  The samples could be analysed using a longer 
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LC gradient (which may further separate peptides, and allow more peptides to be identified 
and used for quantification for the less abundant proteins).  In Section 5.4, single injections 
of the samples were made.  With more sample and replicate labelling, repeat injections of 
each sample would be possible, with the resultant data being combined for analysis.  
Additional peptides may well be identified and quantified in the different runs, as it is unlikely 
that exactly the same peptides would be identified in each run, and technical repeats may 
provide additional information.
99,283,284
  Having performed that analysis, a list of up- and 
down-regulated proteins could be generated, in order to target the analysis towards specific 
proteins.  Alternatively, more sample could be loaded onto the instrument in order to try and 
increase the intensities of the less abundant peptide ions.  However, this would be 
dependent on the intensities of the most abundant ions, as it is possible to saturate the mass 
spectrometric detector.  Therefore, a balance must be struck between increasing the 
intensities of the less abundant ions and saturating the detector with the most abundant 
ions.  It is also possible to deplete for some of the major proteins, in order to reduce the 
complexity of the sample and subsequently, potentially, increase the ability to detect and 
quantify the less abundant proteins in a sample.  Depletion strategies usually involve 
immunoaffinity techniques to remove one or more specific proteins.  An alternative 
chromatographic method, such as HILIC
234
, strong cation exchange
25
 or a high pH reverse 
phase system could also be used. 
An interesting approach would be to analyse a new set of E. coli lysate digest-spiked 
solutions using a wider variety of quantification strategies, such as label-free and iTRAQ, 
alongside dimethyl labelling.  Due to the fact that these samples would be identical (other 
than the label), and exactly what was in them would be known, it would provide an 
interesting comparison of the different labelling strategies (e.g. is one strategy more suited to 
quantification of the spiked proteins, or is one strategy better at identifying spiked proteins at 
1% over 5%).  Having completed the process with a set of standard spiked solutions, a 
variety of real samples could be analysed in the same way and a direct comparison of the 
outcomes made.   
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6.1. Integration 
The different strands of this thesis had been planned as part of a coherent whole, with the 
aim being to recombine these strands to form a new SAM technology for quantitative 
proteomics.  The SAM technology as it stands shows potential as a novel analysis 
methodology for mass spectrometric peptide analysis and the dimethyl labelling strategy has 
the potential to be adapted for use in the SAM technology.  The envisaged workflow can be 
seen in Figure 6.1.   
 
Figure 6.1: Proposed workflow for capturing protein digests on a SAM, with incorporation of 
the dimethyl-derived label 
When the dimethyl labelling work was started, the ultimate aim had been to derivatise a 
ketone for use with the SAM technology.  Formaldehyde has no other functional group, and 
therefore has no functionality to react with the SAM.  Therefore, it is unsuitable for use with 
the SAM technology.  However, a ketone can contain more than one functional group, 
meaning that a second group could be incorporated for reaction with the SAM.  Having 
established dimethyl labelling (which uses an aldehyde) successfully within the proteomics 
facility, the next logical step was to label peptides from a tryptic digest with a simple ketone.   
As a proof of principle that a molecule with a ketone carbonyl group could be used to label 
the peptides, aliquots of a simple BSA digest were labelled with acetone and acetone-d6.  
The labelling chemistry is similar for formaldehyde and acetone.  Although there has been 
much research into dimethyl peptide labelling, there is limited literature on ketone labelling of 
peptides.  One example is the labelling of peptides with acetone, which the authors termed 
‘reductive alkylation by acetone (RABA)’ (Figure 6.2).
285
  In this paper, the group looked at 
Digest proteins 
Label one aliquot with light 
label and one with heavy label  
Combine light and heavy 
labelled peptides 
Attach labelled peptides onto 
SAM 
Form SAM on gold-coated 
MALDI chip 
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labelling standard peptides and tryptic digests of transgenic mouse tissues and human cell 
lysates.   
 
Figure 6.2: Labelling of a generic peptide with acetone (top) or acetone-d6 
The group labelled the peptides with acetone or acetone-d6 using 90% acetonitrile (+0.1% 
formic acid) as the solvent system.  This would add an additional step to the current 
methodology, as the protein digests are performed in TEAB at pH 8.0, and so would need to 
be dried and re-suspended in the 90% acetonitrile (+0.1% formic acid) solvent system.  
Therefore, the possibility of labelling the peptides using an adapted version (using TEAB 
instead of 90% acetonitrile +0.1% formic acid of the RABA labelling strategy) was 
investigated.   
Aliquots of a BSA digest in TEAB were acidified to ~ pH 4.5 using 0.1% formic acid.  One 
aliquot was then labelled with acetone, and the other with acetone-d6.  A 1:1 solution of the 
labelled digests was prepared and then analysed by MALDI-MS.  The resulting mass 
spectrum is shown in Figure 6.3.   
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Figure 6.3: MALDI mass spectrum of a BSA digest labelled with acetone and acetone-d6 (1:1) 
(blue = acetone labelled peptides, red = acetone-d6 labelled peptides) (not all peptide pairs 
are labelled on the mass spectrum, but all identified peptides are detailed in Table 6.1) 
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As can be seen in Figure 6.3, BSA tryptic digest peptides have been successfully labelled 
with acetone and acetone-d6.  There is a mass difference of 6 Da between the acetone and 
acetone-d6 labelled peptides.  In some instances, two labels have been incorporated into 
peptides which include a lysine residue.  This suggests that the peptide has been labelled at 
the N-terminal and also at the lysine side-chain.  No peaks were observed for unlabelled 
BSA digest peptides.  Although no MS/MS data were acquired, the proposed peptide 
assignments for the spectrum shown in Figure 6.3 are given in Table 6.1.  There remain two 
potential peptide pairs which are currently unassigned (m/z 1579.8/1585.8 and m/z 
1960.8/1966.8).   
Table 6.1: Proposed peptide assignments for peaks observed for acetone/ acetone-d6 labelled 
peptides 
Nominal m/z value Number of labels Peptide sequence 
1043 1 ALKAWSVAR 
1085 2 ALKAWSVAR 
1268 2 CASIQKFGER 
1441 1 TVMENFVAFVDK 
1450 1 SLHTLFGDELCK 
1481 1 RHPEYAVSVLLR 
1492 2 SLHTLFGDELCK 
1521 1 LGEYGFQNALIVR 
1543 1 LRCASIQKFGER 
1609 1 DAFLGSFLYEYSR 
1681 1 KVPQVSTPTLVEVSR 
1709 1 MPCTEDYLSLILNR (unmodified Cys) 
1724 2 KVPQVSTPTLVEVSR 
1755 1 MPCTEDYLSLILNR 
1771 1 KFWGKYLYEIARR 
1911 1 RPCFSALTPDETYVPK 
2019 2 SLHTLFGDELCKVASLR 
 
As can be seen from the data presented in Figure 6.3 and Table 6.1, peptides from aliquots 
of a BSA digest were successfully labelled with acetone and acetone-d6.  This serves as a 
critical proof of principle that peptides can be labelled with a ketone (using a protocol based 
on a combination of the dimethyl labelling strategy used, and the RABA labelling 
strategy
285
), and is the crucial first stage in combining the different strands of the work in this 
thesis.    
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6.2. Conclusions 
The work in this thesis has consisted of three different strands: creating SAMs on a gold-
coated MALDI chip to capture peptides for mass spectrometric analysis, novel removal of 
immobilised material from the gold-coated MALDI chips and solution-based chemical 
labelling of tryptic protein digests for quantitative mass spectrometric analysis.   
There are many potential benefits to the capture and analysis of peptides using gold-
immobilised SAMs for mass spectrometric analysis.  These include: 
(i) All chemistry and analysis occurs in situ on the gold-coated MALDI chip, minimising 
transfers and thus reducing sample losses, which are the main drawback of solution 
phase multistep and derivatisation-based protocols.  
(ii) Capture of peptide(s) on the SAM concentrates a sample, which useful when dealing 
with small sample amounts.  
(iii) Unreacted reagents can be washed from the gold-coated MALDI chip before analysis, 
allowing the use of non-volatile buffers, such as PBS, where in solution-phase 
proteomic workflows typically demand a desalting step.  Solid phase capture offers an 
alternative to these procedures, which is worth evaluating.   
(iv) All steps occurring on a multi-well plate which offers a convenient medium throughput 
sample handling and analysis process. 
The approach, as it stands, still has significant drawbacks, the major one of which is the 
yield of the peptide capture chemistry.  Our plans to exploit ‘click’ chemistry (see Section 
6.3), which is noted for its good yields, should offer the potential for addressing this 
drawback and improving the overall levels of analyte at which the approach is applicable.   
In Chapter 2, a thiol-derived SAM (with and without the incorporation of the chemical tag 4-
BrPhe) was used to capture a variety of peptides for mass spectrometric analysis.  Levels of 
peptide capture were lower for peptides captured on the untagged activated SAM than for 
peptides captured on the activated 4-BrPhe-tagged SAM.  In experiments with and without 
the use of the 4-BrPhe, peaks were observed for unreacted SAM after peptide capture.  An 
investigation using H2
18
O-containing PBS for 4-BrPhe coupling and peptide capture on the 
activated SAM suggested that the presence of peaks associated with unreacted SAM was 
not due to hydrolysis of the activated SAM.  This suggested that the reason for the peaks 
associated with the unreacted SAM could be due to inefficient chemistry occurring with the 
SAM.  It is likely that a combination of inefficient activation of the SAM and inefficient capture 
of the peptide on the activated SAM led to the presence of peaks associated with unreacted 
SAM.   
In Chapter 3, a disulfide-derived SAM was used (as an alternative to the thiol-derived SAM 
used in Chapter 2) to capture a variety of peptides for mass spectrometric analysis.  The 
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disulfide-derived SAM contained a pre-activated component, in the form of an NHS ester 
disulfide (removing the need for an on-chip activation step, and meaning one less step in 
construction of the SAM-peptide structure).  The peptide capture reaction with the SAM has 
been reduced from an overnight reaction to a one hour reaction.  This considerable time 
saving could potentially mean that the entire process (from SAM formation to peptide 
capture and analysis) could take place over two days instead of the original three overnight 
steps.  The data in Chapter 3 (Sections 3.3 and 3.4) suggest that the presence of Phe at the 
N-terminus reduces the efficiency of capture of the Phe-containing species on the disulfide-
derived SAM.  This could be due to aggregation occurring within the peptide solution, due to 
the hydrophobic nature of Phe, and/or π-stacking of the aromatic side chain.  However, 
peptide capture was more successful when a lower amount (0.05 nmol) of peptide was 
spotted on the disulfide-derived SAM than on the thiol-derived SAM (5 nmol).  This was an 
improvement from the thiol-derived SAM used in Chapter 2.   
In Chapter 4, two plasma instruments were used to remove a SAM from the gold-coated 
MALDI chips.  Both of these plasma instruments removed a thiol-derived SAM from the gold-
coated MALDI chips.  The proposed method would be to wash the matrix from the gold-
coated MALDI chip, and then treat the gold-coated MALDI chip with plasma effluent.  In this 
instance, the SAM could be removed from the wells of the gold-coated MALDI chip in less 
than 10 seconds.  This is a considerable decrease in the time currently taken to clean the 
gold-coated MALDI chip with piranha solution (up to 30 minutes to clean a chip), and no 
corrosive solutions are needed.   
In Chapter 5, dimethyl labelling of peptides from tryptic digestions was performed.  Standard 
samples were labelled with either light or heavy formaldehyde and samples mixed in a 
variety of ratios (both L:H and H:L), and the solutions were analysed by MALDI-MS and LC-
ESI-MS.  The ratios generated from the LC-ESI-MS data were closer to the ratios of the 
standard solutions, resulting in LC-ESI-MS being carried forward as the analysis method for 
further work in the chapter.  Two software packages (PS and MD) were tested for data 
analysis of the LC-ESI-MS data, with MD providing better results than PS.  Dimethyl 
labelling and relative quantification was successfully performed on a complex standard 
sample, and also on a ‘real’ set of samples (muscle protein samples).  The complex 
standard samples provided a set of criteria which could be applied to the muscle protein 
samples in order to determine the parameters outside of which a protein ratio could be 
deemed a potential positive quantification result.  Dimethyl labelling of muscle protein 
samples showed that some proteins appear to be differentially abundant in unstretched and 
stretched muscle protein samples, some of which correspond with results obtained by 
emPAI analysis of the same cell extracts.  Other potential positive quantification ratio results 
need further investigation.   
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6.3. Future Work 
Peptides from a BSA tryptic digest have successfully been labelled with acetone and d6-
acetone.  This paves the way for combining the SAM technology and the in-solution dimethyl 
labelling strands of the work discussed in this thesis (Figure 6.1).  The chemical label would 
be bifunctional, comprising a ketone for reductive alkylation of a peptide and an orthogonal 
group to react with the SAM (Figure 6.4).  An alkyne could allow reaction with an azide-
functionalised SAM using ‘click’ chemistry.  One of the most common forms of ‘click’ 
chemistry is the reaction of an azide and alkyne in the presence of a copper catalyst (known 
as a copper-catalysed azide-alkyne cycloaddition).
286–288
   
 
Figure 6.4: Schematic of the chemical label, including a carbonyl group and an azide group 
For example, light and heavy versions of a suitable chemical tag could be generated using 
either hydrogen/deuterium (Figure 6.5) or 
12
C/
13
C (Figure 6.7).   
 
Figure 6.5: A potential chemical label using hydrogen and deuterium to generate the light and 
heavy labels (X indicate positions of either hydrogen or deuterium) 
The molecule shown in Figure 6.5 contains the two key features needed for this strategy: a 
carbonyl group (for reaction with the peptide) and an alkyne (for reaction with the SAM).  In 
the case of the potential hydrogen/deuterium chemical label shown in Figure 6.5, both light 
and heavy versions would need to be synthesised.  For the chemical label in Figure 6.5, the 
mass difference between the light and heavy labels would be 5 Da.   
In 1975, Sih et al. published a paper detailing the asymmetric total synthesis of (-)-
prostaglandin E1 and (-)-prostaglandin E2.
289
  As part of the synthesis of (-)-prostaglandin E2, 
1-hexyn-5-one was synthesised (synthesis up to this point shown in Figure 6.6).  Ethyl 
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acetoacetate was condensed with 3-bromo-1-propyne to generate 1-hexyn-5-one in a 70% 
yield.  
 
Figure 6.6: Potential synthetic scheme for synthesis of hydrogen (light) label289 
For the light chemical label, the molecule could be synthesised by reacting ethyl 
acetoacetate with 3-bromo-1-propyne (Figure 6.6).  Similarly, the heavy chemical label could 
be synthesised by reacting a deuterated ethyl acetoacetate (which would need to be 
synthesised) with 3-bromo-1-propyne.   
In the case of the potential 
12
C/
13
C chemical label shown in Figure 6.7, the light version is 
commercially available.  The heavy version would need to be synthesised.  This could be 
synthesised by reacting (
13
C2)acetaldehyde with lithium (
13
C2)acetylide, followed by oxidation 
of the resulting secondary alcohol.   
 
Figure 6.7: A potential chemical label using 12C and 13C to generate the light and heavy labels 
(* indicate positions of either 12C or 13C) 
In 2007, Foot et al. published a paper detailing the cyclisation of O-propargylic 
hydroxylamine derivatives.
290
  As part of this synthesis, the authors reacted acetaldehyde 
with lithium acetylide to form an alcohol, which would be an ideal starting place for the 
synthesis of the 
13
C chemical label.  A proposed synthesis for the 
13
C chemical label shown 
in Figure 6.7 is shown below (Figure 6.8). 
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Figure 6.8: Proposed synthesis of the 13C chemical label (* indicates 13C position) 
The oxidation of the alcohol to ketone shown in Figure 6.8, would need to be performed 
using conditions tolerant of the alkyne functionality.  In 2003, Kang et al. published a paper 
which featured the oxidation of 3-butyn-2-ol to 3-butan-2-one, which used a Jones oxidation 
for the conversion.
291
  This would therefore be worth exploring during the synthesis of the 
label shown in Figure 6.7. 
For the chemical label in Figure 6.7, the mass difference between the light and heavy 
chemical labels would be 4 Da.  This is the same mass difference as between the light and 
heavy formaldehyde labels used in Chapter 5.  Using the 
12
C/
13
C chemical label would be 
structurally different to the hydrogen/deuterium chemical labels.  The molecular weight of the 
labels would be lower than the hydrogen/deuterium chemical labels due to needing fewer 
CH2 groups in order to incorporate the different labels.  However, there is the possibility that 
due to the close proximity of the two functional groups required for this strategy, the 
12
C/
13
C 
chemical label may not be suitable.   
Both the proposed hydrogen/deuterium and 
12
C/
13
C chemical labels contain a terminal 
alkyne group to react with an azide-terminated SAM.  A potential azide-terminated thiol 
which could be used is shown in Figure 6.9, and has been synthesised by a collaborator with 
the group.
207
  This molecule contains an alkyl chain for rigidity, and also a PEG region to 
resist non-specific peptide adsorption.  The presence of both of these regions has been 
shown to be important for future SAM components based on the work in Chapters 2 and 3.   
 
Figure 6.9: Potential ‘reactive’ component of the SAM 
A potential spacer molecule which could be used with the azide-terminated thiol is shown in 
Figure 6.10.
207
  This alcohol-terminated thiol could be synthesised (within the group) with 
either four or five PEG groups.   
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Figure 6.10: Potential spacer component of the SAM (where n = 4 or 5) 
The chemical tags and SAM components would need to be tested in the proposed workflow.  
An important consideration would be whether the hydrogen/deuterium version or the 
12
C/
13
C 
alternative is the optimum chemical label.  The ease and cost of synthesising the labels 
should be considered, as one of the benefits of dimethyl labelling is that it is relatively cheap 
compared with other quantitative proteomics strategies.  Another important consideration 
when choosing the chemical label is the success of reaction with both peptides and the gold-
immobilised azide-functionalised SAM.  There must also be no preference for either the light 
or heavy labelled peptides to react with the immobilised SAM.  Studies would need to be 
performed which compared the quantification data generated from the labelled peptides and 
the labelled peptides ‘clicked’ on the SAM, in order to ensure that data obtained from the 
peptides ‘clicked’ on the SAM are consistent with those obtained from the labelled peptides 
in solution.   
There are examples in the literature of biological molecules being immobilised on solid 
surfaces.  In 2006, Sun et al. published a paper in which they showed immobilisation of 
carbohydrates and proteins onto solid surfaces using Diels-Alder and copper-catalysed 
azide-alkyne cycloadditions.
292
  The authors used a single-component SAM to immobilise a 
number of components onto the solid surface, including the protein thrombomodulin.  The 
immobilisation of the protein was conducted in PBS (which would be compatible with the 
current methodology), using butanol, tris(triazolyl)amine solution and copper sulfate solution.  
The system was incubated at 4 °C for 72 hours without agitation (which again fits with the 
existing use of the gold-coated MALDI chips).  Yang et al. detailed a carbohydrate 
microarray for the detection of glycan-protein interactions in 2015.
293
  A sodium ascorbate 
and copper sulfate solution was used in a phosphate buffer system.  In 2014, Choi et al. 
published a paper detailing the regio- and chemoselective immobilisation of proteins on gold 
surfaces.
294
  Proteins were modified to include an alkyne moiety, which was subsequently 
used to capture the protein on the surface of an azide-terminated SAM.  A phosphate buffer 
system was again used for the immobilisation of proteins on the gold surface.   
Based on the work by Sun et al., Yang et al. and Choi et al., experiments using the proposed 
chemical tags for the future work of this project could use PBS as the solvent system.  This 
would retain some of the conditions established during original work conducted during the 
course of this thesis.   
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An alternative strategy to consider, should the above ideas prove inefficient, could include 
selective reactivity of different functional groups on the peptide to attach the peptide to the 
SAM and also the label to the peptide.  This is based on the isobaric peptide termini labelling 
(IPTL) strategy.
295–297
  Here, an alternative enzyme to trypsin (endoproteinase Lys-C) is 
used to digest the protein, which cleaves on the carboxyl side of lysine residues (essentially 
producing peptides with amino groups at both termini).
298
  Peptides are labelled on the C-
terminal lysine residues with either 2-methoxy-4,5-dihydro-1H-imidazole or tetradeuterated 
2-methoxy-4,5-dihydro-1H-imidazole.  The labels selectively react with the C-terminal lysine 
residues over the N-terminal amino group.  This leaves the N-terminal free for further 
reaction with tetradeuterated succinic anhydride or succinic anhydride.  The mix of 2-
methoxy-4,5-dihydro-1H-imidazole with tetradeuterated succinic anhydride and 
tetradeuterated 2-methoxy-4,5-dihydro-1H-imidazole with succinic anhydride creates 
isobaric masses.   
Based on the IPTL strategy, a chemical label could thus be devised which reacts with the C-
terminal lysine residues of the peptides.  The N-terminal could then be reacted with the 
SAM, in order to anchor the labelled peptides to the surface of the gold-coated MALDI chip.  
However, this would be a non-isobaric strategy, as the SAM components would not be 
isotopically labelled.   
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7.1. General methods 
PBS at pH 7.4, with a concentration defined as ‘10 ×’ was obtained from Invitrogen.  A 
working concentration of 1 × (137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4 and 2 mM 
KH2PO4) was obtained by dilution with deionised water.  The working concentration of 1 × 
was pH adjusted to pH 8.0 using 0.1 M NaOH.  All other reagents were supplied by Sigma 
Aldrich, unless otherwise stated.  Solvents were supplied by Fisher Scientific, except for 
TEAB (1M, pH 8.0) which was purchased from Sigma Aldrich.  Peptides were supplied by 
Sigma Aldrich, with their purities taken as supplied.  Peptides were examined mass 
spectrometrically, and no peptide contaminants were detected.  Trypsin was supplied by 
Promega.   
 
7.1.1. Mass spectrometry 
7.1.1.1. solariX  
Positive-ion MALDI mass spectra were obtained on a Bruker 9 Tesla solariX FT-ICR-MS 
instrument.  It was operated with a Nd:YAG smartbeam™ laser (355 nm) with power setting 
of 40%.  Mass spectra were acquired over the m/z range 500-3000 with a transient length of 
2.5166 s to give a resolution of 440,000 at m/z 400.  Each spectrum was acquired using 200 
laser shots, a frequency of 200 Hz, and an ‘average spectra’ setting of 10.   
The following ion transfer settings were used.  Source optics: capillary exit, 100 V; deflector 
plate, 230 V; funnel 1, 100 V; skimmer 1, 15 V; funnel RF amplitude 180 Vpp.  Octopole: 
frequency, 5 MHz; RF amplitude, 390 Vpp.  Transfer optics: ToF, 2.000 ms; frequency, 4 
MHz; RF amplitude 390 Vpp;.   
Mass spectra were externally calibrated using a spot containing Bruker Daltonics Peptide 
Calibration Standard II.  Peptide Calibration Standard II was dissolved in a mixture of 
acetonitrile and 0.1% TFA (1:2 v/v).   
THAP was dissolved in acetonitrile (10 mg/mL).  The solution was vortexed for 30 seconds.  
For sample wells, 0.3 μL of the THAP matrix solution was spotted on top of the already dried 
sample on each well, and the spot was left to air dry.  For calibrant wells, 1 μL of the 
calibrant solution was spotted on the well, with 1 μL of THAP matrix solution, and the spot 
was left to air dry.   
Spectra were obtained using Bruker solariXcontrol software and processed with Bruker 
DataAnalysis 4.0.   
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CID-MALDI mass spectra were obtained using argon as the collision gas, a collision energy 
of 45.0 V and an isolation window of m/z 4.0.  A laser power setting of 45% was used.  A 
transient length of 0.9088 s was used giving a resolution of 160,000 at m/z 400.   
 
7.1.1.2. ultraflex  
Positive-ion MALDI mass spectra were obtained on a Bruker ultraflex III instrument.  It was 
operated in reflectron mode, with a Nd:YAG smartbeam™ laser with attenuation setting of 
25%.  Mass spectra were acquired over the m/z range 800-4000.  Mass spectra were 
externally calibrated against an adjacent spot containing six peptides (des-Arg
1
-bradykinin, 
904.681; angiotensin I, 1296.685; Glu
1
-fibrinopeptide B, 1750.677; ACTH (1-17 clip), 
2093.086; ACTH (18-39 clip), 2465.198; ACTH (7-38 clip), 3657.929.).  Monoisotopic 
masses were obtained using the peak-picking SNAP averagine algorithm (C 4.9384, N 
1.3577, O 1.4773, S 0.0417, H 7.7583) and a S/N threshold of 2.   
CHCA was dissolved in acetonitrile:water (50:50) + 0.1% TFA (10 mg/mL).  The solution was 
vortexed for 30 s and then centrifuged for 1 minute.  100 µL of the supernatant was pipetted 
into a new microcentrifuge tube, and 100 µL of acetonitrile:water (50:50) + 0.1% TFA was 
added to create the matrix solution.  1 μL of the sample solution was spotted on a steel 
MALDI target plate, with 1 μL of CHCA matrix solution.  The spots were left to air dry.   
For each spot, the ten strongest ions, with S/N greater than 30, were selected for MS/MS.  
Fragmentation was performed in LIFT mode without the introduction of a collision gas.  The 
default calibration was used for MS/MS spectra, which were baseline-subtracted and 
smoothed (Savitsky-Golay, width 0.15 m/z units, cycles 4); monoisotopic peak detection 
used a SNAP averagine algorithm (C 4.9384, N 1.3577, O 1.4773, S 0.0417, H 7.7583) with 
a minimum S/N of 6.  Bruker flexAnalysis software (version 3.3) was used to perform 
spectral processing and peak list generation. 
Tandem mass spectral data were submitted to database searching using a locally-running 
copy of the Mascot program (Matrix Science Ltd., version 2.4), through the Bruker PS 
interface (version 2.1).  Search criteria specified: enzyme, trypsin; fixed modifications, 
carbamidomethyl (C); variable modifications, oxidation (M), dimethyl(Heavy_K) (K), 
dimethyl(Heavy_N-term) (N-term), dimethyl(Light_K) (K) and dimethyl(Light_N-term) (N-
term); peptide tolerance, 250 ppm (initial searches performed using 100 ppm peptide 
tolerance, but known labelled peptide pairs were missed during the searches.  Therefore, 
search parameters widened to allow these values to be included in the database search.  
Mascot Expect values were interrogated to monitor high mass error ppm values); MS/MS 
tolerance, 0.5 Da (standard setting used within the department); instrument, MALDI-TOF-
TOF (the version and size of the database can be obtained from the Mascot result page). 
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Kings database (an in-house database) accessed between 18/06/2014 (694 sequences) and 
31/07/2014 (707 sequences)).  Results were filtered to accept only peptides with p < 0.05.   
 
7.1.1.3. maXis HD 
Samples were loaded onto a nanoAcquity UPLC system (Waters) equipped with a 
nanoAcquity Symmetry C18 5 µm trap (180 µm x 20 mm, Waters) and a nanoAcquity 
BEH130 1.7 µm C18 capillary column (75 m x 250 mm, Waters) (BSA digests)/ nanoAcquity 
HSS T3 1.8 µm C18 capillary column (75 m x 250 mm, Waters) (E. coli lysate spiking 
experiments/muscle protein sample experiments).  The trap wash solvent was 0.1% (v/v) 
aqueous formic acid and the trapping flow rate was 10 µL/min.  The trap was washed for 5 
min before switching flow to the capillary column.  The column temperature was 60 °C.  The 
two mobile phases were: 0.1% (v/v) aqueous formic acid (solvent A) and acetonitrile 
containing 0.1% (v/v) formic acid (solvent B).  The flow rate for the capillary column was 350 
nL/min (BSA digests)/ 300 nL/min (E. coli lysate spiking experiments/muscle protein sample 
experiments).  The gradient profile for the BSA digests was as follows: initial conditions 2% 
solvent B (2 min), followed by a linear gradient to 35% solvent B over 20 min.  The gradient 
profile for the E. coli lysate spiking experiments/muscle protein sample experiments was as 
follows: linear 2-30% solvent B over 125 min then linear 30-50% solvent B over 5 min.  In all 
instances, the gradient culminated in a wash with 95% solvent B for 2.5 min, prior to 
returning to initial conditions and re-equilibrating for 25 min before subsequent injections.  
The nanoLC system was interfaced with a maXis HD LC-MS/MS system (Bruker Daltonics) 
with a CaptiveSpray ionisation source (Bruker Daltonics).  Positive ESI- MS & MS/MS 
spectra were acquired using AutoMSMS mode.  Instrument control, data acquisition and 
processing were performed using Compass 1.7 software (microTOF control, Hystar and 
DataAnalysis, Bruker Daltonics).  Instrument settings were: ion spray voltage: 1,450 V, dry 
gas: 3 L/min, dry gas temperature 150 °C, ion acquisition range: m/z 150-2,000. For the BSA 
digests, AutoMSMS settings were: MS: 0.5 s (acquisition of survey spectrum), MS/MS (CID 
with N2 as collision gas): ion acquisition range: m/z 350-2,000.  For the E. coli lysate spiking 
experiments/muscle protein sample experiments, the additional settings quadrupole low 
mass: m/z 300, transfer time: 120 ms, collision RF: 1,400 Vpp, MS spectra rate: 5 Hz were 
recorded.   
Precursors were fragmented using a fixed cycle time of 3 s (BSA digests/E. coli lysate 
spiking experiments)/1 s (muscle protein sample experiments) using a dynamic method 
adapting spectra rates between 1 and 10 Hz (BSA digests)/2 and 12 Hz (E. coli lysate 
spiking experiments)/5 and 20 Hz (muscle protein sample experiments) based on precursor 
intensities with an absolute threshold of 655 counts.  The collision energy and isolation width 
settings were automatically calculated using the AutoMSMS fragmentation table, preferred 
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charge states were 2-4 and singly charged ions were excluded.  A single MS/MS spectrum 
was acquired for each precursor and former target ions were dynamically excluded for 48 s 
with reconsideration of excluded precursors for fragmentation if their intensity rose by a 
factor of 4 within this time. 
 
7.1.2. Cleaning of gold-coated MALDI chips 
A gold-coated MALDI chip was placed in a Petri dish and cleaned with piranha solution (3:1 
conc. H2SO4: 35% H2O2) [caution hazardous].  A freshly prepared solution was poured over 
the gold-coated MALDI chip in the dish and left for approximately 30 minutes, with 
occasional agitation, until bubbles were no longer observed on the gold-coated MALDI chip 
surface.  Piranha solution was neutralised using sodium hydroxide in deionised water, and 
the gold-coated MALDI chip was washed with deionised water and acetonitrile and dried 
under a stream of nitrogen.   
 
7.2. Chapter 2 
7.2.1. Thiol-derived SAM formation (Figure 2.4) 
Stock solutions of the two SAM components, (HS(CH2)17(OCH2CH2)3OH and 
HS(CH2)17(OCH2CH2)6OCH2COOH), were prepared in DMSO (0.4 mg/mL) and stored at -18 
°C.  For experiments, the stock solutions were diluted to 0.1 mg/mL and these were mixed in 
a 4:1 molar ratio (alcohol:acid thiols).  Aliquots (0.4 μL) of this mixed solution were spotted 
onto the wells of the gold-coated MALDI chip.  The gold-coated MALDI chip was sealed in a 
Petri dish and left overnight at ambient temperature then washed with acetonitrile and dried 
under a stream of nitrogen. 
 
7.2.2. NHS/EDC activation (Figure 2.9 and Figure 2.12) 
A solution containing NHS (2 mg, 25 mM) and EDC (12.8 mg, 100 mM) was prepared in 
anhydrous DMF (1 mL).  Aliquots (1 μL) of this solution were spotted onto the wells of the 
gold-coated MALDI chip.  The gold-coated MALDI chip was sealed in a Petri dish at ambient 
temperature for one hour then washed with acetonitrile and dried under a stream of nitrogen.   
 
Chapter 7 Experimental 
255 
 
7.2.3. PFP/EDC activation 
Solutions of PFP (32 mg, 180 mM) and EDC (35 mg, 180 mM) were prepared in anhydrous 
DMF (1 mL).  Equal volumes of the two solutions were combined, and aliquots (1 μL) of the 
resulting solution were spotted onto the wells of the gold-coated MALDI chip.  The gold-
coated MALDI chip was sealed in a Petri dish at ambient temperature for one hour then 
washed with acetonitrile and dried under a stream of nitrogen.   
 
7.2.4. NHSS/EDC activation 
A solution of NHSS (2 mg, 25 mM) and EDC (12.8 mg, 100 mM) was prepared in anhydrous 
DMF or acetonitrile (1 mL).  Aliquots (1 μL) of this solution were spotted onto the wells of the 
gold-coated MALDI chip.  The gold-coated MALDI chip was sealed in a Petri dish at ambient 
temperature for one hour then washed with acetonitrile and dried under a stream of nitrogen. 
 
7.2.5. 4-Bromophenylalanine coupling to the thiol-derived SAM 
(Figure 2.10) 
A solution of 4-BrPhe (6.3 mg, 50 mM) in 50:50 (v:v) DMF:PBS (1×, titrated to pH 8.0 with 
0.1 M NaOH) (0.5 mL) was prepared.  This solution was sonicated and centrifuged.  Aliquots 
of the supernatant (1 μL) were spotted onto the gold-coated MALDI chip.   
A piece of filter paper was placed in the bottom of a Petri dish and wetted with deionised 
water (1 mL), to ensure the gold-coated MALDI chip did not dry out.  The gold-coated MALDI 
chip was sealed in the Petri dish and left overnight at ambient temperature.  The gold-coated 
MALDI chip was washed with acetonitrile and dried under a stream of nitrogen.   
 
7.2.6. Peptide capture on the thiol-derived SAM (Figure 2.13 and 
Figure 2.16) 
Peptides were prepared at the specified concentration using PBS (1×, titrated to pH 8 with 
0.1 M NaOH).  Aliquots (1 μL) were spotted onto the wells of the gold-coated MALDI chip.  A 
piece of filter paper was placed in the bottom of a Petri dish, and wetted with deionised 
water (1 mL), to ensure the gold-coated MALDI chip did not dry out.   
For investigations using H2
18
O-containing PBS, a piece of filter paper was placed in the 
bottom of the dish with the gold-coated MALDI chip spotted with the H2
18
O-containing PBS, 
and anhydrous DMF was pipetted onto the filter paper until it was covered.  
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In both methods, the Petri dish was sealed and the gold-coated MALDI chip left at ambient 
temperature overnight.  The gold-coated MALDI chip was washed with acetonitrile and dried 
under a stream of nitrogen.  The peptides were analysed by MALDI-MS and the expected 
products are shown in Table 7.1.   
Table 7.1: Peptides used for capture reactions and their corresponding product peaks 
observed by MALDI-MS analysis 
Peptide Molecular 
mass /  
g mol
-1 
Expected product ion 
(Tagged SAM) [M+Na]
+
 / 
m/z 
 
Expected product ion 
(SAM) [M+Na]
+
 / m/z 
 
Gly-Ala 146 1404/1406 - 
Leu-Gly-Gly 245 1503/1505 1278 
Gly-Gly-Val 231 1489/1491 1264 
Gly-Pro-Gly-Gly 286 - 1319 
Thr-Tyr-Ser 369 - 1402 
Gly-Gly-Gly 189 - 1222 
Phe-Gly-Gly 279 - 1312 
 
7.3. Chapter 3 
7.3.1. Disulfide-derived SAM formation (Figure 3.3) 
Stock solutions of the two disulfide-derived SAM components, (SCH2CH2(OCH2CH2)6OCH3)2 
and (SCH2CH2O(CH2CH2O)7CH2CH2COON(CO)2(CH2))2, were prepared in DMSO (0.4 
mg/mL) and stored at -18 °C.  For experiments, the stock solutions were diluted to 0.1 
mg/mL and these were mixed in a 4:1 molar ratio (mPEG:NHS disulfides) by combining the 
two disulfide solutions in a 2.5 μL:1 μL (mPEG:NHS disulfides) ratio in a new 
microcentrifuge tube.  Aliquots (0.4 μL) of this mixed solution were spotted onto the wells of 
the gold-coated MALDI chip.  The gold-coated MALDI chip was sealed in a Petri dish and 
left overnight at ambient temperature then washed with acetonitrile and dried under a stream 
of nitrogen. 
 
7.3.2. Peptide coupling (Figure 3.7) 
Peptides were prepared at the specified concentration using PBS (1×, titrated to pH 8 with 
0.1 M NaOH).  Aliquots (1 μL) were spotted onto the wells of the gold-coated MALDI chip.  A 
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piece of filter paper was placed in the bottom of a Petri dish, and wetted with deionised 
water (1 mL), to ensure the gold-coated MALDI chip did not dry out.  The Petri dish was 
sealed and the gold-coated MALDI chip left at ambient temperature overnight.  The gold-
coated MALDI chip was washed with acetonitrile and dried under a stream of nitrogen.  The 
peptides were analysed by MALDI-MS and the expected products are shown in Table 7.2.   
Table 7.2: Peptides used for capture reaction and their corresponding product peaks observed 
by MALDI-MS analysis 
Peptide Molecular 
mass /  
g mol
-1 
Expected product ion 
(Tagged SAM) [M+Na]
+
 / m/z 
 
Expected product ion 
(SAM) [M+Na]
+
 / m/z 
 
Gly-Ala 146 1404/1406 - 
Leu-Gly-Gly 245 1503/1505 1278 
Gly-Gly-Val 231 1489/1491 1264 
Gly-Pro-Gly-
Gly 
286 - 1319 
Thr-Tyr-Ser 369 - 1402 
Gly-Gly-Gly 189 - 1222 
Phe-Gly-Gly 279 - 1312 
 
7.3.3. 4-Bromophenylalanine/phenylalanine coupling  
A solution of 4-BrPhe (6.3 mg, 50 mM) or phenylalanine (8.6 mg, 50 mM) in 50:50 (v:v) 
DMF:PBS (1×, pH-adjusted to pH 8.0 with 0.1 M NaOH) (0.5 mL) was prepared.  This 
solution was sonicated and centrifuged, and dilutions made with 50:50 (v:v) DMF:PBS (1×, 
pH-adjusted to pH 8.0 with 0.1 M NaOH).  Aliquots of the supernatant (1 μL) were spotted 
onto wells on the gold-coated MALDI chip.   
A piece of filter paper was placed in the bottom of a Petri dish and wetted with deionised 
water (1 mL), to ensure the gold-coated MALDI chip did not dry out.  The gold-coated MALDI 
chip was sealed in a Petri dish and left overnight at ambient temperature.  The gold-coated 
MALDI chip was washed with acetonitrile and dried under a stream of nitrogen.   
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7.4. Chapter 4 
7.4.1. SAM formation 
A stock solution of the SAM component, (HS(CH2)17(OCH2CH2)3OH) was prepared in DMSO 
(0.4 mg/mL) and stored at -18 °C.  For experiments, the stock solution was diluted to 0.1 
mg/mL.  Aliquots (0.4 μL) were spotted onto the wells of the gold-coated MALDI chip.  The 
gold-coated MALDI chip was sealed in a Petri dish and left overnight at ambient temperature 
then washed with acetonitrile and dried under a stream of nitrogen. 
7.4.2. Operation of kHz plasma instrument 
An atmospheric pressure kHz plasma instrument was used.  The instrument consists of a 
simple electrode design with the powered electrode positioned 1 cm above the end of the 
quartz glass tube and the grounded electrode a further 2 cm above it.  The quartz tube had 
an outer diameter of 6 mm and inner diameter of 4 mm, and a length of 100 mm.  A gas flow 
of 2 standard litres per minute (SLM) of helium and various oxygen admixtures (ranging from 
0 – 1.0%) were used.  The kHz power supply was a high voltage pulsed nanosecond supply, 
with pulse voltage -3 - 18 kV at 75 Ω.   
A gold-coated MALDI chip was placed under the quartz tube, on a plastic holder, with the 
end of the quartz tube a specified distance from the surface of the gold-coated MALDI chip.  
The gas flow was set to 2 SLM, with the specified percentage of oxygen added to the helium 
using a mixing control unit.  The plasma was then generated by voltage application to the 
electrodes.   
The gold-coated MALDI chip was moved so that the required well was under the end of the 
quartz tube, by using a pair of plastic tweezers.  Timing of the cleaning was performed using 
a digital timer.   
 
7.4.3. Operation of RF plasma instrument 
A 13.56 MHz RF plasma instrument was operated at atmospheric pressure.  The setup 
consists of one ground and one powered electrode driven by an RF generator at a frequency 
of 13.56 MHz applied through a matching unit.  Typical operating powers are 15-25 W.  The 
instrument was run with helium feed gas and varying oxygen or nitrogen admixtures. 
A gold-coated MALDI chip was placed on a plastic holder, below the casing for the two 
electrodes, with the end of the electrodes 2 mm from the surface of the gold-coated MALDI 
chip.  The gas flow was set to 1 SLM, with the specified percentage of oxygen or nitrogen 
added to the helium using a mixing control unit.  The plasma was then generated by voltage 
application to the electrodes.   
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The gold-coated MALDI chip was moved so that the required well was under the end of the 
electrodes by using a pair of plastic tweezers.  Timing of the cleaning was performed using a 
digital timer.   
 
7.5. Chapter 5 
7.5.1. Tryptic digestion 
Up to 100 µg of protein was dissolved in TEAB (20 µL, 0.5 mM) in a 1.5 mL microcentrifuge 
tube.  To this, tris-(2-carboxyethyl-phosphine) (TCEP) solution (2 µL, 50 mM) was added.  
The solution was vortexed and incubated at 60 °C for 1 h.  Methyl methanethiosulfonate 
(MMTS) solution (1 µL, 200 mM) in isopropanol was added.  The resulting sample solution 
was vortexed and incubated at ambient temperature for 10 minutes.   
Trypsin solution (0.5 mM TEAB) was added to the protein solution to give a final 
trypsin:protein ratio between 1:100 and 1:20 (w/w).  The solution was then incubated in a 
heating block at 37 °C overnight.  An aliquot of the digest was then purified using a 10 µL 
C18 ZipTip, to clean the sample up for MALDI-MS analysis (see Section 7.5.3 for protocol).   
 
7.5.2. Dimethyl labelling 
For light or heavy dimethyl labelling, peptides (< 25 µg) were dissolved in TEAB (100 µL, 
100 mM).  For light dimethyl labelling, formaldehyde (4 µL, 4% (v/v)) was added.  For heavy 
dimethyl labelling, D2-formaldehyde (4 µL, 4% (v/v)) was added.  The solutions were 
vortexed and centrifuged briefly.  To each solution, sodium cyanoborohydride solution (4 µL, 
0.6 M) was added.  The solutions were vortexed and centrifuged briefly and then incubated 
at ambient temperature for 1 h in a fume hood.  The labelling reactions were then quenched 
by adding ammonia solution (16 µL, 1% (v/v)), vortexed and centrifuged briefly.  Formic acid 
(8 µL, 5% (v/v)) was then added to each.  The differentially labelled solutions were then 
combined in defined ratios by volume to generate a series of ratio solutions.   
For MALDI mass spectrometric analysis, aliquots of the solutions were purified using a 10 µL 
C18 ZipTip before mass spectrometric analysis (see Section 7.5.3 for protocol).   
For LC-ESI mass spectrometric analysis, aliquots of the standard solutions were acidified to 
pH ~2 using a formic acid solution (10%) prior to mass spectrometric analysis.   
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7.5.3. ZipTip treatment 
Conditioning (50:50 water:acetonitrile + 0.1% TFA) and washing (water + 0.1% TFA) 
solutions were prepared.  A 10 µL C18 ZipTip was attached to a pipette, which was set to 
dispense 10 µL.  The tip was conditioned twice by aspirating and expelling (to waste) 
aliquots (10 µL) of the conditioning solution, and then washed twice by aspirating and 
expelling (to waste) with aliquots (10 µL) of the washing solution.  The sample solution was 
then loaded onto the ZipTip by repeated aspiration/expulsion of sample solution (10 µL) 
through the ZipTip 10 times.  The solid phase, to which peptides were bound was washed by 
aspirating and expelling (to waste) two aliquots (10 µL) of the washing solution.  The 
peptides were eluted from the ZipTip by aspirating an aliquot (10 µL) of the conditioning 
solution and expelling it into a clean 0.5 mL microcentrifuge tube.  This aliquot of 
conditioning solution was then aspirated and expelled back into the same centrifuge tube a 
further 9 times to increase sample recovery. 
 
7.5.4. ProteinScape processing 
7.5.4.1. MALDI-MS 
Tandem mass spectral data were submitted to database searching using a locally-running 
copy of the Mascot program (Matrix Science Ltd., version 2.4), through the Bruker PS 
interface (version 2.1).  Search criteria specified: enzyme, trypsin; fixed modifications, 
methylthio (C); variable modifications, oxidation (M), dimethyl(Heavy_K) (K), 
dimethyl(Heavy_N-term) (N-term), dimethyl(Light_K) (K) and dimethyl(Light_N-term) (N-
term); peptide tolerance, 250 ppm; MS/MS tolerance, 0.5 Da; instrument, MALDI-TOF-TOF 
(the version and size of the database can be obtained from the Mascot result page.  Kings 
database accessed between 18/06/2014 (694 sequences) and 31/07/2014 (707 
sequences)).  Results were filtered to accept only peptides with a p-value of 0.05 or lower.   
 
7.5.4.2. LC-ESI-MS  
Tandem mass spectral data were submitted to database searching using a locally-running 
copy of the Mascot program (Matrix Science Ltd., version 2.4), through the Bruker PS 
interface (version 2.1).  Search criteria specified: enzyme, trypsin; fixed modifications, 
methylthio (C); variable modifications, oxidation (M), dimethyl(Heavy_K) (K), 
dimethyl(Heavy_N-term) (N-term), dimethyl(Light_K) (K) and dimethyl(Light_N-term) (N-
term); peptide tolerance, 10 ppm; MS/MS tolerance, 0.1 Da; instrument, maXis (the version 
and size of the database can be obtained from the Mascot result page.  Kings database 
accessed between 18/06/2014 (694 sequences) and 31/07/2014 (707 sequences)).  Results 
were filtered to accept only peptides with a p-value of 0.05 or lower.   
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7.5.5. Mascot Distiller processing 
A new project was created for each data file.  A peak list was generated using the standard 
maXis method parameters.  Mass spectra were submitted to a locally-running copy of the 
Mascot program (Matrix Science Ltd., version 2.4).  Search criteria specified: enzyme, 
trypsin; fixed modifications, methylthio (C); variable modifications, oxidation (M), dimethyl 
(K), dimethyl (N-term), dimethyl:2H(4) (K), dimethyl:2H(4) (N-term), dimethyl:2H(6)13C(2) 
(K) and dimethyl:2H(6)13C(2) (N-term); quantification, dimethylation; peptide tolerance, 100 
ppm; MS/MS tolerance, 0.1 Da; instrument, maXis (the version and size of the database can 
be obtained from the Mascot result page.  Kings database accessed between 18/06/2014 
(694 sequences) and 31/07/2014 (707 sequences).  EcoProt database accessed between 
27/02/2015 (4287 sequences) and 02/03/2015 (4287 sequences).  Uniprot_mouse database 
accessed between 07/08/2015 (22123 sequences) and 11/08/2015 (22123 sequences)).  
Results were filtered to accept only peptides with an p-value of 0.05 or lower.  Results 
reported as median (correlation threshold 0.7, std. err. threshold 0.3).   
7.5.6. FDR determination 
FDR values were determined by searching against a decoy database.  The automatic decoy 
database search option was used on the Mascot search form.  This option ensures that 
every time a protein sequence from the target database is tested, a decoy sequence of the 
same length is automatically generated and tested.  FDR values were recorded as peptide 
matches above identity threshold 
Table 7.3: FDR values calculated for analysis in Section 5.2.1.1 (- = no results from peptide 
search) 
Ratio prepared 
(L:H) 
Solution 1 
FDR / % 
Solution 2 
FDR / % 
Solution 3 
FDR / % 
0.1:1 0.00 0.00 0.00 
0.2:1 0.00 0.00 0.00 
0.33:1 0.00 0.00 0.00 
0.5:1 0.00 0.00 0.00 
0.67:1 0.00 0.00 0.00 
1:1 0.00 0.00 0.00 
1:1 (H:L) 0.00 0.00 0.00 
1.5:1 0.00 0.00 0.00 
2:1 0.00 0.00 0.00 
3:1 0.00 0.00 0.00 
5:1 - 0.00 0.00 
10:1 0.00 0.00 0.00 
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Table 7.4: FDR values calculated for analyses in Section 5.2.1.2 
Ratio 
prepared 
(L:H) 
PS MD 
Solution 1 
FDR / % 
Solution 2 
FDR / % 
Solution 3 
FDR / % 
Solution 1 
FDR / % 
Solution 2 
FDR / % 
Solution 3 
FDR / % 
0.1:1 1.77 0.80 0.00 0.00 2.13 0.00 
0.2:1 1.30 0.00 0.56 0.00 0.00 0.00 
0.33:1 0.75 0.57 1.20 0.00 0.00 0.00 
0.5:1 0.00 1.69 0.00 0.00 0.00 0.00 
0.67:1 1.29 1.06 0.81 0.00 0.00 0.00 
1:1 0.37 0.41 1.76 0.00 0.00 0.00 
1:1 (H:L) 1.35 0.63 1.16 0.00 0.00 0.00 
1.5:1 0.00 1.35 0.42 0.00 0.00 0.00 
2:1 0.87 0.53 0.99 0.68 0.87 0.00 
3:1 0.60 1.69 0.61 0.85 0.00 0.00 
5:1 2.01 1.32 1.60 0.00 0.00 0.00 
10:1 0.00 1.57 1.54 0.00 0.00 0.00 
 
Table 7.5: FDR values calculated for analyses in Section 5.2.2 
Ratio Replicate FDR / % 
L:H 
1 0.00 
2 0.00 
3 0.00 
H:L 
1 0.00 
2 0.00 
3 0.97 
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Table 7.6: FDR values calculated for analyses in Section 5.3 
Solution  
Solution 1 FDR 
/ % 
Solution 2 FDR 
/ % 
Solution 3 / 
FDR % 
L:H 1% 0.27 0.29 0.23 
L:H 5% 0.26 0.27 0.84 
H:L 1% 0.24 0.26 0.15 
H:L 5% 0.91 0.26 0.26 
 
Table 7.7: FDR values calculated for analyses in Section 5.4 
Solution Replicate FDR / % 
U:S1 
 
L:H 0.24 
H:L 0.00 
U:S2 L:H 0.00 
H:L 0.30 
 
7.6. Chapter 6 
7.6.1. Tryptic digestion 
Up to 100 µg of protein was dissolved in TEAB (20 µL, 0.5 mM) in a 1.5 mL microcentrifuge 
tube.  To this, TCEP solution (2 µL, 50 mM) was added.  This sample solution was vortexed 
and incubated at 60 °C for 1 h.  MMTS solution (1 µL, 200 mM) in isopropanol was added.  
The resulting sample solution was vortexed and left at room temperature for 10 minutes.   
Trypsin solution (in 0.5 mM TEAB) was added to the protein solution to give a final 
trypsin:protein ratio between 1:100 and 1:20 (w/w).  The solution was then incubated in a 
heating block at 37 °C overnight.  An aliquot of the digest was then purified using a 10 µL 
C18 ZipTip, to clean the sample up for MALDI-MS analysis (see Section 7.5.3 for protocol).   
 
7.6.2. Labelling of tryptic digestion 
For light or heavy dimethyl labelling, peptides (< 25 µg) were dissolved in TEAB (100 µL, 
100 mM).  Peptide solutions were acidified to ~ pH 4.5 with formic acid solution (0.1%).  
Sodium cyanoborohydride solutions were prepared in acetone and d6-acetone (36 µg/µL).  
To a peptide solution (20 µL), the relevant sodium cyanoborohydride solution (5 µL) was 
added.  The solutions were vortexed and centrifuged briefly and then incubated at ambient 
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temperature for 2 h in a fume hood.  The differentially labelled solutions were then combined 
in a 1:1 (v/v) ratio.   
For MALDI mass spectrometric analysis, an aliquot of the standard solution was purified 
using a 10 µL C18 ZipTip before mass spectrometric analysis (see Section 7.5.3 for 
protocol).   
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µ Mean 
µL Microlitre 
µM Micromolar 
ϕ Potential  
σ Cross section 
σ
2 
Variance 
λ Mean free path 
ν Velocity  
𝜐 Frequency of encounters 
ῡ Mean speed 
1-DGE One-dimensional gel electrophoresis 
2-DGE Two-dimensional gel electrophoresis 
4-BrPhe 4-Bromophenylalanine 
AFM Atomic force microscopy 
Ala Alanine 
ALICE Acid-labile isotope-coded extractants 
APPJ Atmospheric-pressure plasma jet 
Arg Arginine 
B Magnetic field 
BS3 Bis(sulfosuccinimidyl) suberate 
BSA Bovine serum albumin 
CHCA α-Cyano-4-hydroxycinnamic acid 
CID Collision-induced dissociation 
CV Coefficient of variation 
Cy Cyclohexyl 
DA DataAnalysis 
Da Dalton 
DBD Dielectric barrier discharge 
DCC N,N’-Dicyclohexylcarbodiimide 
DHB 2,5-Dihydroxybenzoic acid 
DiLeu N,N-Dimethyl leucine 
DIPEA N,N-Diisopropylethylamine 
DIT Dithranol 
DMF Dimethylformamide  
DMSO Dimethyl sulfoxide 
e
- 
Electron  
ECD Electron capture dissociation 
EDC 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
EG Ethylene glycol 
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Ek Kinetic energy 
emPAI Exponentially Modified Protein Abundance Index 
ESI Electrospray ionisation 
ETD Electron transfer dissociation 
fc Frequency 
FDR False discovery rate 
FT-ICR Fourier transform ion cyclotron resonance 
Gly Glycine 
h Hour  
H:L Heavy:light 
His Histidine 
HPLC High performance liquid chromatography 
HSP Heat shock protein 
Hz Hertz 
ICAT Isotope-coded affinity tag 
ICP Inductively coupled plasma 
ICP-MS Inductively coupled plasma mass spectrometry 
ICR Ion cyclotron resonance 
IPTL Isobaric peptide termini labelling 
iTRAQ Isobaric tag for relative and absolute quantification 
kHz Kilohertz 
L Litre 
L Length  
L:H Light:heavy 
LC Liquid chromatography 
LC-ESI-MS Liquid chromatography-electrospray ionisation-mass spectrometry 
LC-MS Liquid chromatography-mass spectrometry 
LC-MS/MS Liquid chromatography-tandem mass spectrometry 
Leu Leucine 
Leu-Enk Leucine enkephalin 
Lys  Lysine 
m Mass 
m/z Mass-to-charge ratio 
MALDI Matrix-assisted laser desorption/ionisation 
MALDI-MS Matrix-assisted laser desorption/ionisation-mass spectrometry 
MD Mascot Distiller 
MHz Megahertz  
min Minute 
mL Millilitre 
Abbreviations 
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mM Millimolar 
mm Millimetre 
MMTS Methanethiosulfonate 
ms Millisecond 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
Myo Myoglobin 
N Number of tests 
ne Electron density 
NEXAFS Near-edge X-ray absorption fine structure 
ng Number of gas units per unit volume 
ng Nanogram 
NHS N-Hydroxysuccinimide 
NHSS N-Hydroxysulfosuccinimide 
nL Nanolitre  
nmol Nanomole 
no Number density of neutral atoms 
PBS Phosphate buffered saline 
PEG Polyethyleneglycol  
PFP 2,3,4,5,6-Pentafluorophenol 
Phe Phenylalanine 
Phos B Phosphorylase B 
pI Isoelectric point 
pmol Picomole 
Pro Proline 
PS Bruker ProteinScape 
PTM Post-translational modification 
q Charge 
RF Radiofrequency 
rg Radius of an atom of gas 
RON Reactive nitrogen species 
ROS Reactive oxygen species 
s Second 
S Significance level 
S1 Stretched 1 
S2 Stretched 2 
S/N Signal-to-noise ratio 
SAM Self-assembled monolayer 
SD Standard deviation 
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SDgeo Geometric standard deviation 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Ser Serine 
SILAC Stable isotope labelling in amino acid culture 
SLM Standard litre per minute 
Std Dev. Standard deviation 
STM Scanning tunnelling microscopy 
t Time 
T Transient duration 
TCEP Tris-(2-carboxyethyl-phosphine) 
Te Electron temperature 
TEAB Triethylammonium bicarbonate 
TFA Trifluoroacetic acid 
THAP 2’,4’,6’-Trihydroxyacetophenone 
Thr Threonine 
Ti Ion temperature 
TMT Tandem mass tag 
Tneutrals Neutrals temperature 
ToF Time-of-Flight 
Trans Transferrin 
Trp Tryptophan 
Tyr Tyrosine 
U Unstretched 
UV-MALDI Ultraviolet-matrix-assisted laser/desorption ionisation 
V Voltage  
v/v Volume/volume ratio 
Val Valine 
VICAT Visible isotope-coded affinity tag 
Vs Source potential 
w/w Weight/weight ratio 
x Distance from cold surface 
XIC Extracted ion chromatogram 
XPS X-ray photoelectron spectroscopy 
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